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1.  INTRODUCTION 15 
1.1.  Background 
 
The term organophosphate is used to describe many different types of esters of 
phosphoric acids.  These compounds have found use in a diverse range of applications 
including flame retardants, lubricants, and medical therapeutics.  Some of these 
compounds are highly toxic to invertebrates and have been developed as insecticides and 
pesticides.  A small class of these compounds have also been developed as chemical 
warfare agents, known as nerve agents.  However, it is as agricultural insecticides and 
pesticides that organophosphates (OP) have gained widespread use around the world.  
Their almost ubiquitous presence in modern agricultural practices also leads to a higher 
frequency of human exposure.  It is estimated that in 1985 there were approximately 3 
million reported cases of severe acute pesticide poisoning worldwide (World Health 
Organization, 1990).  This figure may be closer to 25 million cases if self-reported data of 
all levels of poisoning severity was used (Jeyaratnam, 1990).  The exact proportion 
involving OP compounds in both estimates is unknown.  Whilst relatively rare in 
developed countries, human OP pesticide poisoning is an ever present problem in 
developing countries especially in rural Asia.  In this region it is not only exposure to OPs 
from agricultural practices that is a clinical problem.  OP compounds are regularly 
implicated in cases of self harm with approximately 200 thousand case fatalities each 
year.  This figure greatly exceeds those cases resulting from environmental exposure 
(Eddleston et al., 2008;Eddleston & Phillips, 2004).  Nerve agents have been deployed 
during military conflicts.  There is evidence that tabun filled munitions were deployed 
during the Iran-Iraq war (1980-1988) (Newmark, 2004).   Nerve agents have also been 
manufactured and released in terrorist attacks against civilian populations (Matsumoto in 
1994 and the Tokyo subway in 1995) (Centre for Nonproliferation, 2001).  
 
Despite the presence of the Chemical Weapons Convention which has been ratified by 
165 member states, the use of either agricultural OPs or nerve agents by terrorist groups 
remains a threat to today’s society.  Fully understanding how OPs affect the human body 
will allow the development of more effective treatment regimes which will benefit those 
either exposed occupationally, through self harm, or via a deliberate release.   
 
1.2.  The cholinergic system 
 
Acetylcholine (ACh) is a neurotransmitter released from synapses at many sites 
throughout the central and peripheral nervous systems (CNS and PNS respectively) in 
vertebrates as well as at excitatory synapses in the invertebrate (i.e. nematodes such as 16 
Caenorhabditis elegans) nervous system (Rand, 2007).  It is the main neurotransmitter 
released in the parasympathetic nervous system and is also released from pre-ganglionic 
synapses in both the sympathetic and parasympathetic nervous systems.  It is also 
released at the junction between smooth/skeletal muscle and the innervating nerve (the 
neuromuscular junction (NMJ)).  With the exception of sympathetic innervation of glands, 
ACh is absent, on the whole, from post-ganglionic sympathetic synapses.  Although ACh 
synapses are abundant throughout the body, the majority of our knowledge of cholinergic 
mechanisms has been gathered through investigation of peripheral cholinergic synapses 
such as the NMJ. 
 
ACh is synthesised in a reaction between Acetyl-CoA and choline.  This is catalysed by 
the enzyme choline acetyltransferase (ChAT) which is exclusive to cholinergic neurones.  
The newly synthesised ACh is then packaged into vesicles along with adenosine 
triphosphate (ATP), proteoglycans, and the ions H
+, Ca
2+ and Mg
2+ prior to release.  As 
the neurone is depolarised by an action potential, the vesicles dock with the presynaptic 
membrane.  The contents of the vesicles are then released by exocytosis into the synaptic 
cleft.  Further release of ACh is terminated by activation of autoreceptors on the 
presynaptic membrane.  Another neurotransmission limiting step is the hydrolysis of the 
ATP released in conjunction with the ACh.  The hydrolysed ATP yields adenosine, which 
then binds to the P1 purinoreceptor, which inhibits the activity of G-protein-linked Ca
2+ 
channels.  At the NMJ, the action of the P1 receptor is performed instead by the P2 
receptor, which has a higher affinity for ATP than adenosine (Naguib et al., 2002). 
 
The newly released ACh diffuses across the synaptic cleft, a distance of approximately 20 
nm to the post-synaptic membrane.  Depending upon the location of the synapse, the 
postsynaptic membrane will be populated with either muscarinic or nicotinic acetylcholine 
receptors (mAChR and nAChR respectively).  Binding of ACh to these structures causes a 
depolarisation of the postsynaptic cell thus either propagating the action potential or 
affecting a target organ/cell to effect a response.  The structure and function of the two 
types of cholinergic receptor will be dealt with in more detail in a later section. 
 
Once ACh has bound to the receptor it rapidly dissociates and is free to circulate again 
within the synaptic cleft.  There is no limit to how many receptors a molecule of ACh can 
theoretically activate in succession; therefore a rate-limiting step is needed to terminate 
the transmitted signal.  This is performed by the enzyme acetylcholinesterase (AChE) 
which hydrolyses the ACh into its constituent parts (Massoulie et al., 1993).  The recently 
cleaved choline is then recycled into the nerve terminal of the pre-synaptic cell via an 
active uptake system.  Further release of ACh is also reduced by negative feedback on 
the presynaptic neurone by autoreceptors. 17 
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Figure 1.1.  Cholinergic agonists.   
Acetylcholine and carbachol are non-specific agonists and have agonist properties at 
both muscarinic and nicotinic receptors.  Nicotine will only activate nicotinic receptors. 
 
1.2.1.  Muscarinic receptors 
 
To date, five subtypes of the mAChR have been identified.  These are termed M1 to M5 
(Caulfield & Birdsall, 1998;Eglen et al., 2001;Eglen et al., 1996).  The mAChR is a 
metabotropic receptor, which unlike the ionotropic nicotinic receptor does not directly form 
channels to allow ion movement to modulate the cell system in response to the binding of 
an agonist.  Instead, the muscarinic receptor is bound to a guanosine nucleotide binding 
protein (G protein) which acts as a trigger for other second messenger molecules to 
facilitate or inhibit various cellular processes (Caulfield, 1993).   
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Figure 1.2.  Muscarinic antagonists.   
Both atropine and hyoscine show no selectivity for the different subtypes of mAChR.  
Telenzepine and methoctramine shown selectivity for the M1 and M2 subtypes 
respectively. 
 
Five distinct but related genes code for the muscarinic acetylcholine receptor family and 
the amino acid sequence is very highly conserved throughout the mammalian family tree.  
Each mAChR consists of seven transmembrane spanning domains with three intracellular 
loops.  It is to the third intracellular loop, the G protein binds when the receptor is activated 
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by an agonist.  The muscarinic acetylcholine receptors are normally associated with either 
the Gq/11 protein (M1, M3, and M5) or to the Gi/o protein (M2 and M4).  Activation of the 
Gq/11 coupled receptors stimulates the enzyme phospholipase C that in turn stimulates the 
production of two intracellular second messengers, inositol 1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG).  Activation of IP3 and DAG then initiates various intracellular 
processes via the release of calcium from intracellular stores and the phosphorylation of 
many differing enzymes.   In contrast, activation of the Gi/0 protein inhibits the enzyme 
adenylate cyclase thereby reducing the amount of cAMP available within the cell.  There 
is also evidence that this G protein can directly interact with potassium channels causing 
their activation without the need for a second messenger.  Through activation of these 
channels the cell becomes hyperpolarised reducing the likelihood of synaptic activity 
occurring (Delmas & Brown, 2005).  Examples of agonists and mAChR selective 
antagonists are shown in Figure 1.1 and 1.2. 
 
Muscarinic acetylcholine receptors can be found throughout the CNS, with all five 
subtypes being successfully identified.  M1 mAChRs have been shown to be located in 
high densities in the cortex, hippocampus, and striatum (Piggott et al., 2002).  M2 
mAChRs have been reported to be present in high densities in the thalamus and areas of 
the brainstem (Perry et al., 1989;Piggott et al., 2002).  They can also be found in the 
cortex, hippocampus (Levey et al., 1995) and striatum (Rodriguez-Puertas et al., 1997).  
The M3 mAChR subtype has been reported in the hippocampus and cortex (Buckley et 
al., 1988), but is expressed at much lower levels than the M1 and M2 subtypes (Levey et 
al., 1994).  M4 mAChRs are expressed within the hippocampus (Levey et al., 1995), 
cortex (Buckley et al., 1988) and the striatum (Harrison et al., 1996).  Finally, M5 mAChRs 
have been identified on dopaminergic neurons within the ventral tegmental area (Forster 
et al., 2002), substantia nigra , and also in the hippocampus (Vilaro et al., 1990).  As well 
as their anatomical locations, the various mAChR subtypes also show differences in their 
location within the synapse.  The M1 mAChRs are located on postsynaptic membranes 
(Levey et al., 1991), and the M2 subtype is found predominantly on presynaptic 
membranes where it acts as an autoreceptor (McKinney et al., 1993).  The M3 and M4 
subtypes can be found on both pre- and postsynaptic membranes (Rouse et al., 1998).  
 
It is not surprising given the almost ubiquitous nature of the mAChRs that they have been 
shown to have an important role in many functions.  In particular the high densities of 
mAChRs (predominately M1) in the cortex and hippocampus have been shown to play a 
major role in higher cognitive processes such as learning and memory (Levey, 
1996;Hasselmo, 2006).  Other functions including attention (Herrero et al., 2008) and 
sleep (Goutagny et al., 2005;Coleman et al., 2004) have been demonstrated to rely on the 
involvement of mAChR.  Muscarinic receptors within the CNS are also involved in non-20 
executive functions.  An example of this is the M5 mAChR which is required to maintain 
the patency of cerebral vasculature (Hamel, 2004). 
 
Having such a wide ranging involvement in so many functions, it is not surprising that 
mAChR are implicated in many disease states which affect the CNS.  The most dramatic 
and well studied of these is Alzheimer’s disease.  This condition is typified by a 
progressive loss of cognitive ability and the formation of characteristic amyloid β plaques 
in neuronal tissue (Terry, 2006;Blennow et al., 2006).  Apart from the formation of these 
plaques, the other major component of Alzheimer’s disease is the loss of cholinergic 
function including a marked decline in the synthesis of ACh and also deterioration of major 
cholinergic projections to the hippocampus and cortex (Geula et al., 2008).  It is thought 
that whilst the expression of the M1 mAChR is largely unaffected, the number of these 
receptors which are functionally coupled to G proteins is greatly decreased (Tsang et al., 
2006).  This means that although the receptors are present, their activation will not result 
in excitation of the postsynaptic cell membrane.  Changes in the expression of M2 
mAChR in the cortex and hippocampus have also been reported (Lai et al., 2001). 
 
Alteration of mAChR expression and function has also been implicated in the 
pathophysiology of schizophrenia.  Reduction in the density of mAChRs (mostly M1) in the 
hippocampus (Crook et al., 2000), prefrontal cortex (Dean et al., 2002) and caudate 
putamen (Dean et al., 1996) has been shown in the brains of schizophrenic patients.  In 
this condition, genetic changes in the coding for mAChR have been reported.  A single 
nucleotide polymorphism in the structure of the gene coding for the M1 mAChR has been 
identified in the brains of some patients with schizophrenia (Liao et al., 2003).   
 
Other conditions which have shown an involvement of mAChRs include Parkinson’s 
disease (striatal M4 dysfunction (Ding et al., 2006), progressive supranuclear palsy 
(decrease in M2 and M4 mAChR expression in thalamic nuclei (Warren et al., 2007)), and 
drug dependence (M5 mAChR (Basile et al., 2002;Fink-Jensen et al., 2003)). 
 
1.2.2.  Nicotinic receptors 
 
The nicotinic acetylcholine receptor (nAChR) is a ligand gated cation permeable channel, 
which belongs to the superfamily of receptors, which includes the GABAA, glycine, and 5-
HT3A receptors (Dani, 2001).  Each nicotinic receptor is made up of five membrane 
spanning subunits. To date, five different subtypes of receptor subunit have been 
recognised (Table 1.2).  These are termed a (a1 - a10), b  (b1 - b4), e, d and g.  Nicotinic 
acetylcholine receptors can exist as homomeric structures (where all of the subunits are of 
the same type e.g. a7), or heteromeric structures where a mixture of subunit types are 21 
combined to form the receptor.  In the membrane the five subunits are assembled such 
that they form a ring structure with a central pore forming the ion channel.   
 
The nAChR can be further subdivided into muscle-type and neuronal receptors.  Muscle-
type nAChR are composed of (a1)2b1gd.subunits (found in developing muscle and also in 
extrajunctional locations).  In mature muscle they are composed of (a1)2b1ed subunits.  
Neuronal nAChRs in contrast are only ever composed from either the a and b subunits 
either as homomers (all five subunits are the same (a7, a8 and a9)), or heteromers 
(composed of 2 a and 3 b subunits).  The subtype composition of the receptor engenders 
many different characteristics such as agonist affinity, ion permeability and desensitisation 
rates.  These differences, especially the agonist affinity and rate of desensitisation, allow 
for a level of fine adjustment in the modulation of the output (usually the release of other 
neurotransmitters) of neurones expressing these receptors. 
 
Neuronal nicotinic acetylcholine receptors are prevalent throughout the brain and spinal 
cord (Woolf, 1991).  The mRNA of the various subunits has been detected in most areas 
of the brain, with higher concentrations being found in the cerebral cortex, periaqueductal 
grey matter, basal ganglia, thalamus, hippocampus and the cerebellum.  The a7 nAChR is 
the most widely distributed of the homomeric receptors, with the mRNA of this subunit 
being found in the hippocampus, auditory cortex, optical cortex, and mesocorticolimbic 
structures. The a7 homomeric receptor rapidly activates allowing the flow of cations 
especially Ca
2+, but then equally rapidly desensitises.  The rank order of agonist efficacy 
at the a7 receptor is nicotine>cytisine>DMPP>ACh (Lucas-Meunier et al., 2003). The 
a7 receptor is also highly sensitive to choline (which appears to act as an agonist and also 
causes desensitisation) whereas the heteromeric receptors are not (Pereira et al., 2002).  
This then means that this receptor may be activated not only by the release of ACh, but 
also by the major product of its hydrolysis.  This characteristic of the a7 receptor allows for 
fine-tuning of neurotransmitter release modulated by the release of ACh. 
 
The a4b2 nAChR is the most abundant of the heteromeric nAChR within the mammalian 
CNS with high densities of mRNA of the a4 and b2 subunits being found in the cerebral 
cortex and the hippocampus. In contrast to the a7 receptor, the a4b2 receptor has a much 
slower rate of desensitisation, and a differing affinity for cholinergic agonists (ACh and 
nicotine>DMPP>cytisine) (Lucas-Meunier et al., 2003).  
 
The function of the nicotinic nAChR within the CNS is mainly one of a modulator of other 
neurotransmitter systems.  From receptor localisation studies it has been shown that the  
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Figure 1.3.  Nicotinic antagonists.   
Methyllycaconitine is selective for a-bungarotoxin sensitive neuronal nAChR (mainly 
homomers of a7-10 subunits).  Mecamylamine is selective for neuronal nAChR that 
are insensitive to a-bungarotoxin including those composed of multiple a and b 
subunits (e.g. a4b2).   
 
majority of nAChRs are to be found on presynaptic membranes where they modulate the 
release of other neurotransmitters such as dopamine (Wonnacott, 1997).  There is 
however evidence for a direct fast transmission involving nAChRs in the GABAergic 
interneurones of the rat hippocampus and the human cerebral cortex(Albuquerque et al., 
2000). The evidence implies that the various nAChRs have a critical role in maintaining a 
balance between excitation and inhibition within the CNS.  As such, the nAChR has been 
implicated in many cognitive processes such as learning, attention and memory 
consolidation, as well as control of locomotion, noiception, and temperature regulation. 
With the great complexity of subunits and configurations of the nAChR it is not surprising 
that any fault will have implications in the normal functioning of the brain.  Subunit 
aberrations have been implicated in various pathophysiological conditions such as 
nocturnal epilepsy (a deficiency in a2 and a4 subunits), febrile convulsions (Chou et al., 
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2003), Tourette’s syndrome (Gotti et al., 1997), and schizophrenia (Freedman et al., 
2000).  
 
1.2.3.  Acetylcholinesterase and butyrylcholinesterase 
 
AChE is a type 3 hydrolase enzyme which hydrolyses ACh into its constituent parts, 
acetate and choline (Figure 1.4).  The cholinesterase family of enzymes belongs to the 
much larger hydrolase group of enzymes, which also includes other serine esterases and 
protease enzymes such as trypsin.  The different cholinesterase enzymes are named after 
the substrate for which the enzyme shows the highest affinity.  Thus AChE (EC 3.1.1.7) 
has a high affinity for ACh and butyrylcholinesterase (EC 3.1.1.8) has a higher affinity for 
butyrylcholine than ACh.  However, whilst AChE has a high affinity for ACh, it is also able 
to hydrolyse other esters.  Whilst the role of AChE is relatively well defined with respect to 
the hydrolysis of ACh, the physiological role of BuChE is not so clear cut.  Whilst it is 
known that BuChE can hydrolyse ACh, it can also metabolise other compounds such as 
heroin, physostigmine and succinylcholine.  It has been shown however that in some 
individuals, BuChE can be found in extremely low concentrations (or in some cases is 
totally absent) when compared to the normal population, with no apparent physiological 
detriment.  Therefore it has been hypothesised that BuChE, whilst sharing a common 
ancestry with AChE, has evolved into a scavenger but has retained the cholinesterase 
catalytic activity that it shares with AChE (Massoulie et al., 1993).  
 
The cholinesterase enzymes exist either as a sole catalytic unit, or as a complex between 
a catalytic unit and a structural subunit allowing further modification of the enzyme 
characteristics.  The attachment of the structural subunit also allows the enzyme to attach 
to the cell membrane. AChE and BuChE can exist in one of two basic forms, termed 
globular (G) and asymmetric (A). The globular form of the enzyme exists as a monomer 
(G1), dimer (G2), or tetramer (G4).  The multimeric forms of the enzyme are held together 
by disulphide bonds.  The isoforms of the enzyme can be subdivided still further, into 
those which are soluble, those which contain an amphiphilic region (ethanolamine-glycan-
phosphoinositol attached via an amide bond to the C terminus of the structure of the 
catalytic unit) allowing binding with the plasma membrane, and those which have a fully 
hydrophobic chain attached allowing deep attachment within the lipid bilayer of the plasma 
membrane.  In contrast, the asymmetric form can only exist as a homomer (A4, A8, and 
A12).  Structurally, this form of AChE is found as four catalytic subunits which are bound 
together by an attached collagen tail.  Both forms of AChE can be found either tethered to 
the plasma membrane or as soluble entities within the cytosol (Massoulie et al., 1993). 
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Cholinesterase enzymes have two active sites per molecule, which are located in gorges 
deep within the folds of the protein structure.  Each of the gorges contains two regions 
termed the anionic and esteratic sites.  The anionic site comprises of a glutamate residue 
and the esteratic site contains a histamine imidazole ring and serine hydroxyl group.  
These are both necessary for the successful hydrolysis of ACh and similar substrates.  It 
has been postulated that the process of catalysis of the substrate is first initiated by 
nucleophilic attack from the serine hydroxyl residue on the acyl group of the ester 
substrate, resulting in acylation of the serine residue.  Transfer of electrons from the 
aspartate (or glutamate) residue to the serine, thus strengthens the attack.  Reversal of 
the electron flow following acylation of the serine, back to the aspartate (or glutamate) 
residue facilitates hydrolysis of the substrate into its component parts and subsequent 
reactivation of the enzyme(Whittaker, 1993).  The histidine ring is believed to govern this 
process by relaying the electrons between the other two catalytic residues.  The acidic 
anionic group also acts as guide to the correct insertion of the substrate into the esteratic 
site.  An example of this can be shown using ACh as the substrate.  The positively 
charged quaternary nitrogen ion within the ACh molecule is electronically attracted to the 
carboxyl group of the anionic site.  This in turns locates the ester portion of the molecule 
over the esteratic site of the enzyme, thereby allowing efficient cleavage of the substrate 
into its constituent components (Whittaker, 1993).  This is an extremely rapid and efficient 
process, which has been estimated to have a turnover rate of 5000 molecules of ACh per 
molecule/enzyme s
-1.  This equates roughly to a time course of 0.2 milliseconds per 
hydrolysis event. 
 
Both AChE and BuChE can be found throughout the mammalian body system. All 
mammalian muscle contains cholinesterase, with AChE appearing as the dominant 
subtype (Massoulie et al., 1993).  BuChE is also present at low levels, but in certain 
muscle types such as cardiac muscle, the level of BuChE is greatly elevated such that it is 
found in approximately the same concentration as AChE.  Within the CNS, AChE 
predominates, both in areas that have cholinergic properties and also those that have no 
known cholinergic properties, such as the locus coeruleus and the dopaminergic neurones 
of the substantia nigra.  BuChE has been demonstrated to be confined mostly to glial cells 
(Giacobini, 2004) whereas AChE can be found almost ubiquitously throughout the brain in 
the G1 and G4 isoforms (Marquis & Fishman, 1985). 
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Figure 1.4.  The hydrolysis of acetylcholine by acetylcholinesterase 
The active site of AChE comprises of two separate areas, the esteratic (histidine (His) and 
serine (Ser) residue based) and anionic sites (glutamate (Glu) residue based) (A). ACh is 
attracted to the anionic site of the enzyme (B), and the process of hydrolysis begins.  During 
hydrolysis, the serine residue becomes acetylated and a molecule of choline is released (C).  
Following spontaneous hydrolysis of the acetylated serine residue, a molecule of acetate is 
liberated and the enzyme is free to receive another molecule of ACh (D). 
1.2.4.  Volume transmission of ACh within the CNS 
 
Whilst the action of ACh in the peripheral nervous system is largely as a direct 
neurotransmitter (e.g. as seen at the neuromuscular junction), the same cannot be said 
for the action of ACh within the central nervous system.  There is gathering evidence that 
ACh not only acts as a classical neurotransmitter , but also may act by volume 
transmission (Descarries et al., 1997).   
 
The concept of volume or non-synaptic transmission was first proposed for serotonin and 
noradrenaline neurones within the rat cortex.  In this model, there is an ever-present basal 
level of the neurotransmitter within the extracellular space.  Further release of the 
neurotransmitter in response to stimulation results in a transient increase before returning 
to the basal level following elimination of the neurotransmitter.  The superimposed spike 
will then act as a signal to the cholinergic receptors on the neuronal membranes.  The 
basal level is tightly maintained by uptake mechanisms or catalytic enzymes that remove 
the neurotransmitter molecule, preventing further stimulation of the receptors.  In volume 
transmission, these processes do not remove all of the neurotransmitter thus allowing a 
constant basal level to be maintained.  The evidence for this model has come from 26 
ultrastructural analysis which has shown that the axon nerve terminals (both boutons and 
varicosities) found on neurones containing these neurotransmitters showed little of the 
structure commonly associated with synapse formation (such as inclusion of a post-
synaptic membrane) (Descarries et al., 1997).  
 
Investigation of central cholinergic axons has revealed a similar picture for cholinergic 
varicosities.  In the cortex, only 10-20% of observed varicosities have synaptic properties, 
whilst in the hippocampus and the neostriatum the level of synaptic differentiation is lower 
at around 7-9%.  Therefore it is proposed that ACh acts by volume transmission at least in 
areas of the brain which has a dense cholinergic cell population, as the number of 
synaptic structures is far lower than the total number of potential release sites.  This would 
allow for axo-axonic transmission (transmission between adjoining axons) to occur in the 
absence of direct synaptic interfaces (Descarries et al., 1997;Descarries, 1998;Contant et 
al., 1996).  Similarly, the distribution of M2 mAChR on striatal interneurones has been 
shown to be largely asynaptic. This suggests that cholinergic transmission mediated by 
these receptors must take place by a volume transmission-like process  (Bernard et al., 
1998).  It is theorised that the large number of subtypes of the ACh receptors, especially 
the nAChRs with their varying properties, will act as filters to the different levels of ACh 
present and provide the necessary graded transmission of the cholinergic signal.  Further 
evidence for a basal level of ACh comes from the results of microdialysis studies which 
have shown that ACh can be detected even in the absence of AChE inhibitors such as 
physostigmine (Testylier & Dykes, 1996). 
 
1.2.5.  Implications for poisoning 
 
As can be seen from this brief review, the role of cholinergic receptors within the central 
nervous system are numerous and extremely diverse.  Any alteration to the functioning of 
these systems by poisoning with organophosphates will have numerous implications of 
varying severity.  Overstimulation of classical cholinergic synapses may result in 
alterations to the release of other neurotransmitters within areas of the brain that are 
directly modulated by cholinergic receptors. 
 
The volume transmission model of ACh transmission within the CNS has many far-
reaching implications following organophosphate poisoning.  Poisoning would cause an 
increase in the basal level of ACh by inhibiting AChE leading to one of two possible 
outcomes.  Firstly, the inhibition of AChE would cause a rapid increase in the basal level 
of ACh that would overstimulate the various cholinergic receptors regardless of their 
sensitivity for ACh thereby affecting the release of other neurotransmitters.  Secondly, the 
inhibition of AChE and subsequent elevation of basal ACh levels may result in the 27 
stimulated release signal being lost amongst the noise of the increased background.  If 
the case for volume transmission for ACh within the CNS is proven to be correct, this will 
have implications for the design of future clinical management of organophosphate 
poisoned casualties.  The need for a centrally active muscarinic antagonist such as 
atropine remains, but there may also be the need to antagonise the actions of the central 
nAChR as well.  This may decrease the involvement of other neurotransmitter systems 
that will have been affected by this disturbance within the cholinergic system. 
 
It is not just the direct effects of inhibiting AChE that will affect cholinergic 
neurotransmission.  Elevated levels of neuronal activity such as that seen during seizures 
cause a decrease in the level of extracellular calcium.  Calcium is an allosteric modulator 
of the nAChR and is required for the normal functioning of this receptor subtype.  Any 
reduction of the levels of available calcium will dramatically decrease the opening 
probability of the nAChR leading to a failure in signal transmission (Dani, 2001). 
 
1.3.  Cholinergic pathways in the brain 
 
Many areas of the mammalian brain receive a rich cholinergic innervation that has been 
shown to be involved in many cortical functions involving cognition and arousal (Everitt & 
Robbins, 1997).  Deficits in the cholinergic system have been seen in the brains of 
sufferers of neurodegenerative conditions such as Alzheimer’s dementia (Mesulam, 
2004b) and Parkinson’s disease (Bosboom et al., 2004).  Changes in the central 
cholinergic system are also a large part of the degenerative aging processes (Court et al., 
1993).  The rodent brain has been well characterised (Mesulam et al., 1983b), with similar 
studies having been conducted on the brains of primates and humans (Mesulam et al., 
1992b;Mesulam & Geula, 1988;Mesulam, 2004a;Mesulam et al., 1992a;Mesulam, 
1990;Selden et al., 1998).  Whilst there are many similarities between the cholinergic 
innervation of the primate and rodent brain, there are several distinct differences 
especially in the innervation of the cerebral cortex which can make direct comparison 
difficult (Mesulam, 1990). 
 
Using labelled markers of neuronal cholinergic activity such as choline acetyltransferase 
(ChAT), it has been shown that the vast majority of the cholinergic innervation of the brain 
is provided by projection neurones arising from a small number of cholinergic nuclei within 
the basal forebrain and the brainstem (Mesulam, 1990). These cell body groups are often 
not very well delineated from adjoining cellular structures and show markers not only for 
cholinergic neurones but also other transmitters such as GABA (Mufson et al., 2003).  An 
example of this is the medial septal nucleus and it’s projections to the hippocampus.  28 
 
So far eight cholinergic pathways have been defined within the mammalian brain 
(Mesulam, 1995). To avoid the confusion often found with the naming of structure of the 
brain, Mesulam et al., (1983) proposed an alternative nomenclature for the naming of 
each pathway.  Each pathway is designated Ch (for cholinergic) followed by the 
appropriate identifying number (1-8) (Mesulam et al., 1983a).  This nomenclature has 
been adopted for the remainder of this review. Four of these pathways (Ch1-4) originate in 
the magnocellular nuclei of the basal forebrain, including the medial septal nucleus, the 
nucleus of the vertical limb, the nucleus of the horizontal limb, and the nucleus basalis of 
Meynert.  These pathways project to the hippocampus and cortical areas, are involved in 
cognitive processes including sustained attention and memory (Sarter & Bruno, 1997a).  
Two more pathways (Ch 5 and Ch6) arise from the pedunculopontine and laterodorsal 
nuclei and provides the major cholinergic innervation of the thalamus (Mesulam et al., 
1989), the ventral tegmental area (VTA) and substantia nigra (Woolf, 1991).  Cholinergic 
projections from these nuclei have been implicated in arousal (Parikh & Sarter, 
2008;Sarter & Bruno, 1997b), rapid eye movement sleep (Garcia-Rill et al., 2008), control 
of central respiratory patterns (Saponjic et al., 2003), and maintenance of  airway patency 
during sleep (Rukhadze & Kubin, 2007).  The projections to the VTA and substantia nigra 
have been shown to activate dopaminergic neurons in these areas therefore providing 
control over locomotion, feeding and reward behaviours (for review refer to (Yeomans, 
1995).  The final two pathways (Ch7 and Ch8) are contained within the medial habenula 
and parabigeminal nuclei (Mesulam, 1990;Mesulam et al., 1983b;Wenk, 1997).  A 
schematic diagram of these pathways is shown in Figure 1.5. 
 
Not all of the cholinergic innervation of the brain is supplied by projection neurones via the 
pathways described above.  In the striatum the innervation is almost exclusively intrinsic, 
being supplied by cholinergic interneurones contained within the structure (Wilson, 2004), 
although there may be a minor extrinsic component from the Ch6 pathway (Mesulam et 
al., 1992b).   
 
Many disease states and toxic insults can affect the functioning of cholinergic systems 
within the brain (McKinney, 2005).  Following poisoning with nerve agents, a correlation 
between the length and severity of seizures and the severity of neuropathology has been 
reported (Shih et al., 2003).  In animals which have received a convulsive dose of the 
nerve agent soman and survived, there is extensive damage and cell loss in the forebrain 
and hippocampal formation (Petras, 1994;Baille et al., 2001;Baille et al., 2005;Filliat et al., 
1999).  The soman-induced damage is largely indistinguishable from that caused by 
ischemia (Petras, 1994).  These structures are mainly aligned with the Ch1-4 pathways.  
Following the sarin attack on the Tokyo subway system in 1995, exposed survivors 29 
showed a decrease in the volume of grey matter in the temporal cortices and the 
hippocampus.  A decrease in the volume of the white matter of the temporal stem was 
also reported (Yamasue et al., 2007).  In animals exposed to sarin, histological analysis 
reveals cell death occurring in the hippocampus, piriform cortex and thalamic nuclei 
(Grauer et al., 2008). 
 
Similar decreases in cell numbers in the areas of the Ch1-4 pathways have also been 
reported following physical brain trauma such as fluid percussion injury (Schmidt & Grady, 
1995).  Closed head trauma has been shown to primarily affect the cholinergic pathways 
of the forebrain (Salmond et al., 2005).  Whilst the cholinergic pathways that innervate the 
hippocampus and forebrain have been conclusively shown to be involved in cognitive 
processes, other cholinergic nuclei have also been shown recently to have possible roles 
in these processes.  Lesions of the pedunculopontine nucleus (Ch5) have been shown 
recently to result in disruption to operant tasks (lever pressing) and also a possible 
impairment in sustained attention (Rostron et al., 2008).  How the function of this structure 
is affected by anticholinesterase exposure is as yet unclear. 30 
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Figure 1.5.  Schematic of the principal central cholinergic pathways within the 
human brain.  
(A) Pathways Ch1 (arising in the septal nucleus) and Ch2 (arising in the vertical limb 
of the diagonal band). (B) Pathways Ch3 (arising in the horizontal limb of the diagonal 
band) and Ch4 (arising in the nucleus basalis of Meynert).  (C) Pathways Ch5 and 
Ch6 (arising in the pedunculopontine and laterodorsal tegmental nuclei respectively).  
(D) Ch7 arising in the medial habenula nucleus, and Ch8 arising in the parabigeminal 
nucleus. 
 
1.4.  Anticholinesterases, organophosphorus compounds and nerve agents 
 
Anticholinesterases (also sometimes referred to as cholinesterase inhibitors), inhibit the 
action of the cholinesterase family of enzymes either by a reversible or irreversible 
mechanism.  There is in reality a continuum between these two extremes.  What 
determines whether an anticholinesterase is a reversible or irreversible inhibitor is the rate 
at which it either disassociates or is broken down by the enzyme.  The main action of the 
cholinesterases is to hydrolyse chemicals structurally related to esters of choline.  The 
wider class of anticholinesterase compounds shows a wide diversity in chemical structure, 
some of which can be derived from biological sources (e.g. physostigmine) and others of 31 
which are purely synthetic (e.g. parathion).  This project will focus on carbamate and 
organophosphate (OP) anticholinesterase compounds. 
 
The terms organophosphorus and organophosphate have been widely adopted for the 
sake of convenience to describe OP insecticides, but the compounds are typically 
phosphorothionates (central P atom is bonded to three oxygen atoms and a double bond 
to a sulphur atom e.g. chlorpyrifos), phosphorodithioates (structurally similar to 
phosphorothionates but with an additional sulphur atom in place of one of the oxygen 
atoms e.g. malathion), or phosphoroamidothiolates (the central P atom is bonded to 
nitrogen, oxygen (double bond) and sulphur atoms e.g. methamidophos) (Mileson et al., 
1998).   
 
In their original states, many OPs are generally very weak inhibitors of AChE (Jokanovic, 
2001).  However, once within the body these compounds undergo biotransformation into 
oxygen analogs of the parent compound (oxons).  This metabolic transformation occurs in 
both insects and mammals, but is more efficient in the former making them highly effective 
insecticides.  Oxons such as paraoxon (parathion) and chlorpyrifos oxon (chlorpyrifos) 
exhibit a high affinity for AChE and as such are potent inhibitors of the enzyme causing 
the desired lethal effects of the insecticide (Kousba et al., 2004).  The biotransformation 
from relatively innocuous parent compound to the bioactive oxon follows one of five 
known pathways; oxidative desulphuration of the thiophosphate group to form a 
phosphate compound, oxidation of a sulphide group to form sulphones or sulphoxides, 
oxidation of amide groups forming N-dealkylated or N-oxide compounds, hydroxylation of 
akyl groups forming cyclic phosphate esters or ketones, or by other non-oxidative 
mechanisms (Jokanovic, 2001).  The various oxidative processes are mediated by 
cytochrome p450 and other enzymes such as the flavin-containing mono-oxygenases 
(Mileson et al., 1998;Jokanovic, 2001).  The basic structures of two common OP 
pesticides and their respective oxons are shown in Figure 1.6. 
 
OP compounds have found widespread use since first being developed the nineteenth 
century.  Many OP compounds have found use as insecticides, as they exhibit high 
invertebrate toxicity with low vertebrate toxicity.  However, poisoning with OP compounds 
in humans whether intentional (i.e. as an aid to suicide) or unintentional poses a very real 
challenge for clinicians worldwide.  It is suggested that as many as 200 000 deaths in rural 
Asia could be attributed to intentional OP poisoning following ingestion of OP insecticides 
such as chlorpyrifos (Eddleston & Phillips, 2004). 
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Figure 1.6.  Structures of the organophosphate insecticides. 
These differ from the nerve agents by having a sulphur atom double bonded to the 
phosphorus atom instead of an oxygen atom.  Also shown are the respective oxons.  
These are formed when the parent compound undergoes biotransformation within the 
body.  Typically oxons are more potent inhibitors of AChE than the parent compound.  
This is due to the substitution of the sulphur atom with an oxygen atom (double bond). 
 
Nerve agents are a family of highly toxic OP compounds which have found use as both 
military and terrorist weapons.  There are two classes of nerve agents (identified by their 
NATO designation); G agents (G for German) which includes tabun (GA), sarin (GB),  
soman (GD), and cyclosarin (GF); or V agents (Venomous) such as VX (Maynard, 1999).  
The basic structure of organophosphorus nerve agents is shown in Figure 1.7 and the 
structures of the individual compounds are shown in Figure 1.8.  As with OP insecticides, 
the terms organophosphorus and organophosphate have been widely adopted, but the 
compounds are actually phosphoroamidates (tabun), phosphonofluoridates (sarin, soman, 
cyclosarin), and phosphorothiolates (VX).    
 
The discovery of the nerve agents was born out of research into novel insecticides by 
Schrader and co-workers during the 1930s in Germany (Timperley, 2000;Schmaltz, 2006).  
A novel OP which had extremely high mammalian toxicity precluding it from safe use as a 
commercial insecticide was synthesised during this research.  This was the compound 
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which is now known as tabun.  Further investigation of this series of compounds yielded 
the compounds sarin and soman.  VX also shared a common ancestry with OP pesticides 
and was first synthesised in 1952.  Whilst sharing similar chemical structures, the nerve 
agents have very diverse physical properties.  The G agents tend to be volatile and 
therefore present mainly an inhalational hazard (although G agents can also be 
percutaneous hazards).  This also makes them less persistent as the vapour is easily 
dispersed.  In contrast VX is relatively involatile, making it a persistent agent and a 
percutaneous hazard.    Whilst the early G agents (tabun, sarin and soman) were 
weaponised by Germany during the closing years of World War II, they were never 
deployed during this conflict.  However, nerve agents have been used in other conflicts 
most notably the Iran-Iraq war (1980-1988) (Newmark, 2004), as well as internal conflicts 
in Iraq (Black et al., 1994).  Sarin has also been used as a terrorist weapon by the Aum 
Shinrikyo cult in attacks in Matsumoto and Tokyo in Japan (1994 and 1995 respectively).  
There is evidence that this group have also used VX in some of their activities (Centre for 
Nonproliferation, 2001). 
 
The nerve agents and most organophosphorus compounds are potent inhibitors of 
cholinesterase enzymes (Maynard, 1999).  Of prime importance is AChE which 
preferentially hydrolyses ACh into its constituent components choline and acetate, thereby 
limiting its availability for binding and therefore terminating the action of the 
neurotransmitter.  A more detailed description of AChE is given in section 1.2.3.  The 
reaction between AChE and a nerve agent is shown in Figure 1.9.   
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Compound  R1  R2 
Tabun (GA) 
Ethyl N-
dimethylphosphoramidocyanidate 
CH3CH2O  (CH3)2N 
Sarin (GB) 
Isopropyl 
methylphosphonofluoridate 
CH3(CH3)CHO  CH3 
Soman (GD) 
Pinacolyl 
methylphosphonofluoridate 
(CH3)3C(CH3)CHO  CH3 
Cyclosarin (GF) 
Cyclohexyl 
methylphosphonofluoridate  
(C5H10)CHO  CH3 
VX 
O-Ethyl-S-
[2(diisopropylamino)ethyl] 
methylphosphonothioate 
C2H5O  CH3 
 
Figure 1.7. Basic structure of organophosphorus nerve agents.   
The table above shows the different groups present at positions R1 and R2 for each of 
the classical G agents. X can either be a CN group (tabun) or a fluorine atom, F (sarin, 
soman and cyclosarin), or SCH2CH2N(C3H7)2 (VX). 
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In casualties who survive the initial cholinergic crisis the prognosis is generally good, 
although the seizures generated during the intoxication can cause extensive 
neuropathology within the brain (Shih et al., 2003;Myhrer et al., 2005).  Therefore early 
termination of the seizure events is a high priority for the clinician.  Disturbances in EEG 
have been reported in survivors who were exposed to sarin during the terrorist attacks in 
Tokyo (Yanagisawa et al., 2006).   
 
If the casualty can be supported through the initial cholinergic crisis, many may deteriorate 
into a state of muscular paralysis called the intermediate syndrome (Brown & Brix, 1998).  
This is especially associated with poisoning by organophosphorus insecticides.  The 
intermediate syndrome is typified by rapid progression of paralysis of the muscles 
innervated by the cranial nerves, respiratory muscles and proximal limb musculature.  
Death by respiratory failure is not uncommon at this stage of the poisoning.  The onset of 
the intermediate syndrome usually occurs between 1-4 days following exposure to high 
levels of organophosphates (Moretto, 1998).  Whilst the underlying causes of this 
syndrome are not well understood, it has been shown that the magnitude of the exposure 
and muscle injury sustained during the initial cholinergic crisis is well correlated to the 
severity and incidence of the intermediate syndrome (John et al., 2003).  This condition is 
reversible but the casualty places a huge logistical burden on the secondary care 
providers until recovery is complete. 
 
1.5.  Effects of OP compounds in the central nervous system 
 
The actions of organophosphorus compounds (including nerve agents) on the 
cholinesterase enzyme are well known.  There are also reports that have highlighted other 
possible targets for interaction with organophosphates.  Both the inhibition of the 
cholinesterase enzymes and the interaction of organophosphorus compounds with other 
non-cholinesterase targets will now be discussed. 
 
1.5.1.  Cholinesterases 
 
As described in section 1.2.3, cholinesterase enzymes have two active sites (the esteratic 
and the anionic), both of which are involved in the binding and hydrolysis of ACh.  The 
organophosphate compound is actively attracted to a serine hydroxyl residue within the 
esteratic site.  When in close proximity to this serine residue, the electrophilic 
phosphorous atom undergoes nucleophilic attack and the halogen atom (or another group 
such as cyanide or thiocyanate at position X in Figure 1.7) is displaced in favour of the 
serine residue thus effectively phosphorylating or phosphonylating (depending on the OP) 38 
the enzyme (Somani et al., 1992).  This is generally an irreversible reaction resulting in 
the loss of active enzyme, although the enzyme may be released by the actions of 
nucleophilic compounds such as oximes if they are administered soon after poisoning 
(Wong et al., 2000).  The loss of the catalytic activity of AChE leads to a build up of ACh 
within the synapse.  This in turn causes a progressive overstimulation of the postsynaptic 
membrane leading to the overt signs and symptoms of the cholinergic crisis.   
 
A further complication to the dissociation of the enzyme-agent complex is the cleavage of 
the O - C bond within the R2 group resulting in a dealkylated complex (Figure 1.9) 
(Shafferman et al., 1996).  Dealkylation (also called ageing) can occur rapidly following 
poisoning with soman (t1/2 of between 1 and 8.5 minutes depending on species) (Talbot et 
al., 1988), or more slowly in cases of intoxication with other nerve agents e.g. t1/2 sarin ~3 
hours (Worek et al., 2004).  The resulting charge on the enzyme-agent complex resists 
the actions of oximes thereby inhibiting any regeneration of the enzyme.  Oximes will be 
discussed in more detail in therapies section. 
 
Recent advances in genetics have allowed the development of various animal models 
which have specific enzyme mutations.  An AChE knockout mouse model (AChE -/-) has 
been used to study the role of BuChE following the loss of AChE.  With this model it has 
been shown that survival without AChE is possible, although the AChE -/- mice were more 
sensitive to VX than the wild type mouse.  Atropine failed to prevent lethality in the 
knockout mice, showing that either the mAChR of the AChE -/- mouse had become 
desensitised or that excess levels of ACh do not accumulate within their synapses 
(Duysen et al., 2001).  As these mice are devoid of AChE the lethal effects of VX must be 
mediated by another target system such as BuChE.  A study by Chatonnet et al., (2003) 
has shown that BuChE does indeed play a role (at least in the peripheral nervous system) 
in the survival of AChE -/- mice, however BuChE does not totally replace the activities of 
AChE within the CNS, especially at the sites of respiratory rhythm generation in the 
brainstem.  Survival in this case is prolonged by a general down-regulation in the 
response of central respiratory neurones to cholinergic agonists (Chatonnet et al., 2003).   
Similarly, Minic et al., (2003) reported that BuChE does not replace AChE as the 
terminator of the cholinergic signal at the neuromuscular junction of AChE -/- mice, but 
instead acts to limit the release of ACh via a presynaptic mechanism (Minic et al., 2003). 
 
A knockout mouse model which is devoid of plasma and tissue BuChE (BuChE -/-) has 
also been developed (Li et al., 2006).  In contrast to the AChE -/- mouse, the BuChE -/- 
appears to be relatively normal in its physiology, although changes in the function of 
mAChR have been reported (Li et al., 2008).  However, when exposed to the specific 
AChE inhibitors (-) - huperazine A and donezepil, the BuChE -/- mouse exhibited signs of 39 
a pronounced cholinergic overstimulation (convulsions, fasiculations, and changes in core 
temperature) when compared to BuChE +/+ and AChE -/- mice.  Whereas the BuChE +/+ 
and AChE -/- mice survived this challenge, all of the BuChE -/- mice were dead within 10 
minutes of dosing with (-) – huperazine (1.5 mg/kg), and within 110 minutes of dosing with 
donezepil (10 mg/kg).  Death usually occurred during a major tonic convulsion.  The 
action of these compounds shows that BuChE is important in the AChE -/- mouse and has 
a role in controlling levels of ACh probably through hydrolysis of the agonist.  Interestingly, 
exposure to the OP compounds chlorpyrifos oxon and ecothiopate affected all BuChE 
genotypes in equal measure (non-lethal) whereas it caused 100% lethality in the AChE -/- 
mice.  It has been postulated that the reason for the apparent lack of effect of OP 
compounds in the BuChE -/- mouse is due to the high levels of circulating 
carboxylesterase which may act to scavenge the OP (Duysen et al., 2007).  
 
1.5.2.  Carboxylesterase 
 
Carboxylesterase enzymes (EC 3.1.1.1) form a large and complex multigene family of 
enzymes (Satoh & Hosokawa, 1998).  These enzymes have broad substrate specificity, 
and are responsible for the hydrolysis of various ester and amide containing compounds 
including many endogenous compounds such as acyl-glycerols, long chain acyl-CoA 
esters, and many drug compounds such as carbonates, pyrrolizidine alkaloids, cocaine 
and salicylates.  The importance of carboxylesterases in the detoxification of 
organophosphorus insecticides and nerve agents has been well documented (Barata et 
al., 2004;Jokanovic, 2001).  The carboxylesterase enzymes are also responsible for 
converting many pro-drugs into their active forms.  Carboxylesterase enzymes are present 
throughout the body with the highest levels being found in the liver (Satoh & Hosokawa, 
1998), although lower concentrations can be found in the brain (Mori et al., 1999), 
respiratory system (Barr et al., 1998), gastrointestinal tract (Schwer et al., 1997), 
reproductive system (Yan et al., 1995), and the skin (Heymann et al., 1993).  Humans in 
contrast to rodents and guinea pigs, have no carboxylesterase in the plasma fraction of 
the blood (Li et al., 2005). 
 
Carboxylesterases are also inhibited by organophosphorus compounds.  Whilst the 
reactions between the carboxylesterase enzyme and organophosphate compounds are 
largely non-specific, this class of enzyme exhibits higher inhibition rate constants for 
uncharged compounds such as paraoxon, sarin, and soman (Maxwell & Brecht, 2001).  
Various studies have concluded that the scavenging effect of carboxylesterase is an 
important factor in the toxicity of the organophosphate compounds.  It is apparent that this 
protective element of carboxylesterase activity is more important in cases of poisoning 
with compounds that exhibit high AChE inhibition rate constants and therefore are highly 40 
toxic (i.e. paraoxon, sarin, and soman), than those that have relatively lower inhibition 
kinetics and lower toxicities (i.e. DFP) (Dettbarn et al., 1999;Maxwell, 1992). 
 
In contrast to the cholinesterase enzymes, carboxylesterases do not readily undergo the 
ageing reaction and are able to spontaneously reactivate to an active state once bound to 
organophosphorus compounds (Maxwell & Brecht, 2001;Dettbarn et al., 1999).  There are 
six amino acid residues implicated in the ageing process (Masson et al., 1997;Shafferman 
et al., 1996;Maxwell & Brecht, 2001) which are highly conserved between AChE and 
BuChE, whereas carboxylesterase only contains three of the residues (Maxwell & Brecht, 
2001).  The reactivation of the enzyme is also dependent upon the physical properties of 
the organophosphate inhibitor.  It has been reported that with VX, sarin and soman, the 
rate of reactivation decreased with an increase in the size of the inhibitor (Maxwell & 
Brecht, 2001).  
 
1.5.3.  Neuropathy Target Esterase 
 
Neuropathy target esterase (NTE also known as NTE-lysoPLA) is a membrane protein 
found in all neuronal cell types as well as some non-neuronal cells, and has been shown 
to have a role in neural development (Glynn, 1999).  It has been demonstrated that 
poisoning at sub-lethal doses with certain organophosphorus compounds (e.g. tri-
orthocrysylphosphate (TOCP) and chlorpyrifos) can cause a delayed neurotoxic condition 
typified by axonopathy or degradation of distal regions of long axons within the peripheral 
and central nervous systems (Lotti, 2002).  This results in ataxia and paralysis of the lower 
limbs which develops within 14 to 21 days of poisoning.  This has been termed 
organophosphate induced delayed neuropathy (OPIDN) and has been demonstrated to 
be caused by dealkylation (ageing) of the organophosphate ester or amide which is 
covalently bound to the active site of NTE (Lotti, 2002;Glynn, 2003).  Not all 
organophosphorus compounds can age NTE, with a notable exception being soman 
(Crowell et al., 1989).  Other nerve agents such as sarin are also incapable of causing the 
degree of NTE inhibition required to initiate OPIDN (Crowell et al., 1989).  It has been 
demonstrated that pre-treatment with a non-neuropathic inhibitor of NTE such as some 
carbamates (thiobencarb) will protect against the development of OPIDN following a 
subsequent exposure to a neuropathic inhibitor such as DFP.  If given after exposure to a 
neuropathic inhibitor, however, the non-neuropathic inhibitor greatly increases the severity 
of the OPIDN produced and lowers the threshold of NTE inhibition required to produce the 
axonopathy (Moretto, 1998).  
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1.5.4.  Other serine hydrolase enzymes 
 
Acylpeptide hydrolase is a serine hydrolase that has been reported to show a higher 
sensitivity for inhibition by DFP and dichlorvos than AChE (Richards et al., 2000).   Whilst 
the exact biological function of this enzyme is not known, it has been shown to catalyse 
the hydrolysis of N-acylated amino acids from short peptides and therefore may be 
involved in the latter stages of protein synthesis.  This again maybe important in the 
cognitive deficits reported post OP exposure.  However the inhibition of acylpeptide 
hydrolase is highly dependant on the OP inhibitor used.  Whilst DFP is a potent inhibitor of 
the enzyme, sarin at a concentration that causes almost complete inhibition of AChE and 
BuChE in guineas pigs only partially inhibits the activity of acylpeptide hydrolase (Quistad 
et al., 2005).  This shows that it is likely that the inhibition of acylpeptide hydrolase is not 
of clinical importance in the nerve agent poisoned casualty.  However, whilst some of the 
interactions may have a secondary importance to the primary inhibition of AChE, it is now 
being realised that certain serine hydrolase enzymes such as KIAA1363 (an acetyl 
monoalkylglycerol ether hydrolase found in the brain, heart, lungs and kidneys) have a 
role to play in the detoxification of OP compounds (Nomura et al., 2008b). 
 
Serine hydrolase enzymes are key to the normal functioning of many neurotransmitter 
systems.  In addition to the cholinergic system, the cannabinoid system uses serine 
hydrolase enzymes to control the action of the endogenous agonists, anandamide and 2-
arachidonyl glycerol (2-AG).  These enzymes are fatty acid amide hydrolase (FAAH) and 
monoacylglycerol lipase (MAG) respectively (Cravatt et al., 1996;Karlsson et al., 1997).  
Inhibition of FAAH and MAG by OP compounds leads to an accumulation of 2-AG and 
anandamide and a decrease in the levels of arachidonic acid.  This in turns exhibits it self 
overtly as signs of CB1 receptor activation such as deficits in cognitive ability (Nomura et 
al., 2008a).  This is secondary to the main AChE inhibition, however, as almost total 
inhibition of FAAH has been shown to be non lethal and without many overt signs in the 
mouse (Quistad et al., 2002). 
 
Other serine hydrolase enzymes including those that are involved in blood clotting 
(thrombin, plasmin and kallikrein) and digestion (trypsin, α-chymotrypsin and elastin) have 
also been shown to be inhibited by OP compounds (Quistad & Casida, 2000).  The IC50 
values for these reactions are in the order of several µM (50 µM for trypsin inhibited by 
sarin) up to and in excess of 1mM for thrombin inhibited by sarin (Mounter et al., 1963). 
These concentrations are several orders of magnitude greater than the IC50 of erythrocyte 
AChE when exposed to sarin (0.015 µM (Sivam et al., 1984)).  From these data it can be 
seen that the catalytic action of AChE is affected to a greater degree than other enzymes 42 
of this type.  It can therefore be concluded that the predominant effect of OPs especially 
the nerve agents, is to inhibit the cholinesterase enzymes leading to the cholinergic crisis. 
  
1.5.5.  Neurotransmitter receptors 
 
As well as inhibiting AChE, it has been demonstrated that some AChE inhibitors and 
nerve agents can also interact directly with neurotransmitter receptors including the 
muscarinic and nicotinic acetylcholine receptors, and cannabinoid receptors.  In studies by 
Rocha et al., (1998) (Rocha et al., 1998), VX was demonstrated to increase the 
spontaneous release of GABA and glutamate as measured by an increase in the 
frequency and amplitude of miniature post-synaptic potentials in cultured hippocampal 
neurones.  This was found to be TTX-insensitive i.e. action potential independent and 
dose dependent.  The effect also persisted when AChE was inhibited by incubating the 
neurones with 2mM soman (this has been previously shown to inhibit all AChE).  Therefore 
this effect must be due to a non-AChE mechanism although the authors have not 
elucidated further on any possible mechanisms such as receptor interactions. The same 
group have also reported that both VX (Rocha et al., 1999;Rocha et al., 1998) and sarin 
(Rocha et al., 1998) reduce the evoked release of glutamate and GABA from both 
cultured hippocampal neurones and hippocampal slices.  This effect was abolished by the 
pre-incubation of the neurones with atropine, which suggests that the effect was mediated 
by a mAChR.  Similar pre-incubation with various nAChR antagonists failed to block the 
effect.  VX also reduced the rate of firing and amplitude of action potentials recorded from 
current-clamped hippocampal neurones in the presence of CNQX and picrotoxin (Rocha 
et al., 1999).  Chebabo et al., (1999) reported in a similar study that sarin at low 
concentrations (0.3 –1nM) also affected the evoked release of GABA from neurones in the 
hippocampus and this was found to be mediated by pre-synaptic mAChR on GABAergic 
interneurons.  However, sarin did not affect the TTX-insensitive release of GABA as had 
been observed with VX in previous studies (Chebabo et al., 1999). 
 
It is not only the nerve agents that are capable of interacting with cholinergic receptors.  
Organophosphorus insecticides have also been shown to interact with the mAChR. 
Chlorpyrifos oxon, the activated oxygen analogue of chlorpyrifos, has been shown to 
interact directly with the M2 mAChR both in the striatum (Huff et al., 1994) and in cardiac 
cell cultures (Bomser & Casida, 2001) at a site that does not prevent agonists from 
binding to the receptor.  Chlorpyrifos oxon, malaoxon, and paraoxon have also been 
shown to interfere with the second messenger pathways associated with the M2 and M4 
mAChRs.  All three compounds affected the production of cAMP following stimulation with 
forskolin.  This effect was blocked by atropine.  It was deduced that the M2 and M4 
receptor subtypes were involved in this effect as none of the oxons had any effect on 43 
basal or agonist induced phosphoinostide hydrolysis which are both linked to the other 
subtypes of mAChR (Ward & Mundy, 1996). 
 
The nAChR has also been shown to be directly affected by various AChE inhibiting 
compounds, both non-organophosphorus (Smulders et al., 2003;Di Angelantonio et al., 
2004a;Albuquerque et al., 1984) and organophosphorus in nature (Albuquerque et al., 
1985;Katz et al., 1997;Smulders et al., 2004a;Smulders et al., 2004b;Di Angelantonio et 
al., 2004b;Tattersall, 1990).  It has been demonstrated that chlorpyrifos, parathion and 
their related oxons (chlorpyrifos oxon and paraoxon respectively) desensitise the nAChR 
of the electric organ of the Torpedo ray.  This was shown by using a radiolabelled form of 
the non-competitive antagonist (
3[H]-thienyl-cyclohexylpiperidine, 
3[H]TCP). Chlorpyrifos 
oxon significantly inhibited the agonist induced binding of 
3[H]TCP (IC50 5 mM).  The 
remaining compounds also inhibited the binding of 
3[H]TCP but were far less potent than 
chlorpyrifos oxon.  None of the compounds affected the binding of a-bungarotoxin to the 
receptor, although pre-incubation with the compounds increased the inhibition of a-
bungarotoxin binding by carbachol (Katz et al., 1997).  This shows that the OP 
compounds do not bind to the main agonist binding site of the receptor and also that they 
increase the affinity of this site for carbachol.  Such an increase in affinity is seen when 
the receptor is stabilised in a desensitised state and therefore it is postulated that the 
compounds act to desensitise the receptor (Tattersall, 1990).   
 
Several organophosphorus  and carbamate  insecticides are capable of inhibiting the rat 
neuronal a4b2 nAChR (Smulders et al., 2004a).  Exposure to varying concentrations of 
the organophosphorus insecticide caused an inhibition of the current induced by the 
application of 1mM ACh, with the kinetics of the inhibition consistent with the actions of a 
non-competitive inhibitor.  Interestingly it was shown that the oxon forms of malathion and 
parathion had no effect on this current, demonstrating that the thio- form of the compound 
is needed to affect the a4b2 nAChR (Smulders et al., 2004a).  Similar inhibition of the 
ACh-induced current was seen following exposure to carbamate insecticides which 
included fenoxycarb and carbaryl (Smulders et al., 2004b).  Similar inhibition of other 
nAChR (a4b4, a3b2, and a3b4) has also been reported with carbamate insecticides.  The 
rank order of potency of the compounds differed between the different receptor subtypes 
showing that the molecular biology of the receptor is important in the inhibition caused by 
carbamate insecticides (Smulders et al., 2003).  This may also be true for the 
organophosphate induced inhibition.  It has been proposed that the interaction of the 
receptor with the inhibiting compound, be it an organophosphorus or carbamate, follows a 
sequential two step process.  Firstly the inhibitor binds in a reversible non-competitive 
manner to the receptor.  This is then followed by the receptor reverting to a more stable 
blocked or desensitised state (Smulders et al., 2004a;Smulders et al., 2004b). However it 44 
is still not known if the organophosphates and carbamates are actually binding to the 
same site on the receptor or to separate sites which share similar functions.  It should be 
noted however, that the modulation of nAChR function by AChE inhibitors is only reported 
at concentrations at which there would be total inhibition of AChE (Smulders et al., 
2003;Tattersall, 1990).  Therefore this effect is likely to be of little clinical importance in the 
management of casualties. 
 
Whilst the interaction of AChE inhibitors with both types of cholinergic receptor is well 
reported, there is also evidence that some inhibitors also act directly on non-cholinergic 
receptors.  Soman (1mM, a concentration which completely inhibits AChE) has been 
reported to inhibit the NMDA-stimulated release of [
3H]noradrenaline from cortical tissue 
via stimulation of the glutamate receptor and an increase in K
+ concentration.  Similarly 
soman was also shown to inhibit release mediated by the activation of voltage gated 
sodium channels.  Application of the NMDA receptor antagonists AP5, MK801, and 
ketamine, along with the NMDA receptor-ion channel blocker Mg
2+ was shown to modify 
the soman induced inhibition, identifying possible functional sites on the receptor which 
are modified by the application of soman.  As neither atropine nor D-tubocurarine blocked 
this effect, it was concluded therefore that soman interacts directly with some of the 
modulatory sites on the NMDA receptor-ion channel complex.  This study also suggested 
an interaction between soman and voltage gated sodium channels within the cell 
membrane (Tang & Cassel, 1998). 
 
OP compounds are also reported to affect the cannabinoid CB1 receptor, which is 
prevalent throughout the CNS.  Various analogues of methylfluorophosphonate have been 
shown to act as either partial or full agonists at this receptor (Martin et al., 2000).  This is 
in addition to their ability to inhibit the FAAH and MAG hydrolase enzymes as discussed in 
section 1.5.4. 
 
1.5.6.  Gene expression 
 
Several studies that have investigated changes in RNA (mRNA and total RNA) following 
exposure to organophosphorus nerve agents (Damodaran et al., 2003;Williams et al., 
2003;Blanton et al., 2004).  Sarin has been shown to cause upregulation in the amount of 
AChE mRNA in the rat brain.  This was a rapid increase (1-2 hours following exposure) 
which persisted in the cortex, cerebellum, and hippocampus for 24 hours before returning 
to pre-exposure levels.  In the brainstem, AChE mRNA was found to be upregulated for 
more than seven days (Damodaran et al., 2003).  VX has also been shown to cause a 
rapid upregulation (1 – 2 hours post exposure) in expression of mRNA for many neuronal 
genes.  This included genes coding for b2 and a6 subunits of the nAChR, M4 subunit of 45 
the mAChR, and subunits of the GABAA, 5-HT3A, 5-HT5B receptors, as well as the KA2 
subunit of the ionotropic glutamate receptor (Blanton et al., 2004).  It should be noted 
however, that none of these studies carried out investigations into the levels of associated 
proteins.  Therefore it is unknown whether the increase in RNA expression results in a 
functional change in protein expression. 
 
Exposure to soman has been shown to cause an acute inflammatory response within the 
central nervous system (Williams et al., 2003;Zimmer et al., 1997b;Zimmer et al., 1997a).  
Following seizures, changes as early as one-hour post exposure can be seen within the 
brain, particularly in areas prone to seizure generation such as the piriform cortex.  
Zimmer et al. (Zimmer et al., 1997a) have reported that following a single exposure to 
soman (77 mg/kg i.m, 0.9 x LD50) and the resultant seizures, an increase in the levels of 
the intermediate early gene protein product, c-Fos, could be seen as early as 30 - 45 
minutes post exposure within the piriform cortex.  By 24 hours post exposure, there were 
marked neuropathological changes within this area.  This group has also shown that 
astrocytes and microglia within areas of the brain which express elevated levels of Fos 
post soman exposure such as the piriform cortex, undergo a rapid activation in response 
to the exposure (Zimmer et al., 1997b).  Microglia are considered to be one of the primary 
immune response effector cells within the central nervous system, and as such a change 
of this cell type from a resting state to an active (and morphologically different) state can 
be interpreted as an inflammatory response to an insult.  As well as the structural changes 
seen following a neuro-inflammatory response, changes in gene expression for factors 
known to be involved in an inflammatory response have also been recorded post 
exposure to soman.  This included an increase in expression of the cytokines tumor 
necrosis factor-a, interleukin-1b (IL-1b) and interleukin-6 (Williams et al., 2003).  An 
increase in the expression of IL-1b protein has also been reported in the rat brain post 
soman exposure (Svensson et al., 2005).  This is significant, as these cytokines are 
known to be involved in the activation of caspases involved in apoptotic cell death (Wang 
& Shuaib, 2002).  Similar changes in the expression of three cell adhesion molecules (E-
Selectin, intercellular adhesion molecule–1 (ICAM-1), and vascular cell adhesion molecule 
(VCAM)) have also reported (Williams et al., 2003).  
 
1.5.7.  Other identified targets/effects 
 
As well as the major targets of organophosphorus compounds identified above, other 
targets and effects caused by exposure to organophosphorus compounds have been 
identified.  As shown in section 1.5.1 one of the main actions of OP compounds is to 
phosphorylate proteins.  Whilst the phosphorylation of AChE and other cholinesterase 46 
enzymes is relatively well understood, less is known about the actions of these 
compounds on other non serine hydrolase enzymes and proteins.  An example of such a 
protein is the Ca
2+/cAMP Response Element Binding protein (CREB).  CREB is 
phosphorylated by cAMP-dependent kinases, which are in turn activated by an increase in 
synthesis of cAMP caused by activation of adenylyl cyclases.  Once phosphorylated by 
these kinases, CREB is transported into the nucleus of the cell where it acts as a 
transcription factor for many genes.  This translocation of CREB has been shown to be 
controlled (in part) by process mediated by nicotinic receptor activation (Hu et al., 2002). 
CREB has been implicated in many neuronal events such as synaptic plasticity and also 
in cell survival during development.  Chlorpyrifos oxon has been shown to increase the 
phosphorylation of this protein (Schuh et al., 2002).  It is unknown whether the increase in 
phosphorylation is deleterious to normal cell functioning, although by altering the ratio of 
CREB to phosphorylated CREB the transcription of genes necessary for synaptic function 
may be altered.  This may contribute to the cognitive deficits seen following 
organophosphate poisoning.  Alternatively, the increase in phosphorylation may be neuro-
protective as an increase in levels of phosphorylated CREB has been seen in neurones 
post-ischemia (Riccio et al., 1999).  Chlorpyrifos oxon may also alter the translocation 
process by interacting with the nicotinic receptors as previously described. 
 
Exposure to soman (110 mg/kg, ~1 x LD50) has been reported to cause various changes in 
both bone marrow and peripheral blood cells of mice that had also been treated with 
atropine methylnitrate (Collombet et al., 2005).  On the first day post poisoning, a 
significant decrease in the level of peripheral white blood cells and an increase in 
erythrocytes and platelets was reported.   This was followed by a significant decrease on 
day four post poisoning in the levels of haematopoietic progenitor and precursor cells.  
This reduction was thought to be a result of a change in the replication rate of these cells.  
Soman intoxication also caused a later increase in the circulating levels of granulocytes 
and monocytes. This may correspond with the acute inflammatory response previously 
described post soman poisoning (Williams et al., 2003).  
 
In conclusion, it can be seen that organophosphorus compounds (and some of the 
carbamate compounds used for pre-treatment) may potentially have many other far-
reaching effects which cannot be simply attributed to inhibition of AChE and subsequent 
elevation of ACh levels within the synapse.  Identification of these targets and their 
relevance to the clinical management of organophosphate poisoning remains a prime 
objective for research in this area. 
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1.6.  Medical therapies 
 
As discussed in the previous section, OP insecticides and nerve agents cause death 
primarily by inhibiting the AChE resulting in a cholinergic crisis.  Many different 
approaches have been taken in the search for effective medical countermeasures against 
these compounds, although the vast majority have concentrated on the cholinergic aspect 
of the poisoning.  There are two possible complementary avenues to the medical 
management of organophosphate poisoning.  The first approach is to treat and ameliorate 
the cholinergic crisis following poisoning.  The second uses pre-treatment with drugs that 
prevent the inhibition of AChE by the OP, which then complements the therapy approach. 
Both approaches will know be discussed in further detail. 
 
1.6.1.  Therapy 
 
The primary role of this treatment regime is to counteract the cholinergic crisis and 
prevent deterioration of the condition of the casualty until more advanced secondary aid 
can be delivered.  The build-up of unhydrolysed ACh following OP exposure results in a 
massive overstimulation of cholinergic receptors within the synapse causing the signs 
described previously.  It is generally agreed that an anticholinergic drug is the most 
important part of the post poisoning therapy and atropine is the key drug of use in the 
clinical treatment of OP poisoned casualties (Eddleston et al., 2008).  Atropine is a 
competitive non-subtype specific muscarinic antagonist that blocks the actions of the 
excess ACh within both the peripheral and central muscarinic synapses (Yamamura & 
Synder, 1974).  By blocking the muscarinic receptors, atropine ameliorates the major 
signs of the cholinergic crisis (Douglas & Matthews, 1952), although the nicotinic 
symptoms such as fasiculations remain unaffected.  In addition to this, atropine has been 
shown to be an effective terminator of OP-induced seizure activity both in vitro (Harrison 
et al., 2004) and in vivo (Shih & McDonough Jr, 1999;Capacio & Shih, 1991).  However 
there is a time limit to the effectiveness of atropine as an anticonvulsant in 
organophosphate poisoning treatment.  If atropine treatment is delayed beyond 40 
minutes post poisoning, the seizures become refractory to treatment with the 
antimuscarinic drug (McDonough Jr et al., 2000). 
  
The second component of effective post poisoning therapies is an oxime (such as 
pralidoxime or obidoxime) or oxime-like compound such as HI-6.  Oximes are highly 
nucleophilic chemical compounds that are characterised by a –CH=NOH oxime moiety 
attached to either one or two bispyridinium rings.  Oximes and allied compounds are able 
to varying degrees of efficiency to reactivate phosphorylated AChE (Smith et al., 48 
1981;Wong et al., 2000).  This is dependent upon the nucleophilic properties of the oxime 
group attached to the pyridinium ring.  The oxime group conducts a nucleophilic attack on 
the phosphorous atom in the OP-enzyme complex, producing an oxime-phosphonate in 
the process.  The formation of this conjugate reopens the active site of the enzyme to 
begin hydrolysis of ACh as usual.  However this reactivation can only occur in OP-enzyme 
complexes which have not aged (dealkylated see section 1.4).  Therefore oxime therapy 
must be initiated as soon as possible following intoxication.  A further complication is that 
the efficacy of the oxime is dependent upon the OP causing the intoxication (Worek et al., 
2007). 
 
Besides the enzyme reactivating effects attributed to these compounds, there is also 
increasing evidence for beneficial effects which are unrelated to enzyme reactivation 
(Smith et al., 1981).  There are several reports of a direct action of the oxime on the ion-
channel of the nAChR.  This is characterised as a use–dependent open-channel block 
(Alkondon et al., 1988;Alkondon & Albuquerque, 1989;Tattersall, 1993).  Tattersall (1993) 
reported that some oxime and non-oxime compounds such as TMB-4 and SAD-128 
respectively, were able to exert a direct pharmacological action that was not related to the 
AChE reactivation normally associated with these compounds.  The actions of these 
compounds were investigated using the phrenic nerve hemi-diaphragm preparation and 
single channel patch recordings of dissociated muscle cells.  It was shown that there was 
a direct correlation between the neuromuscular recovery of the hemi-diaphragm (as 
measured by recovery of the tetanic contractions of soman-poisoned diaphragms) and the 
level of channel block caused by the compounds.  In the single channel recordings these 
compounds were shown to cause a rapid flickering block of the channel openings.  This 
would have the effect of decreasing the mean current flow through the ion channel without 
altering the burst opening length or channel activation.  This then may relieve some of the 
effects caused by receptor overstimulation following the accumulation of ACh within the 
synapse post poisoning (Tattersall, 1993).  A different mechanism has also recently been 
put forward.  This study found that the noncompetitive block was responsible for restoring 
the decay of the endplate current allowing repolarisation of the endplate to occur.  This is 
in turn relieved the depolarisation block (Turner, 2007). 
 
The use of a benzodiazepine anticonvulsant (such as diazepam) is indicated for use post 
OP poisoning.  Benzodiazepines act by increasing the mean open time of the chloride 
channel formed by the GABAA receptor (Twyman et al., 1989).  The increased influx of 
chloride ions into the cell increases the hyperpolarisation of the membrane, making the 
cell less likely to depolarise and fire an action potential.  The electrographic seizures seen 
during the later stages of acute organophosphate intoxication are the result of excessive 
hypersynchronus discharges from populations of neurons within the brain.  Diazepam and 49 
other benzodiazepines have been shown to be effective in controlling the seizures caused 
by organophosphate intoxication even when administered up to 40 minutes post poisoning 
(McDonough Jr et al., 2000).  As already mentioned in the previous section, the early 
termination of these seizures is critical for the prevention of neuropathology and enhances 
the long term prognosis of the casualty (Shih et al., 2003). 
1.6.2.  Pretreatment 
 
As previously stated, the main target of organophosphates is the AChE enzyme.  
Inhibition of this enzyme causes the majority of the symptoms of the acute cholinergic 
crisis seen following poisoning with OP insecticides or nerve agent.  Protection of AChE 
by some means would allow neurotransmission to continue.  One approach has been to 
use a reversible inhibitor of ACh to sequester a pool of the enzyme.  The reversible 
binding of a carbamate to the active site of AChE will prevent the binding of an OP 
inhibitor to that site, thereby protecting the site from irreversible inhibition.  Carbamates 
such as physostigmine and pyridostigmine bind to the esteratic site of AChE thereby 
prevent the binding of ACh and the subsequent hydrolysis of the transmitter molecule.  In 
terms of pre-treatment it can then be seen that any circulating nerve agent will also be 
unable to bind to the active site of the enzyme molecule bound to a carbamate.  Therefore 
a pool of AChE will be protected from the nerve agent challenge.  The process of 
decarbamylation of the enzyme and subsequent hydrolysis of the carbamate inhibitor is 
relatively slow, and the entire process may take in excess of 4 hours to complete 
depending on which carbamate was being used. The newly decarbamoylated enzyme 
would then be free to hydrolyse ACh in the usual manner.  It must be remembered that 
the decarbamolyation/hydrolysis process will be ongoing during the peak concentration of 
the OP and this helps to maintain a level of AChE, which may be able to hydrolyse the 
excess ACh present within the synapse.  This approach was first demonstrated in 1946 by 
Koster, who showed that pretreating cats with the carbamate, physostigmine, prior to 
exposure to di-isopropylflurophosphate (DFP) protected cholinesterase activity post 
exposure to the OP (Koster, 1946). 
 
Physostigmine has many unwanted side effects however, such as nausea (due in part to 
its CNS action), which preclude it from effective use as a pretreatment for OP poisoning.  
Therefore another candidate was required.  Pyridostigmine, which has a long clinical 
history in the management of myasthenia gravis (Mestinon®), has also been found to 
provide protection against nerve agent-induced lethality when given as a pre-treatment to 
experimental animals prior to exposure.  The current in service provision is that one  
31.5mg tablet of pyridostigmine is taken at 8 hour intervals prior to a potential use of nerve 
agents, or during an attack (maximum of 94.5mg per 24 hour period).  The dose is set so 
that approximately 30% of the AChE enzyme is inhibited (Lennox et al., 1985), this is 50 
much lower than that used to treat myasthenia gravis in which individual doses can range 
between 30 and 120 mg with a maximum daily dose of 0.3 to 1.2g (Joint Formulary 
Committee, 2008).  Whilst it is highly effective in protecting peripheral enzyme from 
inhibition by organophosphates, pyridostigmine being a quaternary compound does not 
penetrate the blood-brain barrier under normal circumstances and therefore is better 
tolerated with fewer side effects than physostigmine.  Pyridostigmine has however, been 
reported to cross the blood-brain barrier and cause regional brain AChE inhibition in 
animal models following exposure to stressors such as electrical shocks and forced swim 
tests (Beck et al., 2003;Friedman et al., 1996).  This finding is however extremely 
controversial however, and there are many other reports showing that stress does not 
facilitate the penetration of pyridostigmine into the brain (Song et al., 2002;Lallement et 
al., 1998). Indeed, in some cases, stress may even cause changes within the blood-brain 
barrier which actually reduce the permeability of the barrier to pyridostigmine (Sinton et 
al., 2000).  It is apparent that the disputed penetration of pyridostigmine into the brain is 
very much dependent on the species and the nature of the stressor used. 
 
Whilst pyridostigmine is effective at providing protection against the lethal effects of nerve 
agent exposure, it does little to counter the incapacitation seen post poisoning.  Nerve 
agent induced incapacitation is believed to be caused in part by inhibition of AChE within 
the central nervous system.  Therefore the current research effort is focussing on the use 
of a centrally active cholinesterase inhibitor such as physostigmine for use as a pre-
treatment.  Whilst physostigmine was one of the first carbamates to be shown to protect 
AChE against inhibition, it was found to have undesirable muscarinic side effects.  Co-
administration of physostigmine with the muscarinic antagonist scopolamine (hyoscine) 
has been shown to reduce the occurrence of the side effects.  This pre-treatment 
combination has been shown to be highly effective in preventing lethality and minimising 
the severity of the incapacitation following nerve agent exposure (Miller et al., 
1993;Wetherell et al., 2002). 
 
Whilst pre-treatments such as pyridostigmine are highly effective in helping to protect 
AChE against the actions of nerve agents, they are only effective if given prior to 
poisoning and a sufficient period of time has elapsed to allow the drug to have an effect.  
If neither of these factors have occurred then the pre-treatment regime is of little or no use 
(Gordon et al., 1978). 
 
1.6.3.  Current and future nerve agent therapies 
 
Currently, the UK armed forces are equipped with pyridostigmine bromide (31.5mg) as a 
pre-treatment (Figure 1.10, Nerve Agent Pre-treatment Set (NAPS)), and a triple 51 
component emergency therapy packaged within an auto-injector (Figure 1.11, 
Combopen®).  The UK Combopen contains 2mg atropine, 500mg pralidoxime 
methanesulfonate (P2S), and 10mg avizafone.  NAPS is taken prior to a potential nerve 
agent attack, with the Combopens used to counteract the effects of nerve agent poisoning 
and prolong life until the casualty can be removed to a clinical environment where 
secondary supportive care can be initiated.  Avizafone is a water-soluble lysine conjugate 
pro-drug of diazepam which allows the three components of the therapy to be prepared in 
water, making the Combopen easier to store and use. 
 
The development of effective medical countermeasures to nerve agent poisoning is an 
ever evolving process.  The ultimate goal is a single shot therapy which has little or no 
reliance on pretreatment and which protects against both the lethal and incapacitating 
effects of nerve agents.  The possible use of physostigmine as a component of the next 
generation of nerve agent therapies has once again been revisited.  Whilst the current 
therapy is highly effective at preventing nerve agent induced lethality, there is still a level 
of incapacitation.  Physostigmine when given in conjunction with scopolamine as a 
pretreatment is more effective at preventing incapacitation and lethality in guinea pigs 
challenged with a variety of nerve agents (Wetherell et al., 2002;Miller et al., 1993).  The 
combination of scopolamine and physostigmine with the oxime HI-6 in a post poisoning 
therapy has also been evaluated.  This combination also alleviated much of the 
incapacitation seen post subcutaneous poisoning (Wetherell et al., 2007;Wetherell et al., 
2006).  The addition of physostigmine to an already AChE compromised system would at 
first seem counterintuitive.  It is hypothesised that the addition of scopolamine counters 
the central muscarinic effects of the cholinergic crisis until such point as physostigmine 
protected AChE is released.  The oxime HI-6 is postulated to have two distinct actions.  
Firstly it regenerates inhibited AChE, and secondly it may have direct actions on the 
nAChR thus alleviating the neuromuscular block seen post nerve agent poisoning 
(Tattersall, 1993).  The structures of existing and putative replacement compounds for 
treating nerve agent poisoning are shown in Figure 1.12. 52 
 
 
Figure 1.10.  Nerve agent pre-treatment set (NAPS). 
This is currently in service with the United Kingdom armed forces (NAPS L1A1).  This 
is a set of 21 tablets each containing 31.5 mg pyridostigmine bromide.  The individual 
would commence taking the tablets when ordered to, based upon intelligence about 
the likelihood of contact with a nerve agent. 53 
 
 
Figure 1.11.  The Combopen (L4A1).   
This is the current in-service medical countermeasure for use post-exposure to nerve 
agents.  It is an autojector device which contains 2mg atropine, 500mg P2S, and 
10mg avizafone (lysine-conjugated diazepam) to be administered by intra-muscular 
injection. The top Combopen shows the device in its stored state.  Before use, the 
grey safety cap must be removed (middle Combopen).  The Combopen is now armed 
and is deployed by pushing the black end of the pen firmly against the thigh and 
holding it there until the injection is complete (5 seconds).  The bottom Combopen 
shows the spring-loaded injection needle that is exposed during the injection. 
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Figure 1.12.  Structures of current and proposed components of nerve agent 
pretreatment and therapy treatment sets. 
 
1.7.  In vitro models 
 
The aim of this study is to develop an in vitro model which will be used to investigate the 
central actions of OP AChE inhibitors.  Currently, there is a paucity of good models in 
which to study these actions.  The selection of possible models for this study has been 
based on a number of criteria.  These included ease of preparation of the model, the 
model having a good intrinsic cholinergic network, the model exhibiting a well-defined 
cholinergic response that can be modulated by anticholinesterases (preferably without the 
need to apply exogenous cholinergic agonists).  The ability of anticholinesterase 
compounds to modulate the response recorded from the model is important as this more 
closely mimics the normal functioning of the brain, relying on existing levels of the 
endogenous cholinergic agonist rather than the effects of exogenous agonists artificially 
applied.  The final requirement of a suitable model is the possible involvement of the area 
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in either incapacitation or lethal effects of organophosphate poisoning.  This section will 
look at several candidate models in more detail. 
 
1.7.1.  Supraoptic Nucleus 
 
The supraoptic nucleus (SON) is situated at the base of the forebrain and is responsible 
for controlling the release of vasopressin and oxytocin.  Intracellular recordings from this 
area have shown that nAChRs mediate synaptic potentials elicited by paired pulse 
stimulation (Hatton & Yang, 2002).  The synaptic potentials were blocked by 
methyllycaconititine (MLA) and a-bungarotoxin (a-BGT), both selective for neuronal a7 
nAChR at the concentrations used, whereas dihydro-b-ethroidine (DHbE), an antagonist 
of a4b2 nAChR, had no effect.  Hatton and Yang also reported dense a-BGT binding in 
dendritic layer and glial lamina of the SON, suggesting a dense population of nAChRs 
(primarily a7).  ACh when applied to neurones within this nucleus has also been shown to 
decrease the inhibition of the local network mediated by the release of GABA.  ACh 
(100mM in the presence of TTX and CNQX) significantly decreased the frequency of 
miniature inhibitory postsynaptic currents (mIPSC) occurrence with no change in the 
amplitude of the events.  The ACh induced decrease in mIPSCs was not affected by the 
addition of atropine and therefore was not mediated by mAChR, but it was blocked by the 
non-specific nAChR antagonist mecamylamine.  Mecamylamine had no effect by itself on 
the appearance and kinetics of the mIPSCs (Li et al., 2001). 
 
As a model, the SON allows a fast nicotinic response to be investigated in a slice that also 
retains the cholinergic input from the diagonal band of Brocca.  Similar nicotinic responses 
may be present elsewhere in the brain in structures more involved in incapacitation, but 
are not as amenable to slice recording. 
 
1.7.2.  Frontal Cortex 
 
The frontal neocortex has been exploited in much the same way as the work conducted in 
the SON as previously described.  Using whole cell patch and intracellular recording 
techniques, a nAChR-mediated fast synaptic potential can be recorded from layer II/III 
pyramidal neurones.  This was resistant to blockade by both excitatory amino acid (EAA) 
antagonists and the GABAA antagonist, bicuculline methyliodide (BMI).  Currents evoked 
by electrical stimulation were reduced by around 50% in the presence of either 100mM 
DHbE or 50mM MLA.  The anticholinesterase neostigmine (10 mM) prolonged the decay 
time constant of the EAA-resistant EPSC.  The evidence presented all points to a nAChR 
controlling this current, although the exact identity of the nAChR cannot be deduced due 56 
to the high concentration of DHbE used.  It has also been suggested that the potentials 
recorded may in fact originate from more than just one excitatory transmitter system and 
may not necessarily solely be mediated by the nicotinic acetylcholine receptor (Chu et al., 
2000).  
 
1.7.3.  Nucleus Accumbens 
 
The nucleus accumbens (NAcc) forms part of the ventral striatum and acts as an interface 
between many portions of the limbic system, including the hippocampus, prefrontal cortex 
and the amygdala.  The NAcc has a primary output into the adjacent ventral pallidum, 
which is involved in the activation and regulation of voluntary movements.  The amplitudes 
of glutamatergic EPSCs recorded from the NAcc were decreased when ACh or carbachol 
was bath applied in the presence of BMI.  Conversely, in the presence of atropine, the 
application of ACh resulted in an increase in the amplitude of the glutamatergic EPSC.  
This was mimicked by the application of DMPP (a nicotinic agonist) and blocked by 
mecamylamine (Zhang & Warren, 2002).  A combined slice incorporating the NAcc and 
the forebrain has also been used to investigate spontaneous epileptiform activity (caused 
by the application of BMI or picrotoxin) originated in the cortex (most likely from the 
adjoining piriform cortex) (Buckby & Lacey, 2001).  Whilst this does not truly meet the 
requirements for a suitable slice model for the current project, it is interesting because it 
demonstrates a biphasic cholinergic effect on the main excitatory glutamatergic drive of 
this brain region.  This may be important in the secondary phase of nerve agent induced 
seizures, in which it is known that other neurotransmitter systems (including glutamate) 
are recruited to maintain the epileptiform activity (McDonough Jr & Shih, 1997).  
 
1.7.4.  Substantia Nigra 
 
The substantia nigra (SN) forms part of the basal ganglia within the mammalian brain, and 
is involved in motor control.  Structurally it can be split into two adjoining areas: the 
substantia nigra pars reticulata (SNr) and the substantia nigra pars compacta (SNc). The 
SN receives cholinergic inputs from the pedunculopontine nucleus and has projections to 
the striatum.  Neurones within the SN are lost during the progression of Parkinson’s 
disease leading to the overt motor control problems that are symptomatic of the disease.  
A horizontal slice preparation which contained the SN and other surrounding structures 
has been used to investigate the effects of applied nicotine on the release of dopamine 
from neurones within the SN (Matsubayashi et al., 2003;Matsubayashi et al., 
2004a;Matsubayashi et al., 2004b;Yu et al., 2000).  Nicotine, when bath applied to 
dopaminergic neurones that are held in the whole cell patch current clamp configuration, 57 
caused a depolarisation of the membrane potential.  This resulted in an increase in 
spontaneous firing of the cell, which was independent of the external calcium ion 
concentration.  The inward current seen during the application of nicotine could be 
blocked by the application of DHbE showing that the current was mediated by the a4b2 
nAChR (Matsubayashi et al., 2003).  Spontaneous miniature inward postsynaptic currents 
were also recorded from dopaminergic neurones within the SN. In the presence of 
atropine (mAChR antagonist), BMI (GABAA antagonist, l-glutamic acid diethyl ester 
(GDEE, a non-selective glutamate antagonist), and TTX it was shown that application of 
either MLA or DHbE could reduce this activity, demonstrating that the activity was 
mediated by a7 and a4b2 nAChRs, respectively (Matsubayashi et al., 2004a).  The same 
group have shown by single-cell polymerase chain reaction (PCR) that the mRNAs coding 
for a4b2 and a7 nAChRs are present within the dopaminergic neurones of the SN 
(Matsubayashi et al., 2004b). 
 
1.7.5.  Hippocampus 
 
The hippocampus is a part of the limbic system that lends itself well to in vitro studies as it 
has a well-defined structure with good delineation of cellular areas.  It is thought to be 
involved in the encoding of memory (Teyler, 1987;Bliss & Collingridge, 1993), and is 
involved in some epileptiform seizures (Coulter, 1999).  At present the hippocampal slice 
is the primary in vitro model used to study the effects of nerve agents (Wood & Tattersall, 
2001;Chebabo et al., 1999;Harrison et al., 2000;Harrison et al., 2004) on the central 
nervous system.  It has also been widely used as a neurotoxicity screen (Fountain et al., 
1992), to study the cellular mechanisms of memory (Yamamoto & Chujo, 1978;Bliss & 
Collingridge, 1993) and epileptogenic seizure activity (Rutecki et al., 1985;Bradford, 
1995).  The hippocampus whilst not having an intrinsic cholinergic pathway, does receive 
cholinergic innervation from the septal nucleus and the diagonal band via the fimbria 
(Lewis et al., 1967;Liu et al., 1998), as well as via the entorhinal cortex (Colgin et al., 
2003).  During preparation of the slice however, the majority of this innervation is severed 
leaving only the distal terminals of the cholinergic afferents from the septal nucleus and 
the diagonal bandransection of this septo-hippocampal pathway in vivo, causes the 
almost complete loss of acetylcholinesterase and ChAT within the hippocampal 
formation(Lewis et al., 1967).  Although the main cholinergic innervation is lost, there are 
still cholinoceptive cells that remain viable within the slice.  The majority of these are 
GABAergic inhibitory interneurones that synapse onto either other interneurones, or onto 
the excitatory glutamatergic pyramidal cells.  The interconnectivity of the inhibitory 
interneurones provides a complex modulation of the output of the local neuronal 
population (Buhler & Dunwiddie, 2001).  It has been shown that nicotinic acetylcholine 58 
receptors (especially a7) can be found in clusters on hippocampal interneurons (Kawai et 
al., 2002).  Studies have also shown that it is the a7 nAChR which is largely responsible 
for the cholinergic modulation of the inhibitory interneuron network, and has been shown 
to be involved in the inhibition and disinhibition of the pyramidal cells (Ji & Dani, 2000). 
The a4b2 nAChR has also been reported to modify the level of inhibition of the 
GABAergic interneurones to a different degree than that caused by a7 nAChR activation 
(Alkondon & Albuquerque, 2001).  It has also been shown that a small population of 
exclusively cholinergic interneurones exists within the rodent hippocampus, although the 
exact function of these neurones is still unknown (Frotscher et al., 2000).   
 
Organotypic slices of the hippocampus have been developed which allow longer-term 
studies to be conducted (Gähwiler, 1988); however, the organotypic hippocampal slice 
shares the same major shortcoming as the acute slice model, namely that the cholinergic 
(and GABAergic) afferent innervation is severed during preparation and undergoes 
subsequent axonopathy during culturing. The loss of the cholinergic afferents has been 
overcome by co-culturing an explant of the septal nucleus with the hippocampus.  This 
has resulted in a viable cholinergic (Gähwiler & Brown, 1985) and GABAergic (Heimrich et 
al., 1996) reinnervation of the hippocampus, mimicking the in vivo septo-hippocampal 
pathway.  
  
Another major part of the hippocampal formation is the dentate gyrus.  This area is 
innervated mostly by the medial and lateral perforant pathways arising in the adjoining 
entorhinal cortex, and also by afferents arising in the septal nucleus.  The principal cell 
type of the dentate gyrus is the granule cell.  The majority of the granule cell bodies are 
located in the granule cell layer of the dentate gyrus with their dendrites extending 
throughout the molecular layer, although ectopic granule cells have also been reported in 
the polymorphic layer of the dentate gyrus (Scharfman et al., 2003;Scharfman et al., 
2007).  Granule cells have been shown to release glutamate following their stimulation by 
the afferent fibres of the perforant path (Scharfman et al., 1990).  There is also a body of 
evidence showing that these cells also express GAD (required for the synthesis of GABA) 
during early development stages, with the expression of the GABAergic phenotype 
decreasing rapidly during the maturation of the dentate gyrus.  Also, the expression of the 
GABAergic phenotype can be upregulated by events such as seizures (Gutiérrez, 2003).  
The dentate gyrus has a long history of being used as a model to study complex activity 
within the brain.  An example of this is long term potentiation (LTP) which is thought to 
underlie some of the processes involved in memory formation and was first demonstrated 
in the perforant pathway (Bliss & Lomo, 1973).  It has been reported that the evoked 
response (glutamatergic) of cells within the molecular layer of the dentate gyrus can be 
modulated by application of the AChE inhibitor physostigmine (Colgin et al., 2003).  59 
Application of 5mM physostigmine caused a decrease in the magnitude of the fEPSP 
amplitude and slope that persisted after washing off the inhibitor.  The effect of 
physostigmine was blocked by atropine showing that the effect was mediated by a 
muscarinic cholinergic receptor.  Similarly, incubation with the cannabinoid CB1 receptor 
antagonist AM251 prior to the application of physostigmine also prevented the decrease in 
response.  Interestingly, the decrease in the fEPSP following the application of 
physostigmine was not observed in slices taken from animals that had received lesions of 
the septal-hippocampal pathway.  This implies that the cholinergic input must arise from 
the septal nucleus/diagonal band complex (Colgin et al., 2003).  This is therefore an 
endogenous cholinergic response which can be modulated by anticholinesterases, and 
therefore fulfils the criteria as laid out in the introduction to this section. 
 
1.8.  Model selection  
 
Historically the actions of organophosphorus compounds such as nerve agents have been 
mainly studied using in vivo models and in vitro models utilising peripheral nerve-muscle 
preparations.  In contrast to this there are very few good in vitro models of central actions 
of nerve agents: in vitro studies of cholinergic systems have almost exclusively used 
application of an external cholinergic agonist such as carbachol to elicit the cholinergic 
response rather than rely on an innate source.  In order to study the effects of 
cholinesterase inhibitors, a suitable model should have an intrinsic cholinergic response.  
Alternatively, a suitable model should exhibit an effect that is in direct response to the 
application of nerve agent.  In this study, the hippocampal slice, specifically the dentate 
gyrus will be used.   
 
1.8.1.  Approach and selection 
 
Due to the nature of the funding of this PhD and the associated customer requirements 
(the work was conducted as part of a customer programme for the Defence Technology 
and Innovation Centre), a pragmatic approach to the selection of the model was taken to 
increase the likely success of this project.  Factors for consideration include the recording 
techniques required, intricacy of the preparation of the slice, stability, and the number of 
slices obtained per animal (acute slices only).  The quality and magnitude of the reported 
cholinergic effect was also considered.  Ideally the selected model would be relatively 
easy to prepare, stable over many hours, with multiple slices being obtained from each 
animal allowing maximum benefit from its use.  The models described in 1.7 were 
assessed against these criteria.   
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The supraoptic nucleus slice model was discounted as it required exogenous cholinergic 
agonists to be applied to show a full response.  Also due to the size of the structure, only 
one slice can be reliably produced per animal which increases the technical risk.  This 
would also increase the number of animals used during the study.  In contrast, the size of 
the NAcc and SN structures allow several slices to be prepared from each animal.  This 
has the obvious benefit of reducing the total number of animals used.  Again, both of 
these models rely on the application of exogenous cholinergic compounds to elicit a 
response and so were discounted.  The frontal cortex model has the benefit of allowing 
many preparations to be obtained from a single animal.  Also the nicotinic responses as 
described can be elicited by electrical stimulation and not by applied exogenous agonists 
which is again one of the criteria for selection.  As such this would make the frontal cortex 
a suitable model for this project.  However the hippocampus was chosen in preference 
due to its well documented anatomical structure and pathways. 
 
The dentate gyrus model has been shown to retain an intrinsic cholinergic response 
(Colgin et al., 2003), which allows the classical effects of nerve agents i.e. inhibition of 
AChE, to be studied in a CNS preparation without the need to employ exogenous ACh.  
The hippocampal slice is also relatively easy to produce with many being obtained from a 
single animal thereby reducing the total number of animals used.   Previous work has  
reported that the intrinsic response could be measured using extracellular recording 
techniques (Colgin et al., 2003).  This indicates that the dentate gyrus is well suited to the 
proposed investigation.  For these reasons, the dentate gyrus slice model will be used 
during this study. 
 
1.9.  Aim of the study 
 
As stated in section 1.6.3, physostigmine is once again being investigated as a 
component of the next generation of nerve agent therapies.  Physostigmine has shown 
promise as both a pretreatment and post poisoning therapy when used in conjunction with 
scopolamine.  However, the mechanism by which physostigmine is exerting its effect is 
unclear.   
 
This project will test two hypotheses.  Firstly, it is hypothesised that physostigmine is an 
effective pretreatment for nerve agent poisoning and secondly, that physostigmine acts by 
sequestering a pool of AChE and protecting it from subsequent irreversible inactivation by 
nerve agent. 
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To allow both hypotheses to be tested, the dentate gyrus model has been developed and 
the cholinergic response characterised.  Initially the project sought to confirm the findings 
reported previously in the rat dentate gyrus (Colgin et al., 2003).  After confirming the 
results of Colgin et al., subsequent experiments were conducted in dentate gyrus slices 
from the guinea pig.  The guinea pig has been identified previously as being more suitable 
than the rat for predicting the efficacy of nerve agent treatments in primate species 
(Dirnhuber et al., 1979;Berry & Davies, 1970;Inns & Leadbeater, 1983;Gordon et al., 
1978).  One reason for this could be due to species differences in the activity levels of the 
enzyme carboxylesterase.  It has been reported that the activity of this enzyme in rat 
tissues is consistently higher than that measured in guinea pigs and marmosets (de Jong 
et al., 1993).  In this regard the guinea pig is closer to man (Li et al., 2005), and is 
therefore considered to be a better model of nerve agent toxicity.  This is important as 
carboxylesterase binds to OP compounds and nerve agents in a similar manner to AChE.  
Higher levels of activity of this enzyme will therefore mask the true extent of OP-AChE 
interactions.  
 
Following successful development of the model in the guinea pig dentate gyrus slice, the 
interactions between physostigmine and the nerve agent sarin were investigated  The 
dentate slice model is better suited to investigate these interactions than a whole animal 
model, due to the level of control the experimenter has over the available concentrations 
of both compounds.  The importance of the time of application of physostigmine relative to 
sarin and concentration of physostigmine was investigated and a correlation was 
established between the electrophysiological response and tissue ChE activity in slices 
treated with nerve agent.   62 
2.  Materials and Methods 63 
2.1.  Dentate gyrus slice model 
 
2.1.1.  Animal welfare 
 
All procedures involving the use of animals were carried out under a relevant Home Office 
licence and in accordance with the Animals (Scientific Procedures) Act 1986. 
 
2.1.2.   Rat hippocampal slices 
 
Male Porton-Wistar rats (130–260g, Animal Services, Dstl Porton Down) were 
anaesthetised with halothane and killed by decapitation.  The brain was then cleared of 
overlying meninges and dissected free from the skull.  Upon removal the brain was placed 
into an ice cold cutting solution artificial cerebrospinal fluid ( cutting ACSF) containing in 
mM, 189 Sucrose, 3 KCl, 5 MgCl2, 1.2 NaH2PO4, 0.1 CaCl2, 26 NaHCO3, 10 D-glucose 
(gassed with 95% O2, 5% C02).  The brain was then hemisected into two blocks of tissue 
(one for each hemisphere).  Horizontal slices (300 mm thickness) through the tissue block 
were then prepared using a Vibratome (Intracel, Royston, UK) whilst bathed in ice cold 
cutting ACSF.  Slices were then stored in a holding chamber (BSC-PC, Medical Systems 
Corp) at room temperature in an ACSF solution, containing in mM, 120 NaCl, 3 KCl, 1.3 
MgCl2, 1.2 NaH2PO4, 2.4 CaCl2, 26 NaHCO3, 10 D-glucose, (gassed with 95% O2, 5% 
C02).  This solution was also used as the perfusate during recordings. 
 
2.1.3.   Guinea pig hippocampal slices 
 
Male Dunkin Hartley guinea-pigs (300-400g, Harlan UK) were anaesthetised with 
halothane and killed by decapitation.  The brain was the removed as described for the rat 
hippocampal slices.  Both hippocampi were then dissected free from the surrounding 
cortical tissue.  Each hippocampus was then trimmed at both the septal and temporal 
extremities leaving a central block of the hippocampus.  This was then mounted onto a 
vibratome chuck and 300mm thick transverse slices were cut using a Vibratome.  All other 
details for the preparation of the guinea-pig hippocampal slices were identical as those 
detailed above for preparation of rat hippocampal slices.  The unused hippocampus was 
retained for subsequent cholinesterase activity assays. 
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2.1.4.   Extracellular recording 
 
Slices were left to recover for at least 1 hour before being transferred to a recording 
chamber (Zbisc chamber, Medical Systems Corp., New York, USA), where they were 
submerged and continually superfused (10 – 15 ml min
-1) with gassed recording ACSF at 
31° C (± 0.5° C, temperature controlled using an inline heat er (SH-27B Warner Instrument 
Corp., USA).  During equilibration, baseline and drug applications the perfusing ACSF 
was recirculated through the bath.  Following a further equilibration period of 30 minutes, 
a bipolar stimulating electrode (MCE-100, Harvard Apparatus, UK) was placed within the 
molecular layer of the dentate gyrus in a position approximate for the perforant pathway.  
A single glass extracellular recording pipette electrode (GC-150F (Harvard Apparatus, 
Edenbridge, UK) pulled using a Sutter P-97 Flaming/Brown micropipette puller (Sutter, 
Novato, Ca., USA) was also placed within the molecular layer of the dentate gyrus 
(approximate positions shown in Figure 2.1).  The extracellular electrodes had tip 
resistances of between 2 and 9MW when filled with 2M NaCl.  The slice was stimulated 
once every 30 seconds (pulse width 200 msec, amplitude 180 – 300mA) and the amplitude 
of the evoked fEPSP was maximised by lowering the recording electrode into the slice 
until the response was maximal.  Following optimisation of the response, the threshold 
and maximal stimulation currents were determined.   
 
Using paired pulse stimulation (interpulse interval 50ms, stimulation current 90-150µA) the 
portion of the perforant pathway being stimulated was identified.  It has been shown that 
paired-pulse stimulation of the medial portion of the perforant pathway results in an 
inhibition of the second evoked fEPSP.  Conversely, if the lateral perforant pathway is 
being stimulated a facilitation of the second evoked fEPSP is seen (McNaughton & 
Barnes, 1977).  The medial perforant pathway was used exclusively during these studies 
as it had been shown previously to be more sensitive to the actions of anticholinesterase 
compounds (Colgin et al., 2003) 
 
Following identification of the portion of the perforant path, the slice was stimulated every 
30 seconds with stimulus amplitude that gave a response of approximately 70% of the 
maximal response previously determined.  Stimulating the slice in this manner facilitated 
the production of stable fEPSPs.  Baseline fEPSPs were recorded for at least 30 minutes 
before any compounds that were under investigation were applied to the slice.  Slices 
which exhibited a ±10% change in fEPSP amplitude during the baseline period were 
excluded from future analysis. 
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Figure 2.1.  Position of the stimulating (●) and recording electrode (*) within the 
dentate gyrus.   
This positioning allows stimulation of the medial perforant pathway and also recording 
of fEPSPs from the dendritic field of the molecular layer of the dentate gyrus. 
 
2.1.5.   Drug application 
 
All compounds were added to the recording solution reservoir and allowed to perfuse for 
the required time.  This solution was recirculated unless otherwise stated.  Test 
compounds were removed by perfusing the slice with prewarmed and gassed drug-free 
ACSF.  This wash solution was not recirculated and was allowed to drain into a collection 
vessel for disposal.  Cumulative dosing was not used unless otherwise stated.  
 
Time matched controls and vehicle controls were also carried out throughout the studies 
and were interleaved with appropriate treatment groups.  For vehicle controls a 
concentration of the vehicle (dimethyl sulfoxide (DMSO) or ethanol), equivalent to that 
used to dissolve the maximum concentration of drug used was added to the reservoir.  
The maximum final bath concentration of the vehicles used was 0.06% DMSO and 0.10% 
ethanol. 
 
2.1.6.  Data capture and analysis 
 
The programme LTP (v.2.30D, www.ltp-program.com (Anderson & Collingridge, 2001)) 
was used to control the stimulus, capture data and perform on- and off-line analysis.  Data 
were captured at 10 kHz via an ADC-42 interface board (Pico Technologies Ltd, St. 
Neots, UK).  Amplification of the signal was carried out using an AC-DC amplifier 
(Neurolog NL106, Digitimer, Welwyn Garden City, UK) and an Intra 767 electrometer 
(World Precision Instruments, Stevenage, UK) with a final gain of 500x  DC.  The 66 
amplitude of the stimulus was set using a NeuroLog NL510 system (Digitimer).  Both the 
NL106 and NL510 were housed in a Neurolog NL900D (Digitimer).   
 
The LTP software program was used to measure two parameters of the fEPSP during 
data capture and off-line analysis.  The first parameter measured was the amplitude of the 
fEPSP defined as the maximum deflection between the two time points approximate for 
the start and end of the fEPSP (typically measured between 1 and 20ms after the start of 
the stimulus).  This is shown in Figure 2.2.  The second parameter was the initial slope of 
the fEPSP.  This was done by fitting a line to the computer generated representation of 
the captured fEPSP.  An example is also shown in Figure 2.2.  The slope of the fEPSP 
was measured as this can be interpreted as a good measure of synaptic strength.  The 
initial slope is also less likely to be contaminated by other currents (such as those 
produced by feed forward GABAergic inhibitory interneurones) which may reduce the 
amplitude of the response.  Data were then exported into Microsoft Excel 2003 (Microsoft 
Corporation, USA) and then into GraphPad Prism v.4.00 for Windows (GraphPad 
Software, San Diego, USA, www.graphpad.com) for further analysis. 
 
B
A
 
 
Figure 2.2.  Example of a fEPSP and the parameters measured using LTP.  
(A) amplitude is measured between the maximum extent of the negative spike and a 
datum drawn across the top of the deflection.  (B) the slope of the initial negative 
component of the fEPSP is measured as shown.  Vertical scale bar 1.0mV, horizontal 
scale bar 25ms. 
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2.2.   Cholinesterase assay  
 
Guinea-pig hippocampi were used to determine the profile of inhibition of brain 
cholinesterases by the nerve agent sarin.  Whole hippocampi were removed as described 
in section 2.1.3.  The tissue was then chopped using a McIlwain tissue (Mickle Laboratory 
Engineering Co. Ltd, Gomshall, UK) chopper to a thickness of approximately 300µm.  The 
chopped tissue was then held in a mesh bottomed chamber which was suspended in a 
known volume of recording ACSF.  This solution was held at room temperature and was 
gassed with 95% O2, 5% C02.  Sarin was then added to the ACSF to give the required 
final concentration (either 0.01, 0.03, 0.10, 0.30 or 1.00µM).  This was left in the chamber 
for 10 minutes, after which time the ACSF was exchanged for sarin-free ACSF.  After 
another 2 minutes, the hippocampal tissue was removed and placed into an eppendorf 
tube.  Excess fluid was removed and the tissue was frozen at -80ºC until required for 
assay.  Prior to assay samples were allowed to thaw out at room temperature for 30 
minutes.  Each tissue sample was homogenised in a volume of pH8 phosphate buffer to 
give a 10mg/ml tissue suspension, using a motorised pestle homogeniser (Heidolph, 
Wakefield, UK).  
 
The assay used to determine the activity of cholinesterase is based on that described by 
Ellmann (Ellman et al., 1961).  Briefly acetylthiocholine is hydrolysed by active 
cholinesterase to yield thiocholine.  This reacts with dithiobis(nitrobenzoate) (DTNB) to 
yield 5-thionitrobenzoate.  The rate of production of this reaction product is then measured 
using a spectrophotometer at 412nm.  For this assay 500µl of 3mM acetylthiocholine was 
added to 500µl of 250µM DTNB in a 2.5ml cuvette.  400µl of pH 8 phosphate buffer was 
then added before 100µl of the 10mg/ml tissue sample was added.  The cuvette contents 
were then mixed thoroughly.  The rate of reaction was measured at 412nm using a 
spectrophotometer (Libra S22, Biochrom Ltd, Cambridge, UK) set to record the 
absorbance at 10 second intervals over a 180 second run time.  Each sample was run in 
triplicate and each concentration of sarin was repeated twice.  Control slices which 
received no sarin were also carried out.  The reaction rates obtained from this protocol 
were then corrected for the amount of protein present in the sample.  The amount of 
protein was determined using the protocol in section 2.3.  All assays were conducted at 
room temperature. 
2.3.  Protein determination 
 
The amount of protein present within the 10mg ml
-1 tissue homogenate sample was 
determined using a modified Lowry assay (Lowry et al., 1951).  A detailed description of 
the method used is included in appendix A.  The absorbance of the reaction product was 
measured at 700nM using a spectrophotometer (Libra S22).  A standard curve using 68 
known concentrations of protein (bovine serum albumin) was constructed to determine the 
amount of protein in the tissue homogenates.  
 
2.4.  Drug and reagent supply 
 
The nerve agent sarin was synthesised by the Detection Department, Dstl Porton Down.  
This was supplied as a 5mg/ml solution diluted in isopropyl alcohol.  The purity of this 
solution was ≥98.0%.  A 1mM stock solution was made immediately prior to use and was 
diluted as required with a small volume of the recording ACSF. 
 
All other drug compounds and reagents were obtained from Sigma-Aldrich (Poole, Dorset, 
UK) with the exception of AM251 (Tocris Bioscience, Bristol, UK).  Drug compounds were 
prepared using a suitable solvent (distilled water with the exception of picrotoxin (ethanol) 
and AM251 (DMSO) to form a stock solution.  This was then frozen in aliquots at -20ºC 
until required.  Subsequent dilutions were made as required from this stock solution to 
obtain the desired final bath concentration of the compound. 
 
2.5.  Statistical analysis 
 
Data are presented as the mean value ± standard error of the mean (sem). Statistical 
analyses were performed using Graphpad Prism v4.00 for Windows.  The tests conducted 
are stated in the results section of the following chapters.  Statistical significance was 
determined when the value for the probability (p) was less than 0.05. 69 
3.   Characterisation of the dentate gyrus 
slice model 
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3.1.  Introduction 
 
This series of experiments planned to test the hypotheses that physostigmine is an 
effective pretreatment for nerve agent poisoning and secondly, that physostigmine acts by 
sequestering a pool of AChE and protecting it from subsequent irreversible inactivation by 
nerve agent.  The study by Colgin et al., (Colgin et al., 2003) will be used as a basis for 
the set of experiments. 
 
The dentate gyrus slice model was chosen for the reasons described in section 1.8.1, 
namely because it retains an innate cholinergic response after preparation and that this 
preparation is best suited to the planned study.  The dentate gyrus is a part of the 
hippocampal formation, along with Ammon’s horn areas 1-3 (cornu Ammonis (CA1-3)), 
entorhinal cortex, and the subiculum (see Figure 3.1).  The dentate gyrus receives 
neuronal inputs from many different structures including other areas of the hippocampal 
formation, medial septal nucleus, thalamus, hypothalamus and the brainstem.  There are 
also commissural projections to the contralateral dentate gyrus (for an in depth review see 
(Patton & McNaughton, 1995).  The dentate gyrus can be divided into three areas.  These 
are the molecular layer (further divided into the inner, medial, and outer thirds), granule 
cell layer and the hilus (also sometimes referred to as the polymorphic layer) and are 
arranged as shown in Figure 3.1.   
 
One of the major inputs into the dentate gyrus is the perforant pathway from the entorhinal 
cortex.  This originates in layers II and IV-VI of the entorhinal cortex.  The perforant 
pathway has been shown to be mainly excitatory with glutamate as the main transmitter.  
The afferent fibres of this pathway terminate mainly in the outer two thirds of the molecular 
layer of the dentate gyrus, where they form synapses with the dendrites of the principle 
granule cells and also with the inhibitory basket cell interneurons.  This pattern of 
innervation allows for fine control over the excitability of the granule cell population of the 
dentate gyrus.  Whilst the majority of the main cholinergic projection from the medial 
septal nucleus enters the hippocampus via the fimbria, a small proportion of the afferent 
fibres directly innervate the dentate gyrus. 
 
Electrical stimulation of the perforant pathway elicits fEPSPs which can be recorded by 
extracellular means in the molecular layer of the dentate gyrus.  The magnitude of this 
response has been shown to be sensitive to the application of muscarinic antagonists and 
inhibitors of AChE (Melchers et al., 1994;Colgin et al., 2003).  Loss of the septal 
cholinergic input to this area results in a decrease in the expression of AChE with in the 
dentate gyrus (Colgin et al., 2003).   71 
 
The experiments in this chapter have been devised to broadly characterise the response 
elicited in the dentate gyrus.  For this reason, the majority of the experiments are 
conducted with only one concentration of agonist or antagonist.  The concentrations used 
were chosen as they have been shown previously in the literature to be effective.  They 
are also near maximal effective concentrations and in some cases may show less 
selectivity for certain receptor subtypes at the concentration used. 
 
 
 
Figure 3.1.  The hippocampal formation.   
The dentate gyrus (DG) is comprised of three distinct layers, the molecular layer (m) in 
which the apical dendrites of the granule cells terminate, the granule cell layer (g) 
which contains the cell bodies of the granule cells, and the polymorphic layer or hilus 
(p) which contains the basal dendrites of the granule cells.  The rest of the 
hippocampal formation is further divided into areas CA1, CA2 and CA3.  These areas 
can be further subdivided into the stratum oriens (so), stratum pyramidal (sp) which 
contains the cell bodies of the pyramidal cells, stratum radiatum (sr) and the stratum 
lacunosum-moleculare (sl-m).  Also shown is the fimbria (F) which contains the major 
afferent fibres into the hippocampus from structures such as the medial septal 
nucleus.  The subiculum (Sub) which receives a major output from the hippocampus is 
also shown. 
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3.2.  Methods 
 
Rat and guinea pig hippocampal slices were prepared as previously described in section 
2.1.2 and 2.1.3 respectively.   All test compounds were prepared as described in section 
2.4.  Control slices were conducted at various points throughout the study and 
interspersed with treatment groups where appropriate. 
 
Data recorded from each slice were manipulated as follows.  The values recorded for 
each parameter during the 10 minute period immediately prior to the application of the first 
test compound were averaged (mean).  This was used as a baseline value to which all 
data points were then normalised.  Data are presented as percentage changes from this 
value.  Data recorded during the application of test compounds and recovery were 
averaged into 1 minute bins.  This smoothed the data removing any rapid fluctuations (sub 
30 second) from the general trend.  Recovery of the response was measured during two 
epochs following the wash out of the test compound(s).  These were between 10 and 20 
minutes and between 20 and 30 minutes post wash out.  The level of recovery was 
determined as the maximum response during each epoch compared to the maximum 
decrease recorded during the application of the test compound. 
 
3.3.  Effect of reversible inhibition of AChE by physostigmine 
 
In the first series of experiments (Figure 3.2), eight rat dentate slices were exposed to a 
single 30 minute application of 5mM physostigmine followed by a period of washing with 
drug free ACSF.  The application of physostigmine caused a rapid significant decrease in 
the amplitude of the evoked fEPSP to between 78.9 and 90.3 % of baseline (mean 
decrease to 85.7 ± 1.9 % of baseline, p<0.001 (unpaired t-test)).  Similarly, application of 
5mM physostigmine caused a significant decrease in the slope of the evoked fEPSP to 
between 78.1 and 88.8 % of baseline (mean decrease to 84.3 ± 1.8 % of baseline, p<0.01 
(unpaired t-test)).  The decrease was reversed by washing with fresh ACSF (mean 
amplitude recovery to 94.5 ± 3.2 % of baseline during 10-20 minute epoch (p<0.01), and 
to 96.2 ± 3.5 % of baseline during the 20-30 minute epoch (p<0.01).  Recovery was also 
seen in the magnitude of the fEPSP slope at both epochs (94.6 ± 3.7 % of baseline (10-20 
minute epoch, p<0.01) and 95.3 ± 3.9 % (20-30 minute epoch, p<0.01).  
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Figure 3.2.  Effect of 5m m m mM physostigmine on perforant path 
responses recorded from the molecular layer of the dentate 
gyrus in the rat hippocampal slice.   
(A) Effect on the amplitude of the evoked fEPSP. (B) Effect on the 
magnitude of the slope of the fEPSP. (■ physostigmine treated slices n = 
8, ■ time matched controls n = 4, data presented as mean ± S.E.M). 
Example traces are shown above.  Traces i-iii are taken during baseline, 
exposure, and wash from control slices.  Traces iv-vi are taken during 
baseline, exposure to 5mM physostigmine, and wash from exposed slices 
(vertical scale bar 1mV, horizontal scale bar 100ms). 
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Figure 3.3.  Effect of 5m m m mM physostigmine on perforant path 
responses recorded from the molecular layer of the dentate 
gyrus in the guinea pig hippocampal slice.   
Effect on the amplitude of the evoked fEPSP. (B) Effect on the magnitude 
of the slope of the fEPSP. (■ physostigmine treated slices n = 4, ■ time 
matched controls n = 6, data presented as mean ± S.E.M). Example traces 
are shown above.  Traces i-iv are taken during baseline, simulated 
exposure, simulated second exposure, and wash from control slices.  
Traces v-viii are taken during baseline, exposure to 5mM physostigmine, 
addition of 10mM atropine and wash from exposed slices (vertical scale 
bars 1mV, horizontal scale bars 100ms) 
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After confirming the effect in the rat dentate gyrus, the experiments were repeated in 
slices of the dentate gyrus taken from guinea-pigs.  The guinea-pig hippocampus has 
been developed previously as a model to study the seizure-generating effects of OP 
anticholinesterase compounds (Harrison et al., 2000).  The guinea-pig is the small 
laboratory animal of choice for nerve agent studies as it better models the enzyme 
behaviour of man.  In the present study, the guinea-pig dentate gyrus was used to  
investigate other effects of acetylcholinesterase inhibitors on a response other than the 
generation of seizures as previously reported (Harrison et al., 2000).  To compare the 
effects of the two acetylcholinesterase inhibitors between the two species, the work 
carried out previously in the rat dentate gyrus slice was repeated with guinea-pig slices 
(Figure 3.3).  Physostigmine caused a significant decrease in both the amplitude (85.2 ± 
2.9 % of baseline, p<0.05, unpaired t-test) and slope of the fEPSP (82.3 ± 3.6 % of 
baseline, p<0.05, unpaired t-test) recorded from the guinea-pig dentate gyrus (n=6).  
Example fEPSPs recorded during baseline, application of 10µM physostigmine and 
washout in guinea pig dentate gyrus slices are shown in Figure 3.4.  There was no 
statistical difference in the magnitude of the effect of physostigmine between the species. 
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Figure 3.4.  An example of the effect of 10µM physostigmine on the fEPSP 
recorded from the molecular layer of the guinea pig dentate gyrus.   
Trace A is baseline (average of the final 2.5 minutes of the baseline), trace B is the 
effect of a 10 minute application of 10µM physostigmine (average of the final 2.5 
minutes of the sarin application), trace C is the level of recovery achieved between 25 
and 30 minutes post wash out of physostigmine (average of the final 2.5 minutes of 
this recovery epoch).  Vertical scale bar 0.5mV, horizontal scale bar 25ms. 
 
3.3.1.  Effect of atropine on the physostigmine-induced decrease in the dentate gyrus 
 
Previous experiments have shown that the decrease in the evoked EPSP can be 
prevented by application of a muscarinic antagonist (Colgin et al., 2003).  To confirm this, 
atropine (10mM) was applied 30 minutes after the application of physostigmine 76 
(physostigmine was still present in the bath) in six rat dentate slices (mean physostigmine-
induced decrease of the fEPSP amplitude to 78.5 ± 9.2 % of baseline, mean 
physostigmine-induced decrease of the fEPSP slope to 76.1 ± 8.9 % of baseline).  
Application of atropine resulted in a rapid but short-lived reversal of the physostigmine-
induced decrease in the amplitude (10-20 minute epoch recovery to 87.5 ± 6.3 % of 
baseline (p<0.05), 20-30 minute epoch recovery to 83.8 ± 9.9 % of baseline (p<0.01).  A 
similar pattern of recovery was seen in the slope of the fEPSP (10-20 minute epoch 
recovery to 82.1 ± 8.7 % of baseline, 20-30 minute epoch recovery to 79.3 ± 9.6 % of 
baseline), although this recovery was not statistically significant.  Washing with fresh 
ACSF 30-minutes after the application of atropine, caused a further apparent increase in 
the level of recovery of both parameters.  This also however did not reach statistical 
significance (Figure 3.5).   
 
Atropine (10mM) was also applied 30 minutes after the application of physostigmine in 
guinea pig hippocampal slices.  As was seen in the rat slices, atropine caused a rapid 
significant recovery in the evoked response (Figure 3.3).  The amplitude of the fEPSP 
recovered to 98.5 ± 2.2 % of baseline (p<0.01), and the slope recovered to 98.2 ± 2.0 % 
of baseline (p<0.01) during the 10-20 minute epoch.  In contrast to the rat, the level of 
recovery seen following application of atropine was sustained during the 20-30 minute 
epoch (amplitude 96.2 ± 1.7 % of baseline (p<0.01), slope 96.2 ± 2.7 % of baseline 
(p<0.001).  Washing with drug-free ACSF did not cause any further significant recovery of 
either measures of the response compared to that seen following atropine.   
 
Atropine (10µM) when applied for 30 minutes in the absence of physostigmine did not 
have any effect on either the slope or the amplitude of the fEPSP measured in the guinea 
pig dentate gyrus (Figure 3.6). 
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Figure 3.5.  Effect of 10m m m mM atropine on the physostigmine-induced depression of 
perforant path responses recorded from the molecular layer of the dentate 
gyrus in the rat hippocampal slice. 
(A) Effect on the amplitude of the evoked fEPSP. (B) Effect on the magnitude of the 
slope of the fEPSP. (■ drug treated slices n = 6, ■ time-matched controls n = 4, data 
presented as mean ± S.E.M). 
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Figure 3.6.  Effect of 10m m m mM atropine on the perforant path responses recorded 
from the molecular layer of the dentate gyrus in the guinea pig hippocampal 
slice.   
(A) Effect on the amplitude of the evoked fEPSP. (B) Effect on the magnitude of the 
slope of the fEPSP. (■ drug treated slices n = 4, ■ time-matched controls n = 6 data 
presented as mean ± S.E.M).  
 
3.3.2.  Effect of irreversible inhibition of AChE by the nerve agent sarin 
 
In order to investigate whether irreversible inhibitors of AChE have a different effect on the 
dentate gyrus, the nerve agent sarin (1µM) was applied to a series of guinea pig dentate 
gyrus slices for 30 minutes.  Example fEPSPs recorded during baseline, application of 79 
1µM sarin and washout in guinea pig dentate gyrus slices are shown in Figure 3.7.  Sarin 
caused a decrease in both the amplitude (decrease to 83.7 ± 3.7 % of baseline (p<0.05 
unpaired t-test)) and slope (reduction to 81.2 ± 3.8 % of baseline (p<0.01 unpaired t-test)) 
of the fEPSP (Figure 3.8), the magnitude of which was broadly similar to that seen 
previously with physostigmine. 
A                                    B                           C A                                    B                           C
 
Figure 3.7.  An example of the effect of 1µM sarin on the fEPSP recorded from 
the molecular layer of the guinea pig dentate gyrus.   
Trace A is baseline (average of the final 2.5 minutes of the baseline), trace B is the 
effect of a 10 minute application of 1µM sarin (average of the final 2.5 minutes of the 
sarin application), trace C is the level of recovery achieved between 25 and 30 
minutes post wash out of the nerve agent (average of the final 2.5 minutes of this 
recovery epoch).  Vertical scale bar 0.5mV, horizontal scale bar 25ms. 
 
Atropine (10µM) was applied 30 minutes after the application of sarin and caused a 
recovery in both parameters of the fEPSP (10-20 minute epoch; amplitude recovery to 
97.6 ± 4.8 % of baseline (p<0.001), slope recovery to 96.4 ± 5.2 % of baseline (p<0.001).  
The recovery caused by atropine was sustained during the 20-30 minute recovery epoch 
(both parameters p<0.01).  Washing with drug free ACSF did not further increase the level 
of recovery seen compared to that caused by atropine (Figure 3.8).  Figure 3.9 illustrates 
the effect of sarin when applied by itself.  The effect of sarin is covered in more detail in 
Chapter 4. 
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Figure 3.8.  Effect of 1m m m mM sarin and 10m m m mM atropine on the perforant path 
responses recorded from the molecular layer of the dentate gyrus in the guinea 
pig hippocampal slice.   
(A) Effect on the amplitude of the evoked fEPSP. (B) Effect on the magnitude of the 
slope of the fEPSP.  The decrease is modified by the application of 10µM atropine (■ 
drug treated slices n = 4, ■ time-matched controls n = 6 data presented as mean ± 
S.E.M).  81 
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Figure 3.9.  Effect of 1m m m mM sarin on the perforant path responses recorded from 
the molecular layer of the dentate gyrus in the guinea pig hippocampal slice.  
This is an example trace showing the effect of 1mM sarin on the magnitude of the amplitude 
(A) and slope (B) of the fEPSP in one dentate gyrus slice.  Slices exposed to sarin do not 
recover as well as those exposed to physostigmine (note shorter sarin duration compared to 
Figure 3.8).   
 
3.4.  Cholinergic characterisation of the response 
 
As can be seen from the results presented so far, the depression of the amplitude and 
slope of the fEPSP by inhibitors of acetylcholinesterase can be reversed by the non-
specific muscarinic antagonist atropine.  Further studies were conducted to characterise 
the cholinergic component of this effect. 82 
 
3.4.1.  Effect of cholinergic agonists 
 
To test the hypothesis that the inhibition of AChE by physostigmine or the 
organophosphates was causing a build up of ACh, which in turn was stimulating post-
synaptic cholinergic receptors thereby in turn reducing the output of the perforant path, the 
cholinergic agonist carbachol was applied to guinea pig dentate slices.  Carbachol (10µM) 
caused a rapid decrease in the amplitude and slope of the fEPSP (amplitude 73.8 ± 0.8 % 
of baseline (p<0.001 unpaired t-test), slope 69.5 ± 1.0 % of baseline (p<0.001, unpaired t-
test)).  This was a much larger effect than that seen following application of the AChE 
inhibitors (Figure 3.10).  The carbachol induced decrease was reversed by application of 
10µM atropine (10-20 minute epoch recovery of fEPSP amplitude to 93.8 ± 1.4 % of 
baseline (p<0.01), recovery of slope to 92.6 ± 1.9 % of baseline (p<0.01).  Although the 
level of recovery dropped with time (20-30 minute epoch recovery of amplitude to 89.7 ± 
1.4 % of baseline, recovery of slope to 89.0 ± 1.9 % of baseline) both measures remained 
significantly different from those recorded during carbachol application (both measures 
p<0.01). 
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Figure 3.10.  Effect of 10m m m mM carbachol (CCh) on the perforant path responses 
recorded from the molecular layer of the dentate gyrus in the guinea pig 
hippocampal slice.   
(A) Effect on the amplitude of the evoked fEPSP. (B) Effect on the magnitude of the 
slope of the fEPSP.  The decrease is modified by the application of 10µM atropine (■ 
drug treated slices n = 4, ■ time-matched controls n = 6 data presented as mean ± 
S.E.M).  
3.4.2.  Effect of subtype selective muscarinic receptor antagonists 
 
The effect of atropine would suggest that the depressive effect of AChE inhibition is 
mediated by muscarinic acetylcholine receptors (mAChR).  The subtype of these 
receptors can not be resolved using the broad acting antagonist atropine.  Therefore, a 84 
series of experiments utilising receptor subtype selective antagonists of mAChRs were 
conducted using guinea pig dentate gyrus slices.  The concentrations used were chosen 
to include the approximate dissociation constant (Ki) of the two compounds (telenzepine 
0.94nM, methoctramine ~40nM).  Following application of 1µM sarin for 30 minutes, either 
the M1 selective antagonist telenzepine or the M2 selective antagonist methoctramine 
was added to the recording ACSF.  Both compounds were added at a starting 
concentration of 0.03µM for 15 minutes.  The concentration was then increased to 0.30µM 
by cumulative dosing.  After a further 15 minutes the concentration was increased to 
3.00µM.  Following 15 minutes of application of the antagonist at the highest 
concentration, all compounds were washed off the slice.   
 
Sarin caused a decrease in the amplitude and slope of the fEPSP compared to control 
slices (reduction to 83.1 ± 1.0 % of baseline amplitude, reduction to 79.8 ± 1.2 % of 
baseline slope).  Telenzepine at the lowest concentration (0.03µM) caused a small yet 
significant recovery in the amplitude of the fEPSP (recovery to 85.2 ± 1.1 % of baseline 
(p<0.05) although the slope was unaffected. When the concentration was increased to 
0.30µM of telenzepine, there was a small recovery in both the amplitude (recovery to 89.6 
± 1.8 % of baseline, p<0.05) and slope (recovery to 85.7 ± 1.6 % of baseline, p<0.05) of 
the fEPSP.  Finally, increasing the concentration to 3.00µM caused a further increase in 
the recovery of both the amplitude (recovery to 91.7 ± 1.3 % of baseline, p<0.01) and 
slope of the fEPSP (recovery to 87.6 ± 2.0 % of baseline, p<0.01).  The level of recovery 
reached a plateau during the time of antagonist application at the highest concentration.  
The level of recovery was sustained following washing of the slice (Figure 3.11).  
 
Application of the M2 selective antagonist methoctramine (0.03µM) following 1µM sarin 
(causing a reduction to 84.3 ± 1.1 % of baseline amplitude and 79.8 ± 1.0 % of baseline 
slope) caused a small recovery in both the amplitude (recovery to 86.2 ± 0.5 % of baseline 
(p<0.05) and slope (recovery to 82.5 ± 0.7 % of baseline (p<0.05 ) of the fEPSP (Figure 
3.12).  However, this recovery was absent at the next concentration tested (0.30 µM).  A 
small recovery was recorded following application of 3.00µM of methoctramine in both the 
amplitude and slope of the fEPSP (recovery to 84.4 ± 1.2 % of baseline amplitude and 
recovery to 81.4 ± 0.9 % of baseline slope).  This however was not statistically significant. 
  85 
0 15 30 45 60 75 90 105 120 135
60
70
80
90
100
110
time (min)
%
 
o
f
 
b
a
s
e
l
i
n
e
l
Telenzepine
1mM sarin
0.03     0.30    3.00mM
0 15 30 45 60 75 90 105 120 135
60
70
80
90
100
110
time (min)
%
 
o
f
 
b
a
s
e
l
i
n
e
Telenzepine
1mM sarin
0.03     0.30    3.00mM
A
B
 
 
Figure 3.11.  Effect of the M1 mAChR subtype selective antagonist telenzepine 
on the sarin induced decrease of the fEPSP recorded from the molecular layer 
of the dentate gyrus in the guinea pig hippocampal slice.   
(A) Effect on the amplitude of the evoked fEPSP. (B) Effect on the magnitude of the 
slope of the fEPSP (■ drug treated slices n = 4, ■ time-matched controls n = 6 data 
presented as mean ± S.E.M).  
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Figure 3.12.  Effect of the M2 mAChR subtype selective antagonist 
methoctramine on the sarin induced decrease of the fEPSP recorded from the 
molecular layer of the dentate gyrus in the guinea pig hippocampal slice.   
(A) Effect on the amplitude of the evoked fEPSP. (B) Effect on the magnitude of the 
slope of the fEPSP (■ drug treated slices n = 4, ■ time-matched controls n = 6 data 
presented as mean ± S.E.M).  
3.4.3.  Involvement of nicotinic receptors 
 
The dentate gyrus also has a large number of nicotinic receptors, which are mainly 
located on inhibitory interneurons within the molecular layer (Frazier et al., 2003) such as 
basket cells (Jones & Yakel, 1997;Frazier et al., 2003).  To investigate whether there was 
a nicotinic component to the effect of physostigmine, the non-specific nicotinic antagonist 87 
mecamylamine was used instead of atropine following application of 5µM physostigmine 
in four slices from both species.  In the rat dentate gyrus slice, mecamylamine (30mM) had 
a small yet statistically significant effect on the amplitude of the fEPSP (physostigmine 
induced reduction of amplitude to 88.8 ± 2.0 % of baseline (p<0.05 unpaired t-test), 
recovery of amplitude to 91.2 ± 2.2 % of baseline during 10-20 minute epoch of 
mecamylamine administration (p<0.05)).  This effect was transient as the level of recovery 
of the amplitude recorded during the 20-30 minute epoch had reduced.  A similar pattern 
of recovery was recorded in the slope of the fEPSP (Figure 3.13).  Washing with drug-free 
ACSF did not cause any further recovery of either parameter. 
 
In the guinea pig dentate gyrus, following application of 5µM physostigmine  
(physostigmine induced decrease in amplitude to 82.5 ± 2.6 % of baseline (p<0.01 
unpaired t-test), physostigmine induced decrease in slope to 80.2 ± 3.9 % of baseline 
(p<0.01 unpaired t-test), 30µM mecamylamine caused a small yet significant recovery in 
the amplitude and slope of the fEPSP during the 10-20 minute epoch (recovery of 
amplitude to 88.5 ± 2.6 % of baseline (p<0.05), recovery of slope to 87.4 ± 3.6 % of 
baseline (p<0.05)).  In contrast to the rat slices, the level of recovery was sustained during 
the 20-30 minute epoch at a significant (p<0.05 paired t-test) level.  Washing with drug-
free ACSF caused a further increase in recovery of the amplitude of the fEPSP compared 
to that seen with mecamylamine alone (recovery to 95.8 ± 4.6 % of baseline (p<0.05)).  A 
smaller increase in the recovery of the slope parameter was also recorded but this was 
not statistically significant compared to that achieved with mecamylamine alone (Figure 
3.14). 
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Figure 3.13.  Effect of 30m m m mM mecamylamine on the physostigmine induced 
depression of perforant path responses recorded from the molecular layer of 
the dentate gyrus in the rat hippocampal slice.   
(A) Effect on the amplitude of the evoked fEPSP. (B) Effect on the magnitude of the 
slope of the fEPSP. (■ drug treated slices n = 4, ■ time-matched controls n = 4, data 
presented as mean ± S.E.M). 
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Figure 3.14.  Effect of 30m m m mM mecamylamine on the physostigmine induced 
depression of perforant path responses recorded from the molecular layer of 
the dentate gyrus in the guinea pig hippocampal slice.   
(A) Effect on the amplitude of the evoked fEPSP. (B) Effect on the magnitude of the 
slope of the fEPSP. (■ drug treated slices n = 4, ■ time-matched controls n = 6, data 
presented as mean ± S.E.M). 90 
3.5.  Involvement of cannabinoid systems 
 
There are two subtypes of cannabinoid receptor which can be found in mammalian 
tissues.  These are classified as CB1 and CB2.  CB1 receptors are found throughout the 
CNS, whereas the CB2 receptor is mainly confined to the immune system (for review see 
(Howlett et al., 2004)).  Expression of the CB1 receptor is high in the hippocampus 
(Moldrich & Wenger, 2000) with dense immunoreactivity for the receptor in the molecular 
layer of the dentate gyrus and pyramidal cell layer of CA1 and CA3 (Tsou et al., 1998).  
Further studies have shown that the CB1 receptor is located presynaptically on the 
terminals of GABAergic interneurons within the molecular layer of the dentate gyrus 
(Katona et al., 2000).  The CB1 specific antagonist AM251 (8µM) has been previously 
reported to block the depression of the fEPSP in the rat dentate gyrus caused by the 
administration of 5µM physostigmine (Colgin et al., 2003).  
 
3.5.1.  Effect of AM251 on the physostigmine-induced decrease 
 
Initially, the study by Colgin et al., was repeated in the guinea pig dentate gyrus (Colgin et 
al., 2003).  Slices were pretreated with 8µM AM251 for 30 minutes prior to the application 
of 5µM physostigmine.  Application of 8µM AM251 did not cause any significant changes 
in the amplitude or slope of the fEPSP when compared to control slices.  Application of 
5µM physostigmine 30 minutes after the start of the AM251 perfusion resulted in a 
decrease in both the amplitude and slope comparable with that seen in earlier studies 
(reduction in amplitude to 83.8 ± 1.3 % of baseline (p<0.05 paired t-test), reduction in 
slope to 79.3 ± 1.2 % of baseline (p<0.05 paired t-test)).  Washing with drug-free ACSF 
did not result in any significant changes in either parameter (Figure 3.15).  In a second 
series of slices, the concentration of AM251 was raised to 30µM (Figure 3.16).  Again, 
AM251 did not cause any significant changes in either parameter measured.  
Physostigmine (5µM) applied 30 minutes after AM251 again resulted in a significant 
decrease in the amplitude of the fEPSP (reduction of amplitude to 83.4 ± 0.9 % of 
baseline (p<0.05).  The slope of the fEPSP was not significantly affected by the 
application of physostigmine.  Washing with drug-free ACSF resulted in a significant 
recovery of the amplitude (recovery to 93.1 ± 1.2 % of baseline (p<0.01) and slope 
(recovery to 90.5 ± 2.5 % of baseline (p<0.05) of the fEPSP. 91 
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Figure 3.15.  Effect of the CB1 antagonist AM251 (8m m m mM) on the physostigmine 
induced depression of perforant path responses recorded from the molecular 
layer of the dentate gyrus in the guinea pig hippocampal slice.   
(A) Effect on the amplitude of the evoked fEPSP. (B) Effect on the magnitude of the 
slope of the fEPSP. (■ drug treated slices n = 4, ■ time-matched controls n = 6, data 
presented as mean ± S.E.M). 92 
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Figure 3.16.  Effect of the CB1 antagonist AM251 (30m m m mM) on the physostigmine 
induced depression of perforant path responses recorded from the molecular 
layer of the dentate gyrus in the guinea pig hippocampal slice.   
(A) Effect on the amplitude of the evoked fEPSP. (B) Effect on the magnitude of the 
slope of the fEPSP. (■ drug treated slices n = 4, ■ time-matched controls n = 6, data 
presented as mean ± S.E.M). 
 
3.5.2.  Effect of AM251 on the sarin-induced decrease 
 
These studies were then repeated using the irreversible AChE inhibitor sarin.  As reported 
before, 8µM AM251 did not have any significant effects on either the amplitude or slope of 
the fEPSP (Figure 3.17).  Application of 1µM sarin caused a significant reduction in the 93 
amplitude of the fEPSP (reduced to 86.3 ± 2.0 % of baseline (p<0.05)).  Whilst there was 
also a reduction of a similar magnitude in the slope (reduced to 83.4 ± 1.7 % of baseline) 
this was not statistically significant.  Washing with drug-free ACSF caused a recovery in 
both parameters (amplitude recovered to 98.8 ± 3.5 % of baseline (p<0.05), slope 
recovered to 95.2 ± 4.0 % of baseline (p<0.05)).  Increasing the concentration of AM251 
to 30µM did not affect the amplitude or slope (Figure 3.18).  The increased concentration 
of AM251 also failed to modify the reduction in both the amplitude (reduced to 84.1 ± 1.1 
% of baseline (p<0.05)) and slope (reduced to 84.3 ± 0.1 % of baseline (p<0.05)) caused 
by the application of 1µM sarin.  Washing with fresh ACSF did not significantly increase 
the level of recovery seen in both parameters.  94 
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Figure 3.17. Effect of the CB1 antagonist AM251 (8m m m mM) on the sarin induced 
depression of perforant path responses recorded from the molecular layer of 
the dentate gyrus in the guinea pig hippocampal slice.   
(A) Effect on the amplitude of the evoked fEPSP. (B) Effect on the magnitude of the 
slope of the fEPSP. (■ drug treated slices n = 3, ■ time-matched controls n = 6, ■ sarin 
treated slices n = 4 (data adjusted to align sarin application between groups), data 
presented as mean ± S.E.M). 95 
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Figure 3.18.  Effect of the CB1 antagonist AM251 (30m m m mM) on the sarin induced 
depression of perforant path responses recorded from the molecular layer of 
the dentate gyrus in the guinea pig hippocampal slice.   
(A) Effect on the amplitude of the evoked fEPSP. (B) Effect on the magnitude of the 
slope of the fEPSP. (■ drug treated slices n = 3, ■ time-matched controls n = 6, ■ sarin 
treated slices n = 4 (data adjusted to align sarin application between groups), data 
presented as mean ± S.E.M). 
 
3.5.3.  Investigation of species specific differences in the involvement of cannabinoid 
receptors 
 
To ensure that the apparent lack of effect of AM251 in this study was not species related 
(rat dentate gyrus slices were used in the study by Colgin et al.,); this experiment was 96 
repeated in rat dentate gyrus slices.  As observed in the guinea pig dentate gyrus slices, 
8µM AM251 did not have any effect on the amplitude or slope of the fEPSP (Figure 3.19).  
Application of 5µM physostigmine 30 minutes after AM251 caused significant decreases 
in both the amplitude and slope (amplitude reduced to 81.9 ± 2.0 % of baseline (p<0.01), 
slope reduced to 81.0 ± 3.4 % of baseline (p<0.01)).  Washing with drug-free ACSF 
caused a small recovery in the both parameters, however only the recovery of the 
amplitude was significant (p<0.05 paired t-test).  Increasing the concentration of AM251 to 
30µM again did not have any effect on either the amplitude or slope of the fEPSP (Figure 
3.20).  Application of 5µM physostigmine 30 minutes later caused a significant decrease in 
both the amplitude and slope of the fEPSP (amplitude reduced to 79.1 ± 1.4 % of baseline 
(p<0.05), slope reduced to 77.5 ± 1.3 % of baseline (p<0.05)).  Washing with drug-free 
ACSF caused an apparent recovery in both parameters, however only the recovery 
recorded in the slope was statistically significant (p<0.05). 
 
The solvent DMSO was used to produce solutions of AM251.  When applied for 30 
minutes at a concentration equivalent to that used for the highest concentration of AM251 
(0.06% v/v), DMSO did not effect the amplitude or slope of the fEPSP when compared to 
normal control slices.   98 
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Figure 3.20.  Effect of the CB1 antagonist AM251 (30m m m mM) on the physostigmine 
induced depression of perforant path responses recorded from the molecular 
layer of the dentate gyrus in the rat hippocampal slice.   
(A) Effect on the amplitude of the evoked fEPSP. (B) Effect on the magnitude of the 
slope of the fEPSP. (■ drug treated slices n = 4, ■ time-matched controls n = 4, data 
presented as mean ± S.E.M).  
 
3.6.  Involvement of GABAergic pathways 
 
There is anatomical evidence for mAChR being located on GABAergic neurons within the 
hippocampus and the dentate gyrus (van der Zee & Luiten, 1993).  These neurons are 
inhibitory interneurons which regulate the output of the granule cells of the dentate gyrus.  99 
It has been shown that cholinergic agonists are able to exert excitatory effects directly on 
these neurons (Reece & Schwartzkroin, 1991).  To investigate whether the depression of 
the fEPSP following application of sarin was mediated by GABAergic systems, the non-
competitive GABA antagonist picrotoxin (20µM) was added 10 minutes prior to the 
application of 1µM sarin.  As can be seen in Figure 3.21, picrotoxin did not significantly 
affect either amplitude of slope of the fEPSP (the apparent increase in the amplitude of 
the fEPSP was not statistically significant compared to vehicle control).  Application of 
1µM sarin 10 minutes after the picrotoxin did not have any effect on either parameter 
measured.  When both compounds were washed off, there was a gradual decline in both 
the amplitude and slope of the fEPSP.  This however was not significant across both the 
10-20 and 20-30 minute wash epochs (with exception of the slope during the 20-30 
minute epoch, p<0.05).  Vehicle controls were also carried out using ethanol (0.1% v/v).  
This did not have any significant effect on the amplitude of the fEPSP, however there was 
a significant difference in the slopes of slices sham exposed and those that were exposed 
to ethanol (p<0.01 unpaired t-test).  100 
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Figure 3.21.  Picrotoxin (20m m m mM) blocks the sarin induced depression of perforant 
path responses in the guinea pig dentate gyrus. 
(A) Effect on the amplitude of the evoked fEPSP. (B) Effect on the magnitude of the 
slope of the fEPSP. (■ drug treated slices n = 4, ■ vehicle 0.1% ethanol controls n = 4, 
data presented as mean ± S.E.M). Note that the application time of sarin has been 
reduced to 10 minutes.  This is due to the experimental protocol used and the results 
discussed in Chapter 4.  
 
3.7.  Discussion 
 
The aim of the present study was to determine the effects of acetylcholinesterase 
inhibition on the evoked response recorded from the molecular layer of the dentate gyrus.  101 
This study has confirmed and extended the findings of Colgin et al. (Colgin et al., 2003), 
and demonstrates that the inhibition of acetylcholinesterase by physostigmine can modify 
the output of the perforant path in the dentate gyrus, recorded as a decrease in the 
magnitude of the evoked fEPSP.  In addition, the OP anticholinesterase compound, sarin, 
was also shown to be capable of causing a depression in the magnitude of the fEPSP. 
 
The depression of the fEPSP recorded from the molecular layer of the dentate gyrus 
following administration of physostigmine or soman, was almost fully reversed by the 
muscarinic antagonist atropine.  The exact mechanism by which this effect is produced is 
as yet unclear although the involvement of cholinergic mechanisms has been clearly 
demonstrated.  The muscarinic antagonist atropine has been previously reported to 
reverse the decrease in the fEPSP caused by physostigmine and other cholinesterase 
inhibitors (Melchers et al., 1994;Colgin et al., 2003).  Application of the cholinergic agonist 
carbachol (10µM) to the dentate gyrus mimicked the decrease in the amplitude of the 
fEPSP recorded following application of physostigmine.  As with the decrease caused by 
physostigmine, the carbachol-induced decrease was reversed upon application of 
atropine.  This has been previously reported as only affecting fEPSPs caused by 
activation of the medial and not the lateral component of the perforant pathway (Kahle & 
Cotman, 1989).  The actions of atropine and carbachol in this model show that the 
anticholinesterase compounds are causing an increase in the concentration of 
acetylcholine within the synapse by blocking its hydrolysis, rather than having a direct 
agonist-like action on the perforant path or granule cells of the dentate gyrus. 
 
Inhibition of acetylcholinesterase by both OP and non-OP compounds has been shown to 
produce many different effects in the hippocampus (Williamson & Sarvey, 1985;Wood & 
Tattersall, 2001).  Previous work from this laboratory by Harrison et al has confirmed that 
soman (100nM) is capable of causing seizure-like activity that can be recorded from the 
pyramidal cell layer in the CA1 region of the hippocampus (Harrison et al., 2000;Harrison 
et al., 2003;Harrison et al., 2004).  This activity could be could be blocked to a degree by 
the application of muscarinic antagonists such as atropine.  Interestingly the rank order of 
effectiveness of muscarinic antagonists selective for the M1 and M2 receptors was similar 
to that reported here for the dentate gyrus, namely that antagonists of the M1 receptor 
(i.e. telenzepine) were more effective at resolving soman-induced seizures than those 
selective for the M2 receptor such as AF-DX 116 (Harrison et al., 2004).  The 
effectiveness of M1 (and M3) receptor antagonists in blocking seizure activity has also 
been reported in the neocortex (Potier & Psarropoulou, 2004). 
 
From a review of similar studies, the mechanism by which this action is mediated appears 
to involve the M1 muscarinic receptor.  The depression seen following application of a 102 
cholinesterase inhibitor was blocked by application of pirenzipine (Melchers et al., 1994) 
or reduced in a concentration dependent manner (Burgard et al., 1993).  A similar level of 
antagonism was seen following application of the M3/M1 antagonist 4-diphenylacetoxy-N-
methyl-piperidine methiodide (4-DAMP) (Burgard et al., 1993).  However, the M2 receptor 
antagonists methoctramine and gallamine showed no apparent antagonism of the 
cholinesterase inhibitor-induced depression (Colgin et al., 2003;Melchers et al., 1994).  
This is in agreement with what is reported from the current study.  A caveat must be 
applied to these results, however, as the concentrations of antagonists used may also 
have non-selective effects on other mAChR subtypes. 
 
Further evidence to support this conclusion comes from immunohistochemical and lesion 
studies which have shown that M1 receptor can be found throughout the molecular and 
granule cell layers of the dentate gyrus (Levey et al., 1995).  The levels of 
immunoreactivity for the M1 receptor are not affected by lesions of the entorhinal cortex 
affecting the perforant path projections.  However following lesions of the granule cell 
layer, M1 immunoreactivity is completely abolished (Rouse et al., 1998).  This shows that 
the M1 receptor is located postsynaptically on the axons and dendrites of the granule 
cells.  A similar pattern of expression was also seen for the M3 receptor.  The M2 and M4 
receptors were shown to be presynaptically located on the projection fibres of the medial 
perforant path and also presynaptically on other afferent sources within the outer and 
inner thirds of the dentate gyrus (Rouse et al., 1998).  The relative lack of effective of the 
M2 antagonist methoctramine in this study is surprising as it all but rules out a role for 
presynaptic M2 mAChR heteroreceptors on the afferent fibres of the perforant pathway.  
The presence of a presynaptic muscarinic receptor on the afferents of the medial 
perforant pathway within the molecular layer of the dentate gyrus has been reported 
previously (Kahle & Cotman, 1989).  A novel M2-like mAChR which controls the release of 
glutamate in hippocampal synaptosomes has also been reported (Marchi & Raiteri, 1989).  
Muscarinic receptors (mainly M2) have also been shown to modulate the release of 
glutamate from other afferent fibres such as those in the spinal cord (Zhang et al., 2007).  
The M4 mAChR is related to the M2 mAChR and acts to inhibit neuronal activity by 
hyperpolarising the cell (Hasuo et al., 1995).  The M4 mAChR has also been identified as 
being located presynaptically on the fibres of the perforant pathway (Rouse et al., 1998).   
 
As stated above, functionally the results from the current study show that the cholinergic 
effect of AChE inhibitors is likely to mediated by an M1-like mAChR, although this is 
somewhat complicated by studies which have shown M2 or M4 mAChR localised on the 
afferent terminals of the perforant pathway fibres.  One explanation may lie with the 
antagonists and concentrations used.  Methoctramine which is described as being more 
selective for the M2 subtype also shows affinity for other mAChR subtypes with very little 103 
difference between subtypes (Ki 13nM M2, 31nM M4 and 50nM M1 (Dorje et al., 1991)).  
Similarly , telenzepine has been shown to be more selective for the M1 subtype (Ki 0.9nM 
M1 vs 17.8nM at the M2 mAChR (Galvan et al., 1989)).  In the current study, the apparent 
effect of telenzepine at 0.3 and 3µM (Figure 3.11) may in fact be due to a non-specific 
effect on the M2 or putative M4 heteroreceptors on the afferent terminals of the perforant 
pathway thereby modulating the release of glutamate.  The interaction of telenzepine with 
M4 receptors is possible, as although it is classed as being more selective for the M1 
mAChR, it has a very similar profile at the M4 mAChR.  Lazareno et al., (1990) have 
reported that telenzepine has a pKi value of 8.89 ± 0.05 at the M1 mAChR compared to 
8.61 ± 0.05 at a putative M4 receptor in the chicken heart (Lazareno et al., 1990).  The 
similarity in these values show that the selectivity of this compound for the M1 mAChR 
over the M4 mAChR is marginal and that at the concentrations used in this study it may 
be acting at presynaptic M4 receptors on the perforant pathway afferent fibres.  The likely 
identity of this receptor could be uncovered by repeating the current experiment with a 
more selective M4 antagonist such as tropicamide.  
 
This putative role for the M4 (or M2) receptor acting as a presynaptic modulator of 
glutamate release should be accepted with caution.  The endogenous source of ACh in 
the dentate gyrus has been accepted to be the cholinergic septohippocampal afferent 
fibres.  These fibres form synapses with all cell types within the hippocampus, with the 
main termination of the fibres occurring in the supragranular layer (inner third of the 
molecular layer directly beneath the granule cell layer) and also some fibres terminating in 
the hilus (polymorphic layer) (Storm-Mathisen, 1977)  There is little evidence for large 
numbers of axo-axonic synapses on these fibres in the molecular layer close to the 
perforant pathway fibres (Clarke, 1985) and the distance between these two locations is 
such that ACh released synaptically by the septohippocampal fibres is unlikely to act via 
volume transmission on the terminals of the perforant pathway (Brunner & Misgeld, 1994).   
 
The apparent lack of effect of the nicotinic antagonist mecamylamine is a surprising, in 
this study.  Nicotinic acetylcholine receptors (nAChRs) are expressed in great numbers 
throughout the CNS and the hippocampal formation is no exception to this.  Within the 
hippocampus and dentate gyrus, nAChR are expressed on the interneurons rather than 
the principal cells (McQuiston & Madison, 1999;Jones & Yakel, 1997).  There is evidence 
that cholinergic activation of nAChR expressing interneurons is responsible for the 
regulation of the output of the principal cells of CA1 (pyramidal cells) and the dentate 
gyrus granule cells (Rózsa et al., 2008;Frazier et al., 1998;Frazier et al., 2003).  It has 
been shown that activation of α7 subunit containing nAChR within the subgranular 
interneurons of the hilus region of the dentate gyrus results in GABAergic inhibitory post 
synaptic potentials in granule cells (Frazier et al., 2003).  The relative lack of effect of 104 
mecamylamine may be due to limitations of the experimental protocol and also the 
method by which the anticholinesterases are acting to reduce the output of the granule 
cells.  Whilst ACh is an agonist of the nAChR, the product of its hydrolysis, choline, is a far 
more potent agonist of nAChR especially those containing the a7 or a9 subunits (Pereira 
et al., 2002).   
 
The physiological properties of postsynaptic mAChRs in the dentate gyrus (both M1 and 
M3 (Rouse et al., 1998;Rouse & Levey, 1997)) have yet to be fully elucidated.  Direct 
activation of M1 mAChRs present on the dendrites and axons of the granule cells would in 
theory cause excitation of the granule cells.  This theoretical effect is hard to reconcile 
with the results presented in this chapter and those reported in the literature.  However, a 
role for the M1/M3 mAChR present on the granule cells may lie in the control of the 
release of endocannabinoids from the granule cells (Ohno-Shosaku et al., 2003).   
 
Endocannabinoids include anandamide and 2-arachidonoyl-glycerol (2-AG) and are 
synthesised in, and released by neuronal cells in response to depolarisation (Di Marzo et 
al., 1994), especially that caused by cholinergic mechanisms (Bisogno et al., 2005).  The 
synthetic enzyme required for 2-AG formation, diacylgylcerol lipase α (DGL- α), has been 
shown to be expressed in the principal cells of the hippocampus including the granule 
cells of the dentate gyrus.  In contrast this enzyme appears to be absent from the 
interneurons (such as the basket cells) of the dentate gyrus (Katona et al., 2006).  
Postsynaptic M1 and M3 on hippocampal neurons have been reported to be responsible 
for modulating a retrograde signal which is facilitated by endocannabinoids (Ohno-
Shosaku et al., 2003).  Endocannabinoids released by stimulation of the granule cells are 
able to interact with presynaptic CB1 receptors on GABAergic interneurons resulting in a 
decreased release of GABA.  This process is called depolarisation induced suppression of 
inhibition (DSI) and has been recorded in the GABAergic basket cell interneuron of the 
dentate gyrus (Isokawa & Alger, 2005).  The presence of DGL- α and M1/M3 mAChR on 
the granule cells would suggest further evidence for postsynaptic mAChR playing a role in 
modulating the release of endocannabinoids. 
 
The hypothesis that endogenous cannabinoids act as retrograde messengers to inhibit the 
release of glutamate from the perforant path was investigated.  This has been previously 
suggested in earlier reports (Colgin et al., 2003).  It contrast to the study by Colgin, the 
depressive effect of physostigmine (and also sarin) was not blocked by the CB1 antagonist 
AM251 in the current study.  However, it appeared that the fEPSP recorded from slices 
pretreated with AM251 prior to exposure to 1µM sarin recovered quicker than those that 
did not receive AM251 (Figures 3.17 and 3.18).  This was only statistically significant 
(p<0.01 unpaired t-test) in the amplitude and slope of the fEPSP recorded during the 10-105 
20 minute recovery epoch in slices pretreated with 8 µM AM251.  The lack of statistical 
significance in other measures may be an artefact of the low sample number (n=3).  The 
effect on the recovery of physostigmine exposed slices could not be measured due to the 
lack of suitable slices exposed to 5 µM physostigmine alone.  Species differences in the 
efficacy of AM251 between the rat and guinea pig can be ruled out as there was no effect 
of this antagonist in either species in the current study.  Other studies have also reported 
the presence of presynaptic CB1 receptors in the guinea pig hippocampus (Schlicker et 
al., 1997).  One possible reason for the conflicting results is purely practical; i.e. a problem 
with the formulation of the AM251 used in the current study.  This could be ruled out by 
repeating the experiments with a fresh batch of the antagonist or using a different CB1 
antagonist compound.  
 
Despite these conflicting results, there is also some doubt about the validity of Colgin’s 
hypothesis.  There is a paucity of evidence indicating that endocannabinoids can directly 
modulate the release of glutamate from the perforant pathway afferent fibres.  In fact, 
endocannabinoid modulation of glutamate release has recently been shown to occur only 
at the mossy cell – granule cell synapse and not at synapses involving the medial or 
lateral perforant pathways (Chiu & Castillo, 2008).  CB1 receptors have been shown to be 
expressed in large densities in the molecular layer of the dentate gyrus (Herkenham et al., 
1991;Dove Petit et al., 1998), especially on presynaptic terminals of GABAergic 
interneurons within the molecular layer of the dentate gyrus (Hajos et al., 2000).  The vast 
majority of CB1 receptors are expressed by cholecystokinin (CCK) containing basket cells 
in the dentate gyrus and their activation inhibits the release of GABA (Katona et al., 1999).  
Localisation of the receptor on GABAergic neurons allows cannabinoid agonists to 
decrease the release of GABA through DSI thereby fine tuning neuronal output (Hofmann 
et al., 2006).  A small number of nonGABAergic neurons in the mouse dentate gyrus 
(described as possibly being afferent neurons although not identified conclusively) have 
also been reported (Marsicano & Lutz, 1999).   
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Figure 3.22.  A simplified schematic of the connections between the neuronal 
cells of the dentate gyrus. 
The cell shown are the granule cells, the CA3 pyramidal cells, excitatory mossy cells, 
and the various inhibitory interneurons (simplified).  This diagram shows the relative 
topography across the layers of the dentate gyrus (M-molecular layer, G-granule cell 
layer, H-hilus (polymorphic layer).  Also shown are the two main neurotransmitters 
present in the dentate gyrus.  GABA is the main inhibitory transmitter (-) and 
glutamate (Glu) is the main excitatory transmitter (+).  For clarity the hilar interneurons 
represented here include the hilar commissural-association pathway-related (HICAP), 
molecular layer perforant path-associated (MOPP) and hilar perforant path-associated 
(HIPP) subtypes.  Another class of interneuron, the chandelier cell, has been omitted 
for clarity.  These cells form inhibitory synapses with other GABAergic interneurons 
within the inner portions of the molecular layer.  This complicated pattern of 
innervation allows for fine control of the output of the granule cells which is important 
for the generation and maintenance of hippocampal rhythms (Houser, 2007). 
 
From the results presented in this series of experiments it can be seen that endogenous 
acetylcholine is responsible for the decrease in the amplitude of the fEPSP recorded from 
the molecular layer of the dentate gyrus.  However, as shown in Figure 3.21, this is 
facilitated by GABAA receptors.  The non-competitive GABAA receptor antagonist 
picrotoxin blocked the decrease in the fEPSP usually associated with exposure to 1µM 
sarin.  GABAA receptors are expressed by dentate granule cells and are thought to be 
responsible for providing both tonic and phasic inhibition of the cell (Nusser & Mody, 107 
2002;Mtchedlishvili & Kapur, 2006).  GABAA receptors have also been reported on to be 
present on the hilar mossy cells and could play a role in maintenance of the excitability of 
these cells (Nahir et al., 2007).  GABAB receptors have further been shown to be 
important for maintaining tonic inhibition of the granule cell output in vivo (Canning & 
Leung, 2000).   Excitation of the interneuron and the granule cell together has been 
shown to cause a shunt in the charge from the excitatory postsynaptic current which 
abolishes the excitatory NMDA excitatory post synaptic current.  This is modulated by post 
synaptic GABAA receptors (Staley & Mody, 1992).   Such a situation as this can be 
brought about by stimulation of the medial perforant pathway afferent fibres, which form 
excitatory synapses with both the granule cells and the inhibitory interneurons (Zipp et al., 
1989).   
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Figure 3.23.  Cholinergic innervation of the dentate gyrus.   
Cholinergic septohippocampal projection fibres (yellow arrows) terminate mainly in the 
hilar and supragranular layer regions of the dentate gyrus as well as CA3.  Released 
ACh excites the mossy cells and CA3 pyramidal cells causing an increase in the 
activity of the hilar interneurons.  This in turn causes an inhibition of the granule cells.  
ACh also causes a smaller depolarisation of the granule cells which also leads to an 
increase in the level of recurrent inhibition of the granule cells (key as in Figure 3.21).  
 
It is proposed that the following scheme of events occurs during the experiments reported 
here.  Electrical stimulation of the perforant pathway afferent fibres causes a release of 
glutamate.  This excites both the granule cells and also the numerous inhibitory 
interneurons.  Depolarisation of the granule cells then facilitates the release of glutamate 
at the mossy fibre-mossy cell and mossy fibre-CA3 pyramidal cell synapses.   The 108 
feedback loops provided by the dendritic fibres of the mossy cells and CA3 pyramidal cells 
cause an increase in the activity of the hilar interneurons (Figure 3.22).  The interneurons 
release GABA which binds to post synaptic GABAA and GABAB receptors on the granule 
cells causing hyperpolarisation of the cell (Piguet, 1993).  There is also evidence for 
recurrent inhibition between interneurons (Freund & Buzsáki, 1996).  Following release of 
endogenous ACh (Figure 3.23), the overall level of inhibitory drive is greatly increased.  
This is due to the increase in activity of the inhibitory interneurons driven by direct 
activation of mAChR on the interneurons themselves (Dougherty & Milner, 1999), and 
also on the excitatory CA3 pyramidal cells and mossy cells (Deller et al., 1999).  
Application of cholinergic agonists causes an increase in the level of bursting of inhibitory 
interneurons (EPSPs) and IPSP formation in the granule cells themselves (Brunner & 
Misgeld, 1994;Harney & Jones, 2002) and this activity is modulated by both mAChR (van 
der Zee & Luiten, 1993) and nAChR (Jones & Yakel, 1997). This produces a profound 
inhibition of the granule cell output witnessed as a decrease in the magnitude of the 
fEPSP.   
 
Although not shown by the results presented here, it is postulated based on the available 
literature, that endocannabionids may be released by the depolarisation of the granule 
cell.  The released endocannabinoid compound then acts at presynaptic CB1 receptors on 
the GABAergic interneurons to depress the further release of GABA by the process of DSI 
thereby modulating the level of granule cell inhibition.  Endocannabinoids may also play a 
role in decreasing the release of glutamate by a process called depolarisation-induced 
suppression of excitation (DSE).  This is similar to DSI with the exception that it is the 
release of glutamate which is inhibited rather than GABA (Straiker & Mackie, 2005).  This 
process has been reported at the mossy cell-granule cell synapse and is likely to be 
enhanced by the cholinergic septohippocampal fibres (Chiu & Castillo, 2008).  Further 
evidence for this comes from the identification of CB1 receptors in locations within the 
inner third of the molecular layer of the dentate gyrus corresponding with the location of 
mossy cell-granule cell synapses (Katona et al., 2006). 
 
A novel action of AChE inhibitors on the GABAergic septohippocampal afferent fibres in a 
slice model of the medial septal diagonal band has also been reported.  Physostigmine 
and other AChE inhibitors have been shown to increase the rate at which these afferent 
fibres fire.  Conversely, impulse flow in the cholinergic septohippocampal afferents is 
greatly decreased (Wu et al., 2003).   As the GABAergic fibres preferentially innervate 
interneurons within the hippocampus it would provide a strong signal to disinhibit the 
granule cells.  This increase in the output of the granule cell would be seen as a 
maintenance or increase in the amplitude of the fEPSP and not the decrease seen in the 
present study.  The differing results may be due in part to the greater density of 109 
cholinergic septohippocampal fibres in the dentate gyrus slice compared to their 
GABAergic counterparts thus tipping the balance overall towards inhibition of the granule 
cells.    
 
In conclusion, the results from this study have confirmed that the output from the perforant 
path in the dentate gyrus can be modified by the acetylcholinesterase inhibitor 
physostigmine.  This was seen as a decrease in the amplitude of the evoked field 
potential recorded from the molecular layer of the dentate gyrus in the rat and guinea pig, 
with no significant differences between the two species.  This finding was extended by 
using the nerve agent sarin that resulted in a decrease similar to that observed following 
application of physostigmine in the guinea pig.  The physiological pathways involved in 
this response are complex and probably represent a series of inter-related processes 
which are occurring at the same time.  This study has confirmed that the dentate slice 
model retains an intrinsic cholinergic response which is most likely to be mediated by 
afferent terminals of cholinergic septohippocampal projection fibres.  This means that this 
model is therefore well-suited for investigating the effects of nerve agents and other 
compounds on a model of a CNS cholinergic response. 110 
4.   Investigation of the interactions 
between physostigmine and the nerve 
agent sarin 111 
4.1.  Introduction 
 
This study has been designed to begin to investigate the mechanisms of the interaction 
between physostigmine and the nerve agent sarin in the dentate gyrus slice model.  This 
builds upon the characterisation of the model and the effects of the individual compounds.  
 
Physostigmine has been proposed as a component of the next generation nerve agent 
therapy and pretreatment sets.  This is not a new concept of use for physostigmine as it 
was first shown in 1946 to offer protection against the organophosphate DFP in cats 
(Koster, 1946).  Physostigmine is a tertiary amine and is able to cross the blood brain 
barrier and inhibit AChE within the CNS.  It is thought that this inhibition of central AChE is 
responsible for the protection against the lethal actions of organophosphates such as the 
nerve agents.  However, the inhibition of central AChE also causes many unwanted side 
effects such as vomiting, disruption of balance and motor control (Proudfoot, 2006).  
These are the result of overstimulation of the cholinergic systems within the CNS.  These 
complications led to the better tolerated pyridostigmine being introduced as a 
pretreatment to counter nerve agent poisoning as it is unable to cross into the CNS in 
normal situations and is largely devoid of the side effects reported with physostigmine 
use. 
 
Due to ongoing research into replacement therapies that are less reliant on pretreatment, 
the use of physostigmine as a therapy for nerve agent poisoning is being investigated 
once more.  To counter the undesirable cholinergic side effects associated with the use of 
physostigmine, the addition of the non-specific muscarinic antagonist scopolamine has 
been proposed.  The use of physostigmine in this way appears at first to be 
counterintuitive.  The addition of another inhibitor of AChE into an already compromised 
system would at first glance be expected to compound the effects of the nerve agent.  
However, in recent animal studies this combination has been proven to be more 
efficacious than current treatments at preventing lethality and improving the level of 
incapacitation seen post poisoning with a range of nerve agents (Wetherell et al., 2006).   
 
4.2.  Methods 
 
Guinea pig hippocampal slices were prepared as previously described in section 2.1.3.   
Physostigmine and sarin were prepared as described in section 2.4.  The optimal 
concentration of physostigmine or sarin was determined by applying a single of 
concentration of the compound following the timeline shown in Figure 4.1.  This was 
repeated with several different concentrations of each compound (0.03 – 30.00µM 112 
physostigmine, and 0.003 – 1.00µM sarin).  Cumulative dosing was not used, and each 
data point was recorded from a single slice.  The time line in Figure 4.2 was used to 
investigate any potential interactions between the two compounds. 
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Figure 4.1.  Timeline used for experiments determining the concentration-effect 
relationships of physostigmine or sarin. 
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Figure 4.2.  Timeline used for experiments investigating the interactions 
between sarin and physostigmine. 
 
Data recorded from each slice were manipulated as follows.  The values recorded for 
each parameter during the 10 minute period immediately prior to the application of the first 
test compound were averaged (mean).  This was used as a baseline value to which all 
data points were then normalised.  Data are presented as percentage changes from this 
value.  Data recorded during the application of test compounds and recovery were 
averaged into 1 minute bins.  This smoothed the data removing any rapid fluctuations (sub 
30 second) from the general trend.  Recovery of the response was measured during two 
epochs following the wash out of the test compound(s).  These were between 10 and 20 
minutes and between 20 and 30 minutes post wash out.  The level of recovery was 
determined as the maximum response during each epoch compared to the maximum 
decrease recorded during the application of the test compound. 
 
Sigmoidal curves were fitted to the concentration-effect data using Graphpad Prism 
V.4.00.using the sigmoidal dose-response (variable slope) function.  The equation for this 
fit was Y= Bottom + (Top-Bottom)/(1/10^((LogEC50-X)*Hill slope)), where X is the 113 
logarithm of concentration and Y is the response.  IC50 values for both compounds were 
then derived from this curve. 
 
4.3.  Characterisation of the effect of physostigmine in the dentate gyrus  
 
To allow determination of a suitable concentration of physostigmine for use in subsequent 
experiments, a concentration-effect relationship for physostigmine in the dentate gyrus 
slice was derived.  A generic timeline for the experiments is shown in Figure 4.1.  Briefly, 
a baseline period lasting at least 30 minutes was recorded before a single concentration 
of physostigmine (0.03-30µM) was applied to the slice for 10 minutes.  Cumulative dosing 
was not used.  The average amplitude of the fEPSP recorded during the baseline was 2.5 
± 0.1 mV and the average slope was 2.6 ± 0.2 mV·msec
-1.  After 10 minutes the recording 
solution was changed for a pre-warmed drug-free recording solution.  The slice was then 
washed for at least 60 minutes.  These data are shown in Table 4.1 and 4.2.  The 
maximum depression of both the amplitude and slope of the evoked fEPSP during the 
period whilst physostigmine was present was determined and used to construct a 
concentration-effect relationship for physostigmine (Figure 4.3).  The maximum 
concentration of physostigmine tested (30µM) caused the amplitude of the fEPSP to 
decrease to 85.9 ± 0.5% of baseline levels (p<0.01 compared to control slices n=4).  A 
similar decrease was also observed in the slope of the fEPSP (82.8 ± 1.3% of baseline, 
p<0.01 compared to control slices n=4).  The concentration of physostigmine which 
caused a 50% depression relative to the maximal inhibition of the fEPSP (IC50) was 
derived as 1.86µM for the effect on the amplitude and 2.22µM for the effect on the slope.  
The recovery of each slice parameter during the washout of the test compounds was 
measured at two adjacent epochs.  These were between 10 and 20 minutes post start of 
washing, and between 20 and 30 minutes post start of washing.  The maximum recovery 
seen during each epoch was then compared with the maximum depression seen during 
the period where the drug was present.  The slice response (both amplitude and slope) 
fully recovered to baseline levels during the wash period at all concentrations of 
physostigmine used (Tables 4.1 and 4.2).  
 114 
-8 -7 -6 -5 -4
-25
-20
-15
-10
-5
0
log10 concentration (M)
%
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
-8 -7 -6 -5 -4
-25
-20
-15
-10
-5
0
log10 concentration (M)
%
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
A
B
 
Figure 4.3.  Concentration-effect relationship for physostigmine in the guinea 
pig dentate gyrus.  
Physostigmine when applied for 10 minutes caused a concentration dependent 
decrease in the amplitude (A) and slope (B) of the evoked fEPSP (mean ± SEM, n=4). 115 
 
Concentration 
(µM) 
Maximum effect 
(% of baseline 
compared to 
control slices) 
Maximum recovery 
achieved  at  10-20 min 
post washing (% of 
baseline) 
Maximum recovery 
achieved  at  20-30 min 
post washing (% of 
baseline) 
0.030  95.6 ± 1.4**  99.6 ± 2.1*
  100.3 ± 3.5 
0.100  91.6 ± 0.7**  100.8 ± 1.3**  102.3 ± 5.5 
0.300  95.1 ± 1.2**  105.1 ± 3.7*  102.3 ± 4.6 
1.000  92.5 ± 1.8**  107.3 ± 3.0*  107.5 ± 4.0 
3.000  87.0 ± 0.7
**  105.9 ± 3.4**  103.9 ± 4.0* 
10.000  83.7 ± 1.0
**  103.9 ± 2.8**  101.4 ± 1.5** 
30.000  85.9 ± 0.5
**  99.2 ± 1.9**  100.3 ± 2.1** 
 
Table 4.1.  The effect of physostigmine at a range of concentrations (0.03-
30.00µM) on the amplitude of the evoked fEPSP.   
Also shown is the maximum recovery achieved during washing with drug-free ACSF 
(mean ± sem, n=4, * p<0.05, ** p<0.01, ***p<0.001 unpaired t-test (maximum effect vs 
control slices), paired t-test (recovery vs maximum effect)). 
 
Concentration 
(µM) 
Maximum effect 
(% of baseline 
compared to 
control slices) 
Maximum recovery 
achieved  at  10-20 min 
post washing (% of 
baseline) 
Maximum recovery 
achieved  at  20-30 min 
post washing (% of 
baseline) 
0.030  94.77 ± 2.07**  99.96 ± 2.46*  100.90 ± 3.64 
0.100  88.17 ± 1.98**  98.32 ± 0.89*  101.50 ± 5.88* 
0.300  92.30 ± 2.55**  104.60 ± 4.00**  101.10 ± 4.77* 
1.000  91.06 ± 1.99**  106.90 ± 2.98*  106.70 ± 4.14 
3.000  83.66 ± 1.54
**  104.00 ± 3.23**  102.20 ± 3.28** 
10.000  79.07 ± 3.32
**  103.20 ± 2.42*  100.80 ± 1.85* 
30.000  82.76 ± 1.26**  97.72 ± 1.52**  96.87 ± 1.54* 
 
Table 4.2.  The effect of physostigmine at a range of concentrations (0.03-
30.00µM) on the slope of the evoked fEPSP.   
Also shown is the maximum recovery achieved during washing with drug-free ACSF 
(mean ± sem, n=4, * p<0.05, ** p<0.01, ***p<0.001 unpaired t-test (maximum effect vs 
control slices), paired t-test (recovery vs maximum effect)). 
 
4.3.1.  Characterisation of the effect of sarin in the dentate gyrus 
 
A concentration-effect relationship for sarin was also constructed.  The average amplitude 
of the fEPSP recorded during the baseline was 2.3 ± 0.1 mV and the average slope was 
2.2 ± 0.1 mV·msec
-1.  Initially a single concentration of sarin (0.003–1µM) was applied for 
10 minutes.  When applied for 10 minutes, sarin also caused a concentration dependent 
decrease in the amplitude (p<0.01 at all sarin concentrations compared to equivalent data 
from time matched control slices) and slope of the fEPSP.  These data are shown in Table 116 
4.3 and 4.4.  From these results a concentration-effect relationship was derived and is 
shown in Figure 4.4.  From this data IC50 values of 0.09µM (amplitude) and 0.02µM 
(slope) were derived.  In contrast to slices exposed to physostigmine, both the amplitude 
and slope of the fEPSP recorded from sarin exposed slices did not recover to pre-
exposure levels following washing of the slice.  This lack of recovery was most 
pronounced in the slope of slices exposed to sarin. 
 
However, it appeared that at lower concentrations the circulating sarin may not have 
reached full equilibrium within the slice.  This was seen as a maximal depression of both 
measures of the fEPSP which did not plateau during the application of the nerve agent.  
Therefore a second concentration-effect curve was constructed from slices which were 
exposed to sarin for 30 minutes (Tables 4.5 and 4.6, and Figure 4.5).  The average 
amplitude of the fEPSP recorded during the baseline was 2.2 ± 0.1 mV and the average 
slope was 2.1 ± 0.1 mV·msec
-1.  Application of 1µM sarin caused the amplitude of the 
fEPSP to decrease to 84.2 ± 2.0% of baseline.  Again the slope showed a decrease of a 
similar magnitude (81.9 ± 2.3% of baseline).  The only IC50 value for this longer application 
that could be derived from the data was that of 0.05µM for the effect on the fEPSP 
amplitude.  No value for the IC50 for the effect on the slope could be mathematically 
derived as the line did not converge.  As seen in the shorter 10 minute application, the 
fEPSP recorded from slices exposed to sarin showed no recovery in either the amplitude 
or slope.   
 
The data recorded from slices exposed to sarin for 30 minutes was not statistically 
different from that recorded in slices exposed to sarin for 10 minutes.  Therefore, to 
maximise the experimental time available, it was decided that slices would be exposed to 
sarin for 10 minutes in subsequent experiments.   
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Figure 4.4.  Concentration-effect relationship for sarin in the guinea pig dentate 
gyrus.  
Sarin when applied for 10 minutes caused a concentration dependent decrease in the 
amplitude (A) and slope (B) of the evoked fEPSP (mean ± sem, n=4). 118 
 
Concentration 
(µM) 
Maximum effect (% of 
baseline compared to 
control slices) 
Maximum recovery 
achieved  at  10-20 
min post washing (% 
of baseline) 
Maximum recovery 
achieved  at  20-30 
min post washing (% 
of baseline) 
0.003  97. 1 ± 0.8**  100.3 ± 1.4  100.0 ± 1.7 
0.010  96.6 ± 0.6**  98.8 ± 1.2  97.6 ± 1.5 
0.030  96.6 ± 0.4**  99.0 ± 1.8  95.6 ± 1.9 
0.100  89.8 ± 1.2
**  90.4 ± 1.3  89.7 ± 1.8 
0.300  86.2 ± 0.8
**  91.9 ± 0.8*  91.7 ± 1.4* 
1.000  84.1 ± 1.8
**  90.0 ± 2.6*  89.3 ± 3.4 
 
Table 4.3.  The effect of a 10 minute application of sarin at a range of 
concentrations (0.003-1.000µM) on the amplitude of the evoked fEPSP.   
Also shown is the maximum recovery achieved during washing with drug-free ACSF 
(mean ± sem, n=4, * p<0.05, ** p<0.01, ***p<0.001 unpaired t-test (maximum effect vs 
control slices), paired t-test (recovery vs maximum effect)). 
 
Concentration 
(µM) 
Maximum effect (% of 
baseline compared to 
control slices) 
Maximum recovery 
achieved  at  10-20 min 
post washing (% of 
baseline) 
Maximum recovery 
achieved  at  20-30 
min post washing (% 
of baseline) 
0.003  95.9 ± 0.9
*  99.6 ± 2.0  99.3 ± 2.3 
0.010  96.0 ± 1.2*  96.4 ± 1.9  94.5 ± 1.4 
0.030  97.4 ± 2.7  96.5 ± 2.3  93.4 ± 2.4 
0.100  87.6 ± 2.4
**  89.3 ± 0.6  89.4 ± 1.4 
0.300  84.4 ± 1.8
**  88.1 ± 1.4  87.1 ± 1.1 
1.000  77.9 ± 2.7
**  85.9 ± 3.9*  85.2 ± 4.8 
 
Table 4.4.  The effect of a 10 minute application of sarin at a range of 
concentrations (0.003-1.000µM) on the slope of the evoked fEPSP.   
Also shown is the maximum recovery achieved during washing with drug-free ACSF 
(mean ± sem, n=4, * p<0.05, ** p<0.01, ***p<0.001 unpaired t-test (maximum effect vs 
control slices), paired t-test (recovery vs maximum effect)). 
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Figure 4.5.  Concentration-effect relationship for sarin in the guinea pig dentate 
gyrus.  
Sarin when applied for 30 minutes caused a concentration dependent decrease in the 
amplitude (A) and slope (B) of the evoked fEPSP (mean ± sem, n=4). 
 
 120 
 
Concentration 
(µM) 
Maximum effect  
(% of baseline 
compared to 
control slices) 
Maximum recovery 
achieved  at  10-20 min 
post washing (% of 
baseline) 
Maximum recovery 
achieved  at  20-30 min 
post washing (% of 
baseline) 
0.003  92.5 ± 1.5**  97.4 ± 2.7*  96.0 ± 3.0 
0.010  91.8 ± 1.5**  100.6 ± 5.2  98.8 ± 5.7 
0.030  89.5 ± 1.3**  96.2 ± 1.6*  94.3 ± 1.2* 
0.100  83.0 ± 0.6**  89.7 ± 1.3*  89.8 ± 1.6* 
0.300  81.2 ± 2.3**  86.9 ± 3.4*  86.3 ± 3.5* 
1.000  80.8 ± 1.0**  89.9 ± 2.1*  89.6 ± 2.1* 
3.000  84.2 ± 2.0**  92.1 ± 3.7  90.2 ± 4.4 
 
Table 4.5.  The effect of a 30 minute application of sarin at a range of 
concentrations (0.003-1.000µM) on the amplitude of the evoked fEPSP.   
Also shown is the maximum recovery achieved during washing with drug-free ACSF 
(mean ± sem, n=4, * p<0.05, ** p<0.01, ***p<0.001 unpaired t-test (maximum effect vs 
control slices), paired t-test (recovery vs maximum effect)). 
 
Concentration 
(µM) 
Maximum effect  
(% of baseline 
compared to 
control slices) 
Maximum recovery 
achieved  at  10-20 min 
post washing (% of 
baseline) 
Maximum recovery 
achieved  at  20-30 min 
post washing (% of 
baseline) 
0.003  90.5 ± 2.7**  97.0 ± 4.0  94.9 ± 4.3 
0.010  88.2 ± 1.6**  99.3 ± 7.2  97.4 ± 7.6 
0.030  88.5 ± 2.0**  93.5 ± 3.4*  91.7 ± 3.1 
0.100  80.4 ± 1.6**  87.5 ± 2.0**  87.4 ± 1.4** 
0.300  74.2 ± 5.3**  82.9 ± 5.4*  80.4 ± 5.4 
1.000  76.6 ± 1.2**  86.8 ± 3.1  85.5 ± 3.7 
3.000  81.8 ± 2.3**  89.1 ± 3.5  86.2 ± 5.1 
 
Table 4.6.  The effect of a 30 minute application of sarin at a range of 
concentrations (0.003-1.000µM) on the slope of the evoked fEPSP.   
Also shown is the maximum recovery achieved during washing with drug-free ACSF 
(mean ± sem, n=4, * p<0.05, ** p<0.01, ***p<0.001 unpaired t-test (maximum effect vs 
control slices), paired t-test (recovery vs maximum effect)). 
4.4.  Interactions between physostigmine and sarin 
 
To investigate any potential time-dependent interactions between the two 
anticholinesterase compounds, physostigmine was applied at various time points relative 
to the start of the sarin exposure.  A timeline for this part of the study is shown in Figure 4. 
2.  A low concentration of physostigmine (0.100µM) was chosen as this had little effect on 121 
the amplitude of the fEPSP by itself as shown in Figure 4.3.  This concentration also 
approximates a concentration achievable in the hippocampus following administration of 
0.2mg/kg physostigmine in the guinea pig.  This is the highest dose of physostigmine 
given in current in vivo assessments of the proposed next generation therapy (Wetherell 
et al., 2006).  This value is also approximate for a concentration of physostigmine that can 
be recorded in the rat hippocampus (Somani & Dube, 1989;Hallak & Giacobini, 1986).  
The average amplitude of the fEPSP recorded during the baseline was 2.2 ± 0.1 mV and 
the average slope was 2.4 ± 0.2 mV·msec
-1.   
 
4.4.1.  Effect of a concurrent application of physostigmine on the sarin-induced 
depression of the fEPSP 
 
Physostigmine when applied concurrently with sarin had no additional effect on the 
magnitude of the sarin-induced depression of the fEPSP amplitude.  This can be seen in 
concentration-effect relationship shown in Figure 4.6 and also in the IC50 of the 
concentration-effect relationship derived from these data (0.02µM for both the amplitude 
and slope of the fEPSP).  This supports the hypothesis that both compounds are acting in 
the same way  in the dentate gyrus and also that the maximum effects reported in Chapter 
3 are in fact the total effect on the cholinergic system present within the slice model.  
When both compounds where washed off the slice (Figure 4.7), there was an initial small 
yet statistically significant recovery in the amplitude of the fEPSP during the 10-20 minute 
recovery epoch recorded from slices exposed to sarin concentrations of 0.03 (p<0.05), 
0.30 (p<0.01) and 1.00µM (p<0.05).  The significance of this recovery was only 
maintained at the two highest concentrations during the next recovery epoch.  The slope 
of the fEPSP only showed a significant recovery at 1.00µM sarin (p<0.05) during the first 
epoch.  This was not maintained through into the second recovery epoch.  Slices exposed 
to 0.30µM sarin showed a significant recovery in the slope of the fEPSP when measured 
during the second epoch (p<0.05).  However the recovery observed in slices exposed to 
sarin at concentrations greater than 0.03µM did not reach baseline amplitudes. 
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Figure 4.6.  Concentration-effect relationship for sarin applied concurrently with 
0.100µM physostigmine for 10 minutes in the guinea pig dentate gyrus (●).   
The data for slices exposed to sarin alone are shown for comparison (●).  As before 
sarin caused a concentration dependent decrease in the amplitude (A) and slope (B) 
of the evoked fEPSP (mean ± sem, n=4). 123 
 
Sarin 
concentration 
(µM) 
Maximum effect  
(% of baseline 
compared to control 
slices) 
Maximum recovery achieved  at  
10-20 min post washing (% of 
baseline) 
Maximum recovery achieved  at  
20-30 min post washing (% of 
baseline) 
0.010  98.8 ± 0.7  103.8 ± 1.2**  102.8 ± 1.3* 
0.030  97.7 ± 0.4  104.3 ± 2.0  103.4 ± 1.8 
0.100  93.9 ± 1.6  96.6 ± 1.5  96.2 ± 1.7 
0.300  86.0 ± 1.1**  93.9 ± 2.3*  95.1 ± 1.9** 
1.000  83.3 ± 2.2**  90.0 ± 1.5**  89.8 ± 1.9** 
 
Table 4.7.  The effect of a concurrent application of 0.100µM physostigmine on 
the sarin induced depression of the amplitude of the evoked fEPSP.   
Also shown is the maximum recovery achieved during washing with drug-free ACSF 
(mean ± sem, n=4, * p<0.05, ** p<0.01, ***p<0.001 unpaired t-test (maximum effect vs 
control slices), paired t-test (recovery vs maximum effect)). 
 
Sarin 
concentration 
(µM) 
Maximum effect  
(% of baseline 
compared to control 
slices) 
Maximum recovery achieved  at  
10-20 min post washing (% of 
baseline) 
Maximum recovery achieved  at  
20-30 min post washing (% of 
baseline) 
0.010  97.5± 0.6  102.1 ± 1.4*  101.8 ± 1.3 
0.030  97.0 ± 0.3  102.4 ± 2.2  101.8 ± 2.6 
0.100  93.9 ± 0.9  94.6 ± 2.3  94.4 ± 2.4 
0.300  86.6 ± 0.6**  93.3 ± 1.8*  94.6 ± 2.1* 
1.000  80.6 ± 3.2**  88.2 ± 2.5**  87.6 ± 2.6** 
 
Table 4.8.  The effect of a concurrent application of 0.100µM physostigmine on 
the sarin induced depression of the slope of the evoked fEPSP.   
Also shown is the maximum recovery achieved during washing with drug-free ACSF 
(mean ± sem, n=4, * p<0.05, ** p<0.01, ***p<0.001 unpaired t-test (maximum effect vs 
control slices), paired t-test (recovery vs maximum effect)). 125 
shown in Figure 4.8.  However in contrast to slices exposed to sarin or sarin concurrently 
with physostigmine, slices pretreated with 0.100µM physostigmine 10 minutes prior to 
sarin exposure showed a large recovery in both the amplitude and slope of the fEPSP at 
all concentrations of sarin tested (Figure 4.9).  The levels of fEPSP recovery observed are 
compared in Figures 4.10, 4.11, 4.12, and 4.13.  With the exception of slices exposed to 
0.10µM sarin, all slices showed a robust recovery which started almost immediately after 
both compounds were washed off the slice.  The recovery seen in slices exposed to 
0.30µM sarin (amplitude 101.9 ± 2.9% of baseline, slope 100.3 ± 1.4% of baseline) and 
1.00µM sarin (amplitude 104.7 ± 43.1% of baseline, slope 109.4 ± 3.4% of baseline) sarin 
was highly significant (0.30µM both parameters p<0.01; 1.00µM both parameters 
p<0.001).  This recovery was sustained across both recovery epochs and also until the 
end of the experiment. 
 
To further test the time-dependency of this finding, a small number of slices (n=4) were 
pretreated with 0.100µM physostigmine either 1 minute or 30 seconds prior to exposure to 
1µM sarin.  Four slices were also treated with 0.10µM physostigmine 1 minute post sarin 
exposure.  This is shown in Figure 4.14.  Altering the time of physostigmine application 
relative to the sarin challenge did not modify the magnitude of the sarin induced 
depression of the fEPSP (with the exception of the slope of slices pretreated with 
physostigmine 1 minute before sarin challenge p<0.05).   Whilst the level of recovery seen 
in slices pretreated with physostigmine appeared to be greater than that seen in slices 
exposed to sarin with no physostigmine, this was not statistically significant during either 
epoch (with the exception of the recovery of the slope of slices pretreated 1 minute before 
sarin challenge during the 10-20 minute epoch p<0.05). 
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Figure 4.8.  Concentration-effect relationship for a 10 minute application of sarin 
applied 10 minutes after 0.100µM physostigmine in the guinea pig dentate gyrus 
(●).   
The data for slices exposed to sarin alone are shown for comparison (●).  As before 
sarin caused a concentration dependent decrease in the amplitude (A) and slope (B) 
of the evoked fEPSP (mean ± sem, n=4). 127 
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Figure 4.9.  The effect of pretreatment for 10 minutes with 0.100µM 
physostigmine on the sarin induced depression of the fEPSP. 
Amplitude (A) and slope (B) of the evoked fEPSP (sarin concentrations shown in 
graph legend; data presented as a mean of 4 slices with error bars omitted for clarity). 128 
 
Sarin 
concentration 
(µM) 
Maximum effect (% of 
baseline compared to 
control slices) 
Maximum recovery 
achieved  at  10-20 
min post washing (% 
of baseline) 
Maximum recovery 
achieved  at  20-30 
min post washing (% 
of baseline) 
0.010  94.7 ± 1.1**  103.9 ± 3.6*  106.1 ± 4.4* 
0.030  94.9 ± 0.6**  101.5 ± 0.7***  101.2 ± 3.2 
0.100  88.6 ± 1.4**  98.6 ± 4.9  99.2 ± 4.9 
0.300  87.1 ± 1.7**  101.9 ± 2.9*  100.3 ± 1.4** 
1.000  85.1 ± 1.4**  104.7 ± 4.1**  109.4 ± 3.4** 
 
Table 4.9.  The effect of a single application of 0.100µM physostigmine 10 
minutes prior to the application of sarin on the amplitude of the evoked fEPSP.   
Also shown is the maximum recovery achieved during washing with drug-free ACSF 
(mean ± sem, n=4, * p<0.05, ** p<0.01, ***p<0.001 unpaired t-test (maximum effect vs 
control slices), paired t-test (recovery vs maximum effect)). 
 
Sarin 
concentration 
(µM) 
Maximum effect  
(% of baseline 
compared to 
control slices) 
Maximum recovery 
achieved  at  10-20 min 
post washing (% of 
baseline) 
Maximum recovery 
achieved  at  20-30 min 
post washing (% of 
baseline) 
0.010  94.3 ± 1.0**  106.1 ± 4.4*  104.0 ± 5.6 
0.030  94.5 ± 3.0**  101.2 ± 3.2**  100.4 ± 3.9* 
0.100  88.1 ± 1.5**  99.2 ± 4.9   96.0 ± 5.6 
0.300  84.9 ± 1.5**  100.3 ± 1.4***  100.2 ± 2.2** 
1.000  78.4 ± 2.2**  109.4 ± 3.4**  110.3 ± 3.8** 
 
Table 4.10.  The effect of a single application of 0.100µM physostigmine 10 
minutes prior to the application of sarin on the slope of the evoked fEPSP.   
Also shown is the maximum recovery achieved during washing with drug-free ACSF 
(mean ± sem, n=4, * p<0.05, ** p<0.01, ***p<0.001 unpaired t-test (maximum effect vs 
control slices), paired t-test (recovery vs maximum effect)). 129 
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Figure 4.10.  Comparison of the level of recovery recorded during the 10-20 
minute epoch post start of washing.  
Data recorded during the 10-20 minute epoch post start of washing in slices that have 
received either no physostigmine (white bar), 0.10µM physostigmine 10 minutes 
before sarin (hatched bar), or a concurrent application of 0.10µM physostigmine (solid 
black bar).  Results are shown for the amplitude (A) and slope (B) of the fEPSP 
compared to the maximum effect of 1µM sarin on each parameter (mean ± sem, n=4, 
* p<0.05, ** p<0.01, ***p<0.001 paired t-test). 130 
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Figure 4.11.  Comparison of the level of recovery recorded during the 20-30 
minute epoch post start of washing. 
Data recorded in slices that have received either no physostigmine (white bar), 
0.10µM physostigmine 10 minutes before sarin (hatched bar), or a concurrent 
application of 0.10µM physostigmine (solid black bar).  Results are shown for the 
amplitude (A) and slope (B) of the fEPSP compared to the maximum effect of 1µM 
sarin on each parameter (mean ± sem, n=4, * p<0.05, ** p<0.01, ***p<0.001 paired t-
test). 131 
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Figure 4.12.  Comparison of the level of recovery achieved during the 10-20 
minute epoch post start of washout. 
(A) amplitude and (B) slope of the fEPSP.  Slices were exposed to either sarin (●), 
0.10µM physostigmine and sarin (●), or 0.10µM physostigmine 10 minutes before 
sarin (●).  Data expressed as mean ± sem, n=4. 132 
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Figure 4.13.  Comparison of the level of recovery achieved during the 20-30 
minute epoch post start of washout 
(A) amplitude and (B) slope of the fEPSP.  Slices were exposed to either sarin (●), 
0.10µM physostigmine and sarin (●), or 0.10µM physostigmine 10 minutes before 
sarin (●).  Data expressed as mean ± sem, n=4. 133 
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Figure 4.14.  The effect of time of physostigmine application relative to sarin 
challenge on the recovery observed. 
Amplitude (A) and slope (B) of the fEPSP after a single challenge with 1.00µM sarin.  
Physostigmine (0.10µM) was added 10 minutes before (█), 1 minute before (█), 30 
seconds before (█) and 1 minute after the sarin challenge (█).  Slices exposed to 
1.00µM sarin with no physostigmine are also shown for comparison (█).  Data 
presented as a mean of 4 slices with error bars omitted for clarity.  Data have been 
adjusted so that the sarin application acts as a datum across conditions. 
  
4.4.3.  Effect of increasing the concentration of physostigmine 
 
A small number of studies were carried out using 3.00µM physostigmine to investigate if 
the concentration of physostigmine as well as time of application was important in the 
recovery of the amplitude of the fEPSP in slices exposed to sarin.  Four slices were 
pretreated with 3.00µM physostigmine 30 seconds prior to challenge with 1.00µM sarin 134 
(Figure 4.15).  Increasing the concentration of physostigmine to 3.00µM significantly 
reduced the magnitude of the sarin-induced depression of the amplitude of the fEPSP 
compared to that recorded from slices that had received no physostigmine (89.8 ± 0.6% of 
baseline amplitude compared to 84.1 ± 1.8% of baseline amplitude in slices which 
received no physostigmine, p<0.05).  The slices showed significant recovery in both 
parameters measured during the 10-20 minute recovery epoch (p<0.01) compared to 
slices which received no physostigmine.  This recovery was sustained during the next 
epoch (amplitude p<0.05 and slope p<0.01). 
 
In a separate study, four slices were concurrently exposed to 1.00µM sarin and 3.00µM 
physostigmine (Figure 4.16).  The increase in physostigmine concentration had no effect 
on the magnitude of the sarin-induced depression of the fEPSP when measured in either 
parameter.  Despite an apparent recovery during both the first recovery epoch (10-20 
minutes), there was no statistical difference between both physostigmine concentration 
used and that recorded from slices exposed to sarin alone.  However the recovery 
observed in slices which received 3µM physostigmine concurrently with the sarin 
challenge reached a statistically significant level during the 20-30 minute recovery epoch.   
 135 
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Figure 4.15.  The effect of physostigmine concentration on the sarin induced 
depression (pretreatment). 
Amplitude (A) and slope (B) of the fEPSP.  Physostigmine at 3.00µM was added 30 
seconds before challenge with 1.00µM sarin.  Data from slices pretreated with 0.10µM 
physostigmine 30 seconds before sarin challenge and slices which received no 
physostigmine are also shown for comparison.  Data presented as mean ± sem n=4. 136 
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Figure 4.16.  The effect of physostigmine concentration on the sarin induced 
depression (concurrent application). 
Amplitude (A) and slope (B) of the fEPSP.  Physostigmine at 3.00µM (-) was added 
concurrently with 1.00µM sarin.  Data from slices which 0.10µM physostigmine 
concurrent with 1.00µM sarin challenge (-), and slices which received no 
physostigmine (-) are also shown for comparison.  Data presented as mean ± sem 
n=4. 
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4.5.  Discussion 
 
The aim of this study was to investigate the actions of the carbamate physostigmine and 
the organophosphorus nerve agent sarin in the dentate gyrus slice model.  The previous 
chapter has shown that this model retains an innate cholinergic response.  The use of the 
dentate gyrus slice model builds upon previous work which has utilised slices of the 
hippocampus (of which the dentate gyrus is part) to study the effects of nerve agents and 
other cholinesterase inhibitors on the production of seizures (Harrison et al., 
2000;Harrison et al., 2004). 
 
To allow a full understanding of the effects of both compounds in the dentate gyrus model, 
the concentration dependent effects of these compounds have been characterised.  The 
production of a concentration-effect relationship for sarin in this model has not been 
reported before and is a novel piece of information furthering our understanding of the 
CNS effects of this compound.  The range of concentrations tested includes those at 
which previous in vitro work has been conducted in the hippocampal slice (Harrison et al., 
2004).  Both compounds caused concentration dependent decreases in the output of the 
medial perforant path measured as a fEPSP in the molecular layer of the dentate gyrus.  
The effect of physostigmine 10µM on the amplitude of the fEPSP (reduction to 83.7 ± 
1.0% of baseline) is of a similar magnitude to that reported previously in the rat dentate 
gyrus slice (Colgin et al., 2003).  The effect reported in the present study has been shown 
to be consistent and robust, and therefore reinforces the suitability of the guinea pig for 
use in OP and nerve agent studies. 
 
A similar study which used the anticholinesterase compound S27 has been reported.  This 
compound is based on the nerve agent soman, and has been structurally altered so that it 
resembles an aged version of the parent agent compound.  This makes it a potent 
inhibitor of AChE which is resistant to intervention by existing therapies such as oximes.  
The results obtained for sarin in the present study compare favourably with those reported 
for S27 (reduction to 84.1 ± 1.8% of baseline compared to 81.0 ± 4.0% reported for S27) 
(Melchers et al., 1994).  These results taken with those presented in chapter 3 show that 
the depression of the fEPSP in the dentate gyrus is mediated by the inhibition of AChE.  
The resultant excess of ACh then acts to stimulate inhibitory GABAergic transmission 
within the dentate gyrus.  This results in a decrease in the excitability of the principal 
granule cells, which is recorded in vitro as a decrease in the amplitude of the fEPSP 
(Canning & Leung, 2000).  
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The concentration-effect relationships shown in Figures 4.2, 4.3 and 4.4 show that 
increasing the concentration of the AChE inhibitor to 30.00µM physostigmine and 3.00µM 
sarin, does little to cause further reductions in the magnitude of the fEPSP.  Comparing 
the findings of the present study and those reported by others in the literature (Melchers et 
al., 1994) (Colgin et al., 2003), it would appear that a reduction of the amplitude of the 
fEPSP by approximately 20% can be considered the maximum depression achievable by 
AChE inhibition.  However, another study using slices taken from guinea pigs reported a 
much larger depression (~50%) when the cholinergic agonist carbachol (20µM) was 
applied (Kahle & Cotman, 1989). 
 
The protective actions of physostigmine in this model are believed to be due to its ability 
to reversibly inhibit the actions of AChE.  Physostigmine acts as a reversible pseudo-
inhibitor of AChE (the term pseudo-inhibitor is used as the inhibition of AChE by 
physostigmine is not truly reversible as the carbamate is metabolised via a process called 
decarbamolyation and is therefore altered during the interaction).  Physostigmine (and 
other carbamates) sequesters a pool of AChE which is effectively inactive during the 
challenge with the nerve agent.  This sequestered enzyme is therefore protected from 
being phosphorylated by circulating nerve agent which would result in the enzyme being 
irreversibly inhibited.  Once the metabolism of the reversible inhibitor has been completed, 
the AChE molecule is free to interact with either ACh or another inhibitor molecule.  This 
process is ongoing during the nerve agent challenge and effectively produces a supply of 
active AChE to allow normal termination of the cholinergic signal.  The organophosphorus 
compound whilst quickly reaching a high plasma concentration is rapidly metabolised to 
the phosphonic acid metabolite and excreted.  It is desirable therefore to select a 
reversible inhibitor of AChE which has a half life longer than the period when the nerve 
agent is at its peak concentration.  The half-life (t1/2) for the decarbamolyation of 
physostigmine in the guinea-pig is 32 minutes (erythrocyte).  It is possible that 
approximately 5% of physostigmine-inhibited AChE will be made available within 1-2 
minutes following application (Wetherell & French, 1991).  The protective inhibition of a 
pool of AChE by physostigmine has been shown theoretically by Green using a dynamic 
kinetic model (Green, 1983).  This has recently been confirmed in vitro  by (Eckert et al., 
2006).   
 
The results from the present study have shown that the effectiveness of physostigmine 
treatment in reversing a nerve agent induced change in the slice response increases with 
the amount of time it is present before the nerve agent challenge.  The protective action of 
physostigmine has been described as prophylactic and has been shown theoretically 
(Green, 1983) and is in agreement with the findings of the present study.  This has been 
shown to also be the case in vivo.  Koster showed that physostigmine given before DFP 139 
protected cats against the lethal effects of the organophosphate (Koster, 1946).  More 
recent studies by Berry and Davies (Berry & Davies, 1970) and Gordon et al., (Gordon et 
al., 1978) have confirmed this and reported that the optimum time between application of 
carbamate (physostigmine, pyridostigmine, mobam, or decarbofuran) and 
organophosphate was between 10 and 60 minutes depending on the carbamate used 
(physostigmine most effective following 10 minutes of pretreatment (Berry & Davies, 
1970;Gordon et al., 1978)).  This correlates well with the results of pharmacokinetic 
studies in rats which showed that following an intramuscular injection of 650µg/kg 
[
3H]physostigmine, the plasma ratio of physostigmine in the brain peaked after 15-22 
minutes before decreasing (Somani & Khalique, 1986).   
 
This time course also approximates to the time required for a steady state of inhibition 
(where inhibition of AChE is balanced by the reactivation of previously inhibited AChE) of 
blood AChE to be reached in guinea pigs (Dawson 1981).  The deacylation step in the 
decarbamolyation process is the rate limiting step in this reaction (Triggle et al., 1998).  
The application interval of 10 minutes used in the present study would therefore allow the 
AChE present within the dentate gyrus to approach this steady state of inhibition.  In 
contrast, organophosphates being more potent inhibitors of AChE are likely to reach a 
steady state of inhibition much quicker following application.  Decreasing the time 
between physostigmine application and nerve agent challenge as in the present study, 
therefore changes the dynamic relationship between the two inhibitors allowing a smaller 
pool of AChE to be protected by physostigmine.  This appears to be independent of the 
concentration of physostigmine used.  Increasing the concentration of physostigmine to 
3.00µM from 0.10µM in the present study did not affect the recovery seen in slices 
exposed to 1.00µM sarin and the higher concentration of physostigmine.  This would 
suggest that the relationship between the two inhibitors when applied together is not 
competitive.  Again this finding supports the hypothesis that proposed by Green (Green, 
1983). 
 
Residual AChE activity can be measured in samples which have been treated with 
supramaximal concentrations of anticholinesterase compounds.  Following inhibition with 
an irreversible inhibitor of AChE, this activity is depressed but will undergo limited 
recovery following removal of the inhibitor.  If the same assay is pretreated with 
physostigmine, the level of residual activity is increased and the AChE activity undergoes 
a rapid recovery following removal of both inhibitors (Eckert et al., 2006).  The time course 
of this effect is similar to that reported for fEPSP recovery in the present study.  It is 
possible that the proportion of AChE not affected by the inhibitor may maintain enough 
control over the level of ACh, to allow transmission from the perforant path into the 
molecular layer of the dentate gyrus.  Delaying the application of physostigmine would 140 
therefore reduce the amount of AChE available to undergo spontaneous reactivation.  
This would therefore explain the depressed recovery seen in slices which received 
physostigmine either concurrent to, or after the sarin challenge.   
 
As well as an effective pretreatment against nerve agent poisoning, physostigmine has 
also been shown to have beneficial effects when applied post poisoning.  Berry and 
Davies (Berry & Davies, 1970) reported that a single application of physostigmine (28-
54µg/kg) 1 minute post challenge with soman effectively increased the LD50 of the nerve 
agent two-fold.  Physostigmine has been used successfully as part of a novel immediate 
therapy combination that prevents lethality and lessens the severity of incapacitation 
observed in guinea pigs challenged with a range of nerve agents (Wetherell et al., 
2006;Wetherell et al., 2007).  As reported above, the relative inability of physostigmine to 
reverse the sarin induced depression of the fEPSP when given concurrently or 1 minute 
after sarin challenge in the current study is intriguing.  In the current study, two 
concentrations of physostigmine (0.10 and 3.00µM) were administered concurrently with 
the sarin challenge.  A significant level of recovery was only seen in slices that received 
the higher 3.00µM application of physostigmine.  No significant recovery was seen in 
slices treated post sarin challenge.   
 
The differences between these findings and those of the in vivo studies may be due to the 
inclusion of other components of the immediate therapy.  In the in vivo studies 
physostigmine was combined with the cholinergic antagonist scopolamine, and the oxime 
HI-6.  The effect of scopolamine in this therapy is two-fold.  Primarily, it counters the 
cholinergic effects of physostigmine and organophosphates (excess ACh) and secondly it 
has limited anticonvulsant properties if given immediately post poisoning.  Oximes have 
the ability to dephosphorylate AChE, thereby removing the nerve agent complex and 
reactivating the enzyme.  As well as the action on AChE, several studies have suggested 
that various oximes have other beneficial effects not related to the reactivation of AChE.  
These include direct interaction with the nicotinic ion channel (Tattersall, 1993;Tattersall, 
1990), and interactions between HI-6 and physostigmine decreasing the rate at which 
AChE is carbamoylated (Dawson, 1994).  The actions of both of these compounds may 
be acting on processes that are not visible using the dentate gyrus slice model and are 
relevant to the whole animal model.  Oximes were not included in the current slice study 
due to a lack of time available to conduct the necessary experiments. 
 
In the military and law enforcement context, pretreatment is a feasible option available to 
the commanding officer in most situations where there is a possible or probable exposure 
of personnel to nerve agents or similar compounds, and the timings used in this project 
reflect this to a large degree.  In contrast whilst the use of OP pesticides is widespread 141 
around the world, the use of any form of pretreatment or prophylaxis is unlikely to occur.  
This may be due to several factors including logistical burden, cost, accountability, and the 
ethical consideration of taking a drug with known side effects on the off chance of 
exposure.  For these reasons, agricultural exposures of humans to OP compounds is 
more likely to continue to be treated as a hospital case with antimuscarinic, anticonvulsant 
and oxime compounds.  Similarly in the event of a deliberate release of nerve agent or 
other OP (i.e. terrorist attack), there would be no opportunity for pretreatment and the 
treatment given post-exposure is also likely to follow the antimuscarinic, anticonvulsant, 
and oxime regime. 
 
In conclusion this study has shown that physostigmine effectively reverses the effects of 
the nerve agent sarin in a model of a central cholinergic response.  This effect was 
dependent on the time between application of physostigmine and the challenge with sarin.  
Whilst the relative lack of effect of a concurrent or delayed application of physostigmine 
agrees with the kinetic model proposed by Green (Green, 1983), the differences between 
this slice model and the results reported in vivo require further investigation.  The addition 
of other components of the proposed next generation therapy (HI-6 and scopolamine) 
would also further extend these findings and allow a better mechanistic understanding of 
the actions and interactions of the therapy compounds in a model of the CNS. 142 
5.    Effect of sarin on the activity of 
AChE in the hippocampus 143 
5.1.  Introduction 
 
The experimental findings discussed in the previous chapters have demonstrated a nerve 
agent induced change in an excitatory response recorded from the dentate gyrus.  This 
effect is mediated by inhibition of AChE, thus prolonging the effect of ACh within the 
dentate gyrus slice.  To date there is a paucity of published data which quantitatively links 
AChE inhibition to a change in an electrophysiological response recorded in vitro.  The 
following work was conducted to investigate the level of inhibition of AChE within slices 
exposed to sarin at the concentrations used in Chapter 4.  This was then compared with 
the level of decrease seen in the fEPSP recorded from the molecular layer of the dentate 
gyrus.  This will be a novel interpretation of the data and will allow the level of AChE 
inhibition needed to have a functional effect in this model to be determined. 
 
The main mechanism of action of OPs and nerve agents is to inhibit AChE.  This in turn 
leads to the physical signs of poisoning and detriment to normal functioning.  The rate at 
which tissue cholinesterases (ChE) present with the dentate slice model are able to 
metabolise suitable substrates was measured using a modified Ellman assay (Ellman et 
al., 1961).  This is a two step assay and the principle reactions of this assay method are 
shown in Figure 5.1.  Briefly, a thiol-bearing substrate (acetylthiocholine or 
butyrylthiocholine) is hydrolysed by ChE to yield thiocholine.  This then reduces the 
chromagen 5,5’- dithiobis-2-benzoate (DTNB) to yield the coloured (yellow) dianion, 5-
thio-2-nitrobenzoic acid (TNB).  The production of TNB is then measured 
spectrophotometrically (change in absorbance) at 412nM.  The rate at which the intensity 
of the yellow product increases is a direct measure of the rate at which ChE is breaking 
down acetylthiocholine or other substrate.  In this assay no inhibitors of other 
cholinesterases such as BuChE were added, so the results presented here are a 
combination of both AChE and BuChE activity. 
 
1)  Acetylthiocholine  Thiocholine + Acetate
2)  Thiocholine + DTNB TNB (yellow)
ChE
1)  Acetylthiocholine  Thiocholine + Acetate
2)  Thiocholine + DTNB TNB (yellow)
ChE
 
 
Figure 5.1.  Principle of the Ellman method for the spectrophotometric 
determination of cholinesterase activity. 
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5.2.  Methods 
 
Whole hippocampi were sliced as described in Chapter 2.  The slices were then exposed 
for ten minutes to sarin across the same concentration range as used in Chapter 4 
(0.003µM-1.000µM), followed by a two minute wash in drug-free recording ACSF.  At least 
two hippocampi from separate animals were exposed separately to each concentration of 
nerve agent.  The tissue was not pooled.  Three replicates were carried out on each 
hippocampal homogenate.  Control slices were treated in the same manner as nerve 
agent treated slices but were not exposed to sarin.  The amount of protein present in each 
homogenate was determined using the method detailed in chapter 2.  All procedures were 
carried out at ambient room temperature (approximately 20ºC). 
 
5.3.  Effect of sarin on hippocampal cholinesterase activity 
 
Homogenates of control slices had a mean ChE activity of 0.004 ± 0.0005 µmol mg
-1 min
-1 
(minimum 0.003 µmol mg
-1 min
-1, maximum 0.005 µmol mg
-1 min
-1, corrected for protein, 
n=4).  Exposure to sarin at the three lowest concentrations tested (0.003µM, 0.010µM and 
0.030µM) caused little change in the level of ChE activity, with an apparent increase in 
activity seen in slices exposed to 0.010µM and 0.030µM sarin.  This however was not 
statistically significant.  In contrast, ChE activity was significantly reduced in the 
homogenates from slices exposed to the three highest concentrations of sarin (p<0.05 
unpaired t-test).  The activity data are shown in Figure 5.2.   145 
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Figure 5.2.  The effect of increasing sarin concentration on the activity of 
cholinesterase within hippocampal slice homogenates.   
Sarin at concentrations above 0.100µM significantly decreased the level of ChE 
activity recorded (*p<0.05, **p<0.01, unpaired t-test compared to control activity).  
Activity values have been corrected for the amount of protein present in the 
homogenate.  Data presented are the mean of three replicates from two separate 
hippocampi ± sem (n=4 control (0µM), n=2 for sarin exposed slices). 
 
5.4.  Correlation of ChE inhibition and functional effect in the dentate gyrus 
  slice 
 
The relationship between hippocampal ChE inhibition and changes in the evoked fEPSP 
was investigated.  The level of ChE inhibition (as a percentage of control slices) was 
plotted against the changes recorded in the size of the fEPSP (presented as percentage 
of maximum change) following exposure to sarin (Figure 5.3).   
 
Whilst the effect of sarin on the amplitude of the fEPSP (-2.9 to -15.9 % difference from 
control (Table 4.3)) was significantly different from control slices at all concentrations 
tested, this covered a range of ChE inhibition from +22.8% (increase in activity compared 146 
to control samples) to -82.2%.  As seen in Figure 5.2 the inhibition of ChE in this model 
was only statistically different from control when it reached a level of between -71.7% to – 
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Figure 5.3.  The relationship between ChE inhibition and functional response. 
Effect of ChE inhibition on the amplitude (A) and slope (B) of the fEPSP recorded from 
the molecular layer of the guinea pig dentate gyrus (mean ± sem, n=4).   
 
82.2% of control.  This was achieved with sarin concentrations of between 0.100 – 
1.00µM.  The greatest effect on the amplitude of the evoked fEPSP was also recorded 
following exposure to these concentrations of sarin.  A similar result was seen in the 
magnitude of the slope of the fEPSP. 
 
5.5.  Discussion 
 
This study has shown that the nerve agent sarin inhibits the activity of ChE within the 
hippocampus in a concentration dependent manner.  The inhibition of ChE can then be 
related to the changes in the fEPSP recorded in the dentate gyrus and presented in the 147 
preceding chapters.  Interestingly the level of ChE inhibition does not appear to be directly 
correlated with the magnitude of the depression seen in the fEPSP recorded post sarin 
exposure.  As shown in Chapter 4, sarin exposure caused a significant decrease in the 
amplitude of the fEPSP at all concentrations tested (Figure 4.4 and Table 4.3).  However 
in comparable hippocampal slices exposed to sarin, the level of ChE inhibition was not 
significantly different from controls until the concentration of sarin exceeded 0.10µM and 
the relative activity of ChE was inhibited by approximately 71%.   
 
One interpretation of the data shown in Figure 5.3 is that the perforant pathway is 
relatively tolerant of low level ChE inhibition.  However at higher levels of ChE inhibition, 
the system becomes less tolerant and functional deficits become more obvious.  This 
raises the possibility that there is reserve capacity of ChE enzymes (including AChE), in 
the hippocampus.  In making any interpretation of this data, however, one must remember 
that this is drawn from a small number of slices (n=2).  To fully understand the relationship 
between the level of ChE inhibition and effect on the fEPSP, more experiments are 
required.  As well as increasing the overall number of replicates, further concentrations of 
sarin which caused inhibition of ChE activity by between 25 and 50% of control would 
need to be tested.  This would allow for the true slope of the relationship shown in Figure 
5.3 to be determined.  
 
If, as postulated here, there is reserve capacity in the functional level of ChE activity in this 
system, it would be a very useful characteristic.  Reserve capacity implies that a 
proportion of available enzyme could effectively be removed from use without any 
significant detriment to function.  In the rat, the absolute minimum level of AChE activity at 
the neuromuscular junction following excess OP inhibitor has been defined as 3% of 
normal (Eckert et al., 2006).  In the guinea pig it has been reported that sarin (42µg/kg (~1 
x LD50)) caused a rapid inhibition of blood (both red blood cell and white blood cell) AChE 
to between 5 and 10% of control values after 10 minutes.  However in the hippocampus 
AChE activity was only reduced to a minimum of approximately 35% of control activity 
after 15 minutes (Shih et al., 2005).  This level of inhibition agrees well with that reported 
in the current study, although it must be remembered that the concentration of agent may 
have been different once metabolic processes in vivo have been taken into consideration.   
Reserve capacity in the level of ChE enzymes has been reported elsewhere within the 
mammalian nervous system including the NMJ (Wood & Slater, 2001). 
 
AChE and the related enzyme BuChE can be found throughout the central and peripheral 
nervous systems (PNS).  There is also evidence that as well as hydrolysing choline 
esters, these enzymes are also involved in many non-cholinergic processes 
(Balasubramanian & Bhanumathy, 1993;Whittaker, 1993).  In the CNS, AChE can be 148 
found both within areas rich in markers of cholinergic transmission and other areas such 
as the substantia nigra which have little or no cholinergic activity (Holmes et al., 
1997;Llinás & Greenfield, 1987).  BuChE is also found in relatively high concentrations in 
both the CNS and PNS and has been shown to be located in neurons, glia, and 
endothelial cells (for review see (Darvesh et al., 2003).  In the hippocampus, neurons 
staining for BuChE and AChE can be visualised in the stratum pyramidale and stratum 
oriens as well as the polymorphic layer of the dentate gyrus (Darvesh et al., 1998).  In 
studies using AChE knockout mice, BuChE has been shown to be important for survival 
by modulating the action of ACh within the synapses of central respiratory centres 
(Chatonnet et al., 2003;Duysen et al., 2001). However it is reported that BuChE is not 
simply replacing AChE and hydrolysing ACh as it appears to act by reducing the release 
of ACh via a presynaptic modulatory process (Chatonnet et al., 2003).  This has also been 
reported at the neuromuscular junction of this mouse model (Minic et al., 2003). 
 
The level of ChE inhibition caused by physostigmine in the study reported here was not 
investigated.  Physostigmine acts to reversibly inhibit AChE.  The bound enzyme then 
becomes available as the complex undergoes a decarbamolyation reaction.  As this 
process will be continuing as the samples are prepared, it is impossible to have high 
levels of confidence in the levels of inhibition recorded from physostigmine-treated 
hippocampi; the variability between technical and biological replicates will be substantial 
dependent upon the bound/unbound state of the physostigmine. 
 
Comparing the data presented in Chapters 4 and 5, there is an interesting anomaly 
between the two sets of experiments.  The data presented in Chapter 4 (Table 4.3) clearly 
shows that sarin at 0.003, 0.01 and 0.03µM significantly reduces the amplitude of the 
fEPSP.  However the data presented in this chapter shows that there are no significant 
changes in the activity of ChE in slices exposed to these same concentrations of sarin.  
There are two possible explanations for this.  Firstly, ChE inhibition may not be the only 
process involved in reducing the amplitude of the fEPSP.  One explanation for the data 
obtained from slices exposed to the lower concentrations of sarin, is that the sarin may be 
acting directly on the granule cells possibly via muscarinic receptors.  The direct 
interaction between anticholinesterase compounds and muscarinic receptors has been 
reported previously (Huff et al., 1994;Bomser & Casida, 2001).  It is conceivable that such 
a process may be taking place in tandem with that mediated by ChE inhibition.  Further 
experiments in which slice ChE was totally inhibited before the application of sarin, would 
be required to test this theory.  The second explanation for this discrepancy is due to the 
limitations of the Ellman method and also the small number or replicates used in the 
current study.   
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The relative activity of ChE within the samples used is lower than most of those reported 
in the related literature.  This may be largely due to the fact that the data presented in this 
study comes from tissue sample which included the total protein fraction and not that 
collected after centrifugation.  Centrifugation and analysis of the resultant pellet would 
result in a lower volume of protein per unit activity thereby raising the level of activity per 
unit volume.  The use of a detergent such as Triton-X 100 may also increase the level of 
activity as a result of solubilising the cell.  The results presented in the current study 
should be taken with the caveat that the number of samples is low and there is evidence 
of variability between samples that received the same treatment.  Further work is required 
to confirm these preliminary results.  
 
The current study is novel in that it has addressed the relationship between ChE inhibition 
in the dentate gyrus and changes in an electrophysiological response in CNS tissue.  
Previous studies have shown that ChE inhibitors such physostigmine as can modify the 
output of principal cells of the hippocampus such as the pyramidal cells of CA1 and the 
granule cells of the dentate gyrus (Misgeld et al., 1989;Colgin et al., 2003;Harrison et al., 
2004).  However, ChE activity was not recorded in these slices.  Further work is required 
to fully understand the relationship between ChE inhibition and decrease in functional 
response (as measured in the fEPSP). 
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6.   Discussion 151 
6.1.  Introduction 
 
This study was designed with two primary objectives.  Firstly, to investigate the 
mechanisms of action of anticholinesterase compounds in an in vitro model of a 
cholinergic response in the CNS, and secondly to investigate interactions between two 
different anticholinesterase compounds.   
 
To achieve these aims a model of a cholinergic response in the CNS needed to be 
identified that fulfilled a set of criteria including the ease of preparation, the presence of a 
good intrinsic cholinergic network, and the retention of cholinergic activity which can be 
modulated by anticholinesterase compounds in vitro.  Based on the findings of a literature 
review, a brain slice model of the hippocampus, specifically the dentate gyrus, was 
chosen for use in this study.  Dentate gyrus slices exhibit an excitatory (glutamatergic) 
response following electrical stimulation of the perforant path which can be modified by 
application of compounds which inhibit AChE (Colgin et al., 2003;Melchers et al., 
1994;Colgin et al., 2003) and cholinergic agonists (Kahle & Cotman, 1989).  The effect of 
carbamate AChE inhibitor physostigmine was first confirmed in slices prepared from the 
rat, before being transferred to the guinea pig.  This work was then extended by using the 
nerve agent sarin.  The guinea pig was the preferred species to use as it has been shown 
previously to better predict the efficacy of nerve agent treatments in primate species than 
other small laboratory animals such as the rat (Gordon et al., 1978;Berry & Davies, 
1970;Dirnhuber et al., 1979). 
 
6.2.  Discussion of model characterisation 
 
Several models were highlighted during the initial literature survey, which were of potential 
use for this project.  These are described in chapter 1.  Whilst all of the models fulfilled the 
main criteria required of the final model, a slice model of the hippocampus and dentate 
gyrus was chosen.  The dentate gyrus is a well established model which is relatively easy 
to produce and maintain during experimentation. 
 
A large part of this project was devoted to the characterisation of the fEPSP response 
recorded from the molecular layer of the dentate gyrus following stimulation of the medial 
perforant path.  Application of cholinergic agonists or AChE inhibitors caused an apparent 
decrease in the amplitude of the glutamatergic fEPSP recorded from the molecular layer 
of the dentate gyrus.  From the studies undertaken, several possible separate or 
interrelated processes were identified.  Firstly, glutamate release from the perforant 152 
pathway afferents could have been reduced by activation of a presynaptic mAChR.  A 
decrease in the amount of glutamate released would cause a decrease in the amplitude of 
the recorded fEPSP.  Secondly, a GABAA mediated component responsible for the 
decrease in amplitude of the fEPSP was identified. 
  
6.3.  Discussion of physostigmine-sarin interactions 
 
This project was designed to test two related hypotheses.  These were that physostigmine 
is an effective pretreatment, and the second hypothesis was that physostigmine acts by 
sequestering a pool of AChE by reversibly binding to it, therefore preventing binding and 
inhibition by any circulating nerve agent.  The results presented in Chapter 4 strongly 
support both hypotheses.  The results reported in this chapter clearly show a statistically 
significant effect of time between application of physostigmine and subsequent application 
of the nerve agent sarin on the recovery of the amplitude of the fEPSP.  This was most 
significant when physostigmine was applied 10 minutes prior to the sarin.  This is similar 
to that reported in vivo (Berry & Davies, 1970;Gordon et al., 1978).  In theory, the period 
of time between physostigmine and sarin applications could be extended and the 
beneficial effect of physostigmine should remain.  The data presented in the current study 
lends support to this hypothesis.  The extended pretreatment period would only be 
beneficial if it did not extend past the half-life for the decarbamoylation of physostigmine 
inhibited AChE.  In the guinea pig the half life for red blood cell AChE inhibited by 
physostigmine is 32 minutes and that of plasma ChE is 52 minutes (Wetherell & French, 
1991).  Further experiments would be needed to fully confirm that an increased interval 
between application of physostigmine and sarin furthers this beneficial effect. 
 
Another factor which has an important role in the pretreatment effect of physostigmine is 
bioavailability.  Using the octanol:water partition coefficient method it can be shown that 
sarin is more lipophillic than physostigmine (log P sarin 0.3, physostigmine 1.6) and 
therefore is quicker to enter the tissue of the slice (Czerwinski et al., 2006;Dahlin & Björk, 
2008).  For this reason physostigmine, especially at the relatively low concentration used 
in this study (0.100µM) needs to be in circulation prior to the sarin to allow it to reach (or 
approach) equilibrium within the tissue before the rapid influx of sarin into the slice begins.  
To overcome the disparity of the lipophilicity of the two compounds, physostigmine if 
added in excess will have a beneficial effect on the recovery post sarin challenge by out-
competing the sarin molecules for available AChE; despite the advantage that sarin has 
regarding increased lipophilicity.  This is in effect what has happened in the experiment in 
which the concentration of physostigmine was increased to 3.00µM.  A recent in vivo 
study has also shown that far greater concentrations of physostigmine are needed for it to 153 
be effective against nerve agent poisoning when given post exposure (Wetherell et al., 
2007). 
 
6.4.   Recommendations for future work 
 
This project has demonstrated the interactions between a reversible and irreversible 
inhibitor of AChE (physostigmine and sarin respectively) in a model of a CNS cholinergic 
response.  However, as shown in previous chapters there are several other 
pathways/systems which can be affected by OPs and nerve agents.  Long term effects 
are also reported in animal studies and human exposure case studies.  Understanding the 
mechanisms behind these effects may aid the medical management of casualties and 
identify novel targets for therapeutic intervention. 
 
Firstly, the current study reported in this document could be extended as follows.  To 
properly identify the mAChR present on the presynaptic membrane of the perforant path, 
a more considered concentration-effect experiment would need to be conducted.  In this a 
wider range of compounds which are more selective for the different mAChR subtypes 
would be used across a wider range of concentrations.  This would address the limitations 
of the current study.  Secondly, an in vivo study in which the effect of depressing the 
output of the perforant pathway in the guinea pig should be considered.  This would 
involve in vivo recording of the fEPSP recorded from the intact dentate gyrus and its 
response to differing concentrations of OP or physostigmine given to the animal.  Once 
this dose has been reliably calculated, it would then be given to freely moving guinea pigs 
and their behaviour analysed.  A further refinement of this proposed study would require 
slices of the dentate gyrus to be prepared from these animals and examined as was done 
previously in Chapter 3.  This would allow the physiological effect of depressing the 
perforant pathway fEPSP to be determined with greater confidence.  
 
Using a slice model such as the dentate gyrus used in this study is ideal for use in short 
term studies (lasting several hours).  After this the viability of the slice declines rapidly.  
Longer term studies which were designed to study the long term effects on neuronal 
function after a single high exposure or repeated low-level exposures to a nerve agent 
would be beneficial.  The terrorist releases of sarin during 1994 and 1995 in Japan are 
amongst the best documented accounts of the effects of sarin in humans.  An acute 
exposure to sarin resulted in changes to the structure of the brains of exposed survivors 
(decrease in volume of the insular cortex and the hippocampus (Yamasue et al., 2007)) 
and also prolonged changes in the EEG (Yanagisawa et al., 2006).  It would be beneficial 
to understand the mechanisms behind changes in the brain following such exposures.   154 
Such knowledge may aid the treatment of poisoned casualties leading to a better 
prognosis.  Whilst whole animal studies have the benefit of allowing the researcher to 
investigate the whole system, it is sometimes difficult to focus on specific areas or 
mechanisms.  
 
One approach to overcome this problem is to use organotypic cultures of tissues of 
interest.  To understand the effects of either chronic low level or single exposure of sarin 
on an area of the brain identified as susceptible could be carried out using an organotypic 
culture of the hippocampus.  Typically, thin slices of the brain structure of interest are 
taken from neonatal animals and allowed to grow in a cell culture environment.  A viable 
slice culture retaining the structure of the original brain area is then able to be maintained 
over several weeks rather than the few hours usually associated with acute brain slices.  
Organotypic slice cultures (OTSC) have been routinely used to study damage caused by 
ischemia (McManus et al., 2004), seizures (Bausch et al., 2006), and neurogenesis 
(Sadgrove et al., 2006;Raineteau et al., 2004).   Another benefit of the OTSC is that co-
cultures of related or adjoining structures can be grown together.  This allows neuronal 
connections normally lost during the production of slices to be maintained.  An example of 
this is the septo-hippocampal culture in which an explant of the septal nucleus is cultured 
alongside a hippocampal slice.  This allows a cholinergic/GABAergic pathway to be re-
established in the culture which is usually lost due to the spatial separation of the two 
structures in vivo (Fischer et al., 1999;Gähwiler, 1988;Gähwiler & Brown, 1985;Gähwiler 
et al., 1991).  It is proposed that the current physostigmine-sarin interaction study reported 
in Chapter 4 is repeated in an OTSC system containing a co-culture of the septal nucleus 
and hippocampus.  This would allow the study of the long term (weeks) effect of 
physostigmine alone (as a pretreatment) or in combination with a nerve agent on the 
neuronal infrastructure and level of AChE in the hippocampus.   
 
The current study has shown that at least in the dentate gyrus model, the effects of nerve 
agents are predominately mediated by mAChR (Chapter 3).  However, it has also been 
reported that anticholinesterases can affect neuronal nAChRs (Nagata et al., 
1997;Smulders et al., 2003;Smulders et al., 2004a;Smulders et al., 2004b).  The relative 
lack of effective of the nicotinic antagonist mecamylamine was surprising as the dentate 
gyrus has a population of nAChR (Frazier et al., 2003).  Whilst the various subtypes of 
nAChR are found throughout the CNS, very little is known on how OPs interact with this 
class of receptor.  This is a huge contrast to that which is known about the interactions of 
peripheral nAChR at the neuromuscular junction and OPs.  A study which mirrors that 
reported in Chapter 3 should be carried out using a model (preferably a slice model or 
OTSC) which exhibits a robust nicotinic response. During the literature review for the 
current study, several models came to light which exhibit a response mediated by nAChR.  155 
These include the medial habenula nucleus (Girod et al., 2000),  hippocampus (Frazier et 
al., 1998;Alkondon & Albuquerque, 2001;Dani et al., 2000;Jones & Yakel, 
1997;McQuiston & Madison, 1999;Radcliffe et al., 1999;Vogt & Regehr, 2001), nucleus 
accumbens (Fu et al., 2000), and cortex (Chu et al., 2000).  The majority of these models 
were disregarded due to technical challenges in setting up the model or recording from 
the system.  However, this decision should be revaluated in light of the results presented 
in the current study.  If the involvement of neuronal nAChR is similar to that of the muscle-
type nAChR in the periphery, the targeting of therapies against neuronal nicotinic targets 
may be of future interest especially in counteracting the respiratory depression and 
incapacitation seen post nerve agent poisoning. 
 
Finally, as the current study and review has shown, nerve agents and OPs have other 
effects  besides  causing  seizures.  A  further  in  vitro  study  which  would  enhance  our 
knowledge of one of these effects is proposed.  This is the role of inflammation in brain 
injury  and  recovery  following  nerve  agent  poisoning.    Currently,  the  role  of  the 
inflammatory  process  in  nerve  agent  poisoning  is  poorly  understood  and  may  have  a 
bearing on the treatment and prognosis of casualties.  The control of inflammation plays 
an important part of the homeostasis of the CNS (Wang & Shuaib, 2002;Stollg & Jander, 
1999) and can be activated by a variety of stimuli such as infection (Koontz et al., 2008), 
trauma (Toft-Hansen et al., 2007), seizures (Wang & Shuaib, 2002;Vezzani & Granata, 
2005), and chemical insults (Monnet-Tschudi et al., 2007).  Recent reports have shown 
that the nerve agents soman and sarin cause an acute inflammatory response within the 
CNS which results in the activation of astrocytes and microglia within the brain (Williams 
et  al.,  2003;Chapman  et  al.,  2006).   These  immune  cell  types  once  activated  release 
many different chemical mediators including cytokines and eicosanoids.  Following nerve 
agent  exposure  large  increases  in  the  levels  of  mRNA  for  pro-inflammatory  cytokine 
markers such as IL-1β have been reported (Svensson et al., 2005). Certain cytokines 
have  been  shown  to  affect  neuronal  cell  signalling  and  play  an  important  role  in  the 
activation of pathways which lead to cell death.  Prolonged inflammation therefore may be 
deleterious to cell survival.  If the loss of cells is sufficiently severe, this may result in loss 
of certain functions and other pathophysiological changes in the casualty.  A co-culture 
model of the hippocampus and macrophages has been described (Brana et al., 1999) 
which will allow the interactions between nerve agents and immune cells of the CNS to be 
studied.  Again, better understanding of these underlying processes may result in novel 
treatments to manage the OP poisoned casualty. 
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6.5.  Conclusion 
 
This study has shown that anticholinesterase compounds including physostigmine and 
sarin are capable of modulating the output of the glutamatergic granule cells of the 
dentate gyrus.  The results reported in Chapters 3 and 4 show that ACh and GABA are 
responsible for the modulation of the output of these cells.  Three possible locations for 
this interaction have been identified (Figure 6.1).   
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Figure 6.1.  Proposed sites of action of anticholinesterases in the dentate gyrus. 
This diagram shows the sites likely to be involved in the modulatory effects of 
anticholinesterases in the dentate gyrus.  Sources of endogenous ACh are represented by 
the yellow arrows. 
 
Released ACh causes excitation of the CA3 pyramidal cells (1) and also hilar interneurons 
(2) resulting in an increase in inhibition of the granule cells (note excitation of CA3 
pyramidal cells will also lead to direct excitation of hilar interneurons).  Inhibition of AChE 
in these locations will lead to a continued cholinergic excitation of the two cell types.  A 
third possible location for the action of the anticholinesterases is at the post synaptic 
terminals of the perforant pathway afferent fibres (3).  It is postulated that they may 157 
prolong the action of ACh on pre-synaptic autoreceptors (possibly M4-like) resulting in a 
decreased release of glutamate.  Any one of these three actions (or a combination of 
them) will decrease the excitability of the granule cells.  This is recorded as a decrease in 
the amplitude and slope of the fEPSP. 
 
This study has begun to address the knowledge gap that exists between what is known of 
nerve agent effects in the peripheral nervous system and those in the CNS.  The 
approach taken has been novel in as much as most studies looking at the problem of 
nerve agent and OP poisoning tend to focus on the seizure activity typical of this type of 
poisoning.  Identification of a non-seizure effect allows for a greater understanding of the 
underlying processes that occur following intoxication in the CNS.  The data presented in 
this study is the first direct evidence of the mechanism of action of physostigmine 
protection against nerve agent in the CNS.  This is an important step towards the 
identification and introduction of more centrally effective treatments which will build upon 
the existing therapies to the benefit of the OP poisoned casualty. 158 
7.   Appendix A159 
Lowry protein assay 
 
Reagents 
1.  0.3M NaOH 
2.  0.6M NaOH 
3.  2% NaCO3 
4.  1% Na-K tartrate in 0.5% CuSO4 (pH adjusted to 7.4 with NaOH if precipitate 
forms) 
5.  2mg/ml BSA in water  
6.  1N Folin and Ciocalteaus phenol reagent (dilute stock 1:1 with water) 
 
Method 
1.  Make up standards and unknowns as follows: 
  Dilute BSA 1:1 with 0.6M NaOH to give 1mg/ml in 0.3M NaOH 
  Dilute unknowns 1:1 with 0.6M NaOH 
2.  To duplicate test tubes add the following  (all volumes µl) 
 
0.3M NaOH  1mg/ml  BSA 
in 0.3M NaOH 
Unknown 
diluted  1:1  in 
0.6M NaOH 
Protein (µg) 
200  0    0 
195  5    5 
190  10    10 
175  25    25 
150  50    50 
100  100    100 
50  150    150 
0  200    200 
       
       
180  -  20  ? 
140  -  60  ? 
100  -  100  ? 
 
3.  Mix 49 ml of reagent 3 with 1 ml reagent 4 
4.  Add 1 ml of the above to all tubes and incubate at RT for 15 mins 
5.  Add 0.1 ml of reagent 6 to all tubes 
6.  Incubate for 30 min at RT 
7.  Read A700 using a spectrophotometer (zeroed on blank) 
8.  Plot standard curve and determine unknowns (results will be µg protein in original 
sample (10, 30, 50 µl) 
  N.B. used 200µl tissue 160 
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